FORM 10-Q
UNITED
STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
Form 10-Q
|
|
|
þ
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the quarterly period ended
September 30, 2008
|
or
|
o
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the transition period from
to
|
Commission file number: 0-24975
HLTH CORPORATION
(Exact name of registrant as
specified in its charter)
|
|
|
Delaware
(State of
incorporation)
|
|
94-3236644
(I.R.S. employer
identification no.)
|
669 River Drive, Center 2
Elmwood Park, New Jersey
(Address of principal
executive office)
|
|
07407-1361
(Zip
code)
|
(201) 703-3400
(Registrants
telephone number including area code)
Indicate by check mark whether the registrant: (1) has
filed all reports required to be filed by Section 13 or
15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past
90 days.
Yes
þ No
o
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of
large accelerated filer, accelerated
filer and smaller reporting company in Rule
12b-2 of the
Exchange Act. (Check one):
|
|
|
|
Large
accelerated
filer þ
|
Accelerated
filer o
|
Non-accelerated
filer o
|
Smaller
reporting
company o
|
(Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company
(as defined in
Rule 12b-2
of the Exchange Act).
Yes
o No
þ
As of November 5, 2008, there were 185,561,083 shares of
HLTH Common Stock outstanding (including unvested shares of
restricted HLTH Common Stock issued under our equity
compensation plans).
HLTH
CORPORATION
QUARTERLY REPORT ON
FORM 10-Q
For the period ended September 30, 2008
TABLE OF CONTENTS
WebMD®
, WebMD
Health®
, CME
Circle®
,
eMedicine®
,
MedicineNet®
,
Medscape®
,
MEDPOR®
,
Medsite®
,
POREX®
,
RxList®
,
Subimo®
,
Summex®
,
theheart.org®
and The Little Blue
Booktm
are among the trademarks of HLTH Corporation or its subsidiaries.
2
FORWARD-LOOKING
STATEMENTS
This Quarterly Report on
Form 10-Q
contains both historical and forward-looking statements. All
statements, other than statements of historical fact, are or may
be, forward-looking statements. For example, statements
concerning projections, predictions, expectations, estimates or
forecasts and statements that describe our objectives, future
performance, plans or goals are, or may be, forward-looking
statements. These forward-looking statements reflect
managements current expectations concerning future results
and events and can generally be identified by the use of
expressions such as may, will,
should, could, would,
likely, predict, potential,
continue, future, estimate,
believe, expect, anticipate,
intend, plan, foresee, and
other similar words or phrases, as well as statements in the
future tense.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual
results, performance or achievements to be different from any
future results, performance and achievements expressed or
implied by these statements. The following important risks and
uncertainties could affect our future results, causing those
results to differ materially from those expressed in our
forward-looking statements:
|
|
|
|
|
failure to achieve sufficient levels of usage of WebMDs
public portals;
|
|
|
|
inability to successfully deploy new or updated applications or
services;
|
|
|
|
failure to achieve sufficient levels of utilization and market
acceptance of new or updated products and services;
|
|
|
|
difficulties in forming and maintaining relationships with
customers and strategic partners;
|
|
|
|
inability to attract and retain qualified personnel;
|
|
|
|
anticipated benefits from acquisitions not being fully realized
or not being realized within the expected time frames;
|
|
|
|
general economic, business or regulatory conditions affecting
the healthcare, information technology, Internet and plastics
industries being less favorable than expected; and
|
|
|
|
the other risks and uncertainties described in this Quarterly
Report on
Form 10-Q
under the heading Managements Discussion and
Analysis of Financial Condition and Results of
Operations Factors That May Affect Our Future
Financial Condition or Results of Operations.
|
These factors are not necessarily all of the important factors
that could cause actual results to differ materially from those
expressed in any of our forward-looking statements. Other
factors, including unknown or unpredictable ones, could also
have material adverse effects on our future results.
The forward-looking statements included in this Quarterly Report
on
Form 10-Q
are made only as of the date of this Quarterly Report. Except as
required by law or regulation, we do not undertake any
obligation to update any forward-looking statements to reflect
subsequent events or circumstances.
3
PART I
FINANCIAL INFORMATION
|
|
ITEM 1.
|
Financial
Statements
|
HLTH
CORPORATION
(In
thousands, except share and per share data)
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(Unaudited)
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
1,380,179
|
|
|
$
|
536,879
|
|
Short-term investments
|
|
|
284,789
|
|
|
|
290,858
|
|
Accounts receivable, net of allowance for doubtful accounts of
$1,261 at September 30, 2008 and $1,165 at
December 31, 2007
|
|
|
78,148
|
|
|
|
86,081
|
|
Due from EBS Master LLC
|
|
|
|
|
|
|
1,224
|
|
Prepaid expenses and other current assets
|
|
|
27,190
|
|
|
|
71,090
|
|
Assets of discontinued operations
|
|
|
119,891
|
|
|
|
262,964
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
1,890,197
|
|
|
|
1,249,096
|
|
Marketable equity securities
|
|
|
2,175
|
|
|
|
2,383
|
|
Property and equipment, net
|
|
|
51,766
|
|
|
|
49,554
|
|
Goodwill
|
|
|
211,414
|
|
|
|
217,323
|
|
Intangible assets, net
|
|
|
28,917
|
|
|
|
36,314
|
|
Investment in EBS Master LLC
|
|
|
|
|
|
|
25,261
|
|
Other assets
|
|
|
36,534
|
|
|
|
71,466
|
|
|
|
|
|
|
|
|
|
|
TOTAL ASSETS
|
|
$
|
2,221,003
|
|
|
$
|
1,651,397
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS EQUITY
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accrued expenses
|
|
$
|
44,305
|
|
|
$
|
49,598
|
|
Deferred revenue
|
|
|
81,740
|
|
|
|
76,401
|
|
Liabilities of discontinued operations
|
|
|
100,464
|
|
|
|
123,131
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
226,509
|
|
|
|
249,130
|
|
1.75% convertible subordinated notes due 2023
|
|
|
350,000
|
|
|
|
350,000
|
|
31/8%
convertible notes due 2025
|
|
|
300,000
|
|
|
|
300,000
|
|
Other long-term liabilities
|
|
|
21,184
|
|
|
|
21,137
|
|
Minority interest in WHC
|
|
|
139,250
|
|
|
|
131,353
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
Stockholders equity:
|
|
|
|
|
|
|
|
|
Preferred stock, $0.0001 par value; 5,000,000 shares
authorized; no shares outstanding
|
|
|
|
|
|
|
|
|
Common stock, $0.0001 par value; 900,000,000 shares
authorized; 457,943,786 shares issued at September 30,
2008; 457,803,361 shares issued at December 31, 2007
|
|
|
46
|
|
|
|
46
|
|
Additional paid-in capital
|
|
|
12,504,151
|
|
|
|
12,479,574
|
|
Treasury stock, at cost; 273,397,698 shares at
September 30, 2008; 275,786,634 shares at
December 31, 2007
|
|
|
(2,556,347
|
)
|
|
|
(2,564,948
|
)
|
Accumulated deficit
|
|
|
(8,764,576
|
)
|
|
|
(9,320,748
|
)
|
Accumulated other comprehensive income
|
|
|
786
|
|
|
|
5,853
|
|
|
|
|
|
|
|
|
|
|
Total stockholders equity
|
|
|
1,184,060
|
|
|
|
599,777
|
|
|
|
|
|
|
|
|
|
|
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY
|
|
$
|
2,221,003
|
|
|
$
|
1,651,397
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes.
4
HLTH
CORPORATION
(In
thousands, except per share data, unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
Revenue
|
|
$
|
100,367
|
|
|
$
|
86,034
|
|
|
$
|
271,185
|
|
|
$
|
235,112
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of operations
|
|
|
35,322
|
|
|
|
30,021
|
|
|
|
99,655
|
|
|
|
87,636
|
|
Sales and marketing
|
|
|
26,441
|
|
|
|
22,459
|
|
|
|
77,731
|
|
|
|
67,258
|
|
General and administrative
|
|
|
22,928
|
|
|
|
25,718
|
|
|
|
67,253
|
|
|
|
81,111
|
|
Depreciation and amortization
|
|
|
7,265
|
|
|
|
7,390
|
|
|
|
21,468
|
|
|
|
20,954
|
|
Interest income
|
|
|
9,386
|
|
|
|
10,864
|
|
|
|
29,384
|
|
|
|
30,638
|
|
Interest expense
|
|
|
4,636
|
|
|
|
4,660
|
|
|
|
13,871
|
|
|
|
13,985
|
|
Gain on sale of EBS Master LLC
|
|
|
|
|
|
|
|
|
|
|
538,024
|
|
|
|
|
|
Impairment of auction rate securities
|
|
|
|
|
|
|
|
|
|
|
60,108
|
|
|
|
|
|
Other (expense) income, net
|
|
|
(997
|
)
|
|
|
989
|
|
|
|
(5,807
|
)
|
|
|
5,267
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
tax provision
|
|
|
12,164
|
|
|
|
7,639
|
|
|
|
492,700
|
|
|
|
73
|
|
Income tax provision
|
|
|
7,679
|
|
|
|
2,977
|
|
|
|
34,623
|
|
|
|
4,404
|
|
Minority interest in WHC income (loss)
|
|
|
1,845
|
|
|
|
1,800
|
|
|
|
(929
|
)
|
|
|
2,758
|
|
Equity in earnings of EBS Master LLC
|
|
|
|
|
|
|
8,005
|
|
|
|
4,007
|
|
|
|
22,679
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
2,640
|
|
|
|
10,867
|
|
|
|
463,013
|
|
|
|
15,590
|
|
Income (loss) from discontinued operations, net of tax
|
|
|
93,241
|
|
|
|
5,704
|
|
|
|
93,159
|
|
|
|
(38,780
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
95,881
|
|
|
$
|
16,571
|
|
|
$
|
556,172
|
|
|
$
|
(23,190
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic income (loss) per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
0.01
|
|
|
$
|
0.06
|
|
|
$
|
2.53
|
|
|
$
|
0.09
|
|
Income (loss) from discontinued operations
|
|
|
0.51
|
|
|
|
0.03
|
|
|
|
0.51
|
|
|
|
(0.22
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
0.52
|
|
|
$
|
0.09
|
|
|
$
|
3.04
|
|
|
$
|
(0.13
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted income (loss) per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
0.01
|
|
|
$
|
0.06
|
|
|
$
|
2.06
|
|
|
$
|
0.08
|
|
Income (loss) from discontinued operations
|
|
|
0.50
|
|
|
|
0.03
|
|
|
|
0.41
|
|
|
|
(0.21
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
0.51
|
|
|
$
|
0.09
|
|
|
$
|
2.47
|
|
|
$
|
(0.13
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares outstanding used in computing income
(loss) per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
183,716
|
|
|
|
179,811
|
|
|
|
182,838
|
|
|
|
178,681
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
187,527
|
|
|
|
188,071
|
|
|
|
228,653
|
|
|
|
188,486
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes.
5
HLTH
CORPORATION
(In
thousands, unaudited)
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
556,172
|
|
|
$
|
(23,190
|
)
|
Adjustments to reconcile net income (loss) to net cash provided
by operating activities:
|
|
|
|
|
|
|
|
|
(Income) loss from discontinued operations, net of tax
|
|
|
(93,159
|
)
|
|
|
38,780
|
|
Depreciation and amortization
|
|
|
21,468
|
|
|
|
20,954
|
|
Minority interest in WHC (loss) income
|
|
|
(929
|
)
|
|
|
2,758
|
|
Equity in earnings of EBS Master LLC
|
|
|
(4,007
|
)
|
|
|
(22,679
|
)
|
Amortization of debt issuance costs
|
|
|
2,248
|
|
|
|
2,179
|
|
Non-cash advertising
|
|
|
1,736
|
|
|
|
2,489
|
|
Non-cash stock-based compensation
|
|
|
18,974
|
|
|
|
26,246
|
|
Deferred income taxes
|
|
|
11,934
|
|
|
|
3,710
|
|
Gain on sale of EBS Master LLC and 2006 EBS Sale
|
|
|
(538,024
|
)
|
|
|
(399
|
)
|
Impairment of auction rate securities
|
|
|
60,108
|
|
|
|
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
7,933
|
|
|
|
14,835
|
|
Prepaid expenses and other, net
|
|
|
4,174
|
|
|
|
(198
|
)
|
Accrued expenses and other long-term liabilities
|
|
|
(3,639
|
)
|
|
|
(45,878
|
)
|
Deferred revenue
|
|
|
5,339
|
|
|
|
3,253
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by continuing operations
|
|
|
50,328
|
|
|
|
22,860
|
|
Net cash provided by discontinued operations
|
|
|
28,497
|
|
|
|
24,366
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
78,825
|
|
|
|
47,226
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
Proceeds from maturities and sales of
available-for-sale
securities
|
|
|
117,539
|
|
|
|
356,492
|
|
Purchases of
available-for-sale
securities
|
|
|
(177,150
|
)
|
|
|
(694,522
|
)
|
Purchases of property and equipment
|
|
|
(15,115
|
)
|
|
|
(14,427
|
)
|
Proceeds related to sales of ViPS, EBS, EPS and ACS/ACP, net of
expenses
|
|
|
821,706
|
|
|
|
14,565
|
|
Decrease in net advances to EBS Master LLC
|
|
|
1,224
|
|
|
|
19,921
|
|
Other
|
|
|
148
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) continuing operations
|
|
|
748,352
|
|
|
|
(317,971
|
)
|
Net cash used in discontinued operations
|
|
|
(4,265
|
)
|
|
|
(3,785
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) investing activities
|
|
|
744,087
|
|
|
|
(321,756
|
)
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
Proceeds from issuance of HLTH and WHC common stock
|
|
|
20,725
|
|
|
|
114,077
|
|
Purchases of treasury stock under repurchase program
|
|
|
|
|
|
|
(47,120
|
)
|
Other
|
|
|
343
|
|
|
|
4,300
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by continuing operations
|
|
|
21,068
|
|
|
|
71,257
|
|
Net cash used in discontinued operations
|
|
|
(76
|
)
|
|
|
(130
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by financing activities
|
|
|
20,992
|
|
|
|
71,127
|
|
Effect of exchange rates on cash
|
|
|
(604
|
)
|
|
|
1,042
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
843,300
|
|
|
|
(202,361
|
)
|
Cash and cash equivalents at beginning of period
|
|
|
536,879
|
|
|
|
614,691
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period
|
|
$
|
1,380,179
|
|
|
$
|
412,330
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes.
6
HLTH
CORPORATION
(In thousands, except share and per share data,
unaudited)
|
|
1.
|
Background
and Basis of Presentation
|
Background
HLTH Corporation (HLTH or the Company)
is a Delaware corporation that was incorporated in December 1995
and commenced operations in January 1996 as Healtheon
Corporation. HLTHs Common Stock began trading on the
Nasdaq National Market under the symbol HLTH on
February 11, 1999 and now trades on the Nasdaq Global
Select Market. The Company changed its name to Healtheon/WebMD
Corporation in November 1999 and to WebMD Corporation in
September 2000. In October 2005, WebMD Corporation changed its
name to Emdeon Corporation in connection with the initial public
offering of equity securities of WebMD Health Corp.
(WHC). In connection with the November 2006 sale of
a 52% interest in the Companys Emdeon Business Services
segment, the Company transferred its rights to the name
Emdeon and related intellectual property to Emdeon
Business Services. Accordingly, in May 2007, the Company changed
its name to HLTH Corporation.
WHCs Class A Common Stock began trading on the Nasdaq
National Market under the symbol WBMD on
September 29, 2005 and now trades on the Nasdaq Global
Select Market. As of September 30, 2008, the Company owned
48,100,000 shares of WHC Class B Common Stock, which
represented 83.1% of the total outstanding Class A Common
Stock (after accounting for the impact of certain WHC shares to
be issued pursuant to the purchase agreement for the acquisition
of Subimo, LLC) and Class B Common Stock of WHC. WHC
Class A Common Stock has one vote per share, while WHC
Class B Common Stock has five votes per share. As a result,
the WHC Class B Common Stock owned by the Company
represented, as of September 30, 2008, 96.2% of the
combined voting power of WHCs outstanding Common Stock.
Basis of
Presentation
The accompanying consolidated financial statements include the
consolidated accounts of HLTH Corporation and its subsidiaries
and have been prepared in United States dollars, and in
accordance with U.S. generally accepted accounting
principles (GAAP). The consolidated accounts include
100% of the assets and liabilities of the majority-owned WHC and
the ownership interests of minority stockholders of WHC are
recorded as minority interest in WHC in the accompanying
consolidated balance sheets.
The Companys 48% ownership in EBS Master LLC was accounted
for under the equity method through February 8, 2008, the
date of the sale of the Companys investment in EBS Master
LLC. See Note 3 for further details.
On February 21, 2008, the Company announced its intention
to sell its ViPS and Porex businesses. On July 22, 2008,
the Company completed the sale of ViPS. Accordingly, the results
of the Companys ViPS and Porex segments are presented as
discontinued operations in the accompanying consolidated
financial statements. See Note 2 for further details.
Interim
Financial Statements
The unaudited consolidated financial statements of the Company
have been prepared by management and reflect all adjustments
(consisting of only normal recurring adjustments) that, in the
opinion of management, are necessary for a fair presentation of
the interim periods presented. The results of operations for the
three and nine months ended September 30, 2008 are not
necessarily indicative of the operating results to be expected
for any subsequent period or for the entire year ending
December 31, 2008. Certain information and footnote
disclosures normally included in financial statements prepared
in accordance with U.S. GAAP have been condensed or omitted
under the Securities and Exchange Commissions (the
SEC) rules and regulations.
7
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The unaudited consolidated financial statements and notes
included herein should be read in conjunction with the
Companys audited consolidated financial statements and
notes for the year ended December 31, 2007, which are
included in the Companys Current Report on
Form 8-K
filed with the SEC on June 27, 2008.
Accounting
Estimates
The preparation of financial statements in conformity with
U.S. GAAP requires management to make certain estimates and
assumptions that affect the amounts reported in the consolidated
financial statements and accompanying notes. The Company bases
its estimates on historical experience, current business
factors, and various other assumptions that the Company believes
are necessary to consider to form a basis for making judgments
about the carrying values of assets and liabilities, the
recorded amounts of revenue and expenses, and the disclosure of
contingent assets and liabilities. The Company is subject to
uncertainties such as the impact of future events, economic,
environmental and political factors, and changes in the
Companys business environment; therefore, actual results
could differ from these estimates. Accordingly, the accounting
estimates used in the preparation of the Companys
financial statements will change as new events occur, as more
experience is acquired, as additional information is obtained
and as the Companys operating environment changes. Changes
in estimates are made when circumstances warrant. Such changes
in estimates and refinements in estimation methodologies are
reflected in reported results of operations; if material, the
effects of changes in estimates are disclosed in the notes to
the consolidated financial statements. Significant estimates and
assumptions by management affect: the allowance for doubtful
accounts, the carrying value of prepaid advertising, the
carrying value of long-lived assets (including goodwill and
intangible assets), the amortization period of long-lived assets
(excluding goodwill), the carrying value, capitalization and
amortization of software and Web site development costs, the
carrying value of investments in auction rate securities, the
provision for income taxes and related deferred tax accounts,
certain accrued expenses, revenue recognition, contingencies,
litigation and related legal accruals and the value attributed
to employee stock options and other stock-based awards.
Seasonality
The timing of the Companys revenue is affected by seasonal
factors. Advertising and sponsorship revenue within the WebMD
Online Services segment is seasonal, primarily as a result of
the annual budget approval process of the advertising and
sponsorship clients of the public portals. This portion of
revenue is usually the lowest in the first quarter of each
calendar year, and increases during each consecutive quarter
throughout the year. Private portal licensing revenue within the
WebMD Online Services segment is historically highest in the
second half of the year as new customers are typically added
during this period in conjunction with their annual open
enrollment periods for employee benefits. Finally, the annual
distribution cycle within the WebMD Publishing and Other
Services segment results in a significant portion of the revenue
in this segment being recognized in the second and third quarter
of each calendar year.
Net
Income (Loss) Per Common Share
Basic income (loss) per common share and diluted income (loss)
per common share are presented in conformity with Statement of
Financial Accounting Standards (SFAS) No. 128,
Earnings Per Share (SFAS 128). In
accordance with SFAS 128, basic income (loss) per common
share has been computed using the weighted-average number of
shares of common stock outstanding during the period, increased
to give effect to the participating rights of the convertible
redeemable exchangeable preferred stock. Diluted income (loss)
per common share has been computed using the weighted-average
number of shares of common stock outstanding during the period,
increased to give effect to potentially dilutive securities and
assumes that any dilutive convertible notes were converted, only
in the periods in which such effect is dilutive. Additionally,
for purposes of calculating diluted income (loss) per common
share of the Company, the numerator has been adjusted to
consider the effect of potentially dilutive securities of WHC,
which can dilute the portion of
8
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
WHCs net income (loss) otherwise retained by the Company.
The following table presents the calculation of basic and
diluted income (loss) per common share (shares in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
Numerator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
2,640
|
|
|
$
|
10,867
|
|
|
$
|
463,013
|
|
|
$
|
15,590
|
|
Convertible redeemable exchangeable preferred stock fee
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
174
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations Basic
|
|
|
2,640
|
|
|
|
10,867
|
|
|
|
463,013
|
|
|
|
15,764
|
|
Interest expense on convertible notes, net of tax
|
|
|
|
|
|
|
|
|
|
|
8,324
|
|
|
|
|
|
Effect of WHC dilutive securities
|
|
|
(203
|
)
|
|
|
(436
|
)
|
|
|
(326
|
)
|
|
|
(658
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations Diluted
|
|
$
|
2,437
|
|
|
$
|
10,431
|
|
|
$
|
471,011
|
|
|
$
|
15,106
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from discontinued operations, net of
tax Basic and Diluted
|
|
$
|
93,241
|
|
|
$
|
5,704
|
|
|
$
|
93,159
|
|
|
$
|
(38,780
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock
|
|
|
183,716
|
|
|
|
179,811
|
|
|
|
182,838
|
|
|
|
171,643
|
|
Convertible redeemable exchangeable preferred stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,038
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares Basic
|
|
|
183,716
|
|
|
|
179,811
|
|
|
|
182,838
|
|
|
|
178,681
|
|
Employee stock options, restricted stock and warrants
|
|
|
3,811
|
|
|
|
8,260
|
|
|
|
3,800
|
|
|
|
9,805
|
|
Convertible notes
|
|
|
|
|
|
|
|
|
|
|
42,015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted weighted-average shares after assumed
conversions Diluted
|
|
|
187,527
|
|
|
|
188,071
|
|
|
|
228,653
|
|
|
|
188,486
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic income (loss) per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
0.01
|
|
|
$
|
0.06
|
|
|
$
|
2.53
|
|
|
$
|
0.09
|
|
Income (loss) from discontinued operations
|
|
|
0.51
|
|
|
|
0.03
|
|
|
|
0.51
|
|
|
|
(0.22
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
0.52
|
|
|
$
|
0.09
|
|
|
$
|
3.04
|
|
|
$
|
(0.13
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted income (loss) per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
0.01
|
|
|
$
|
0.06
|
|
|
$
|
2.06
|
|
|
$
|
0.08
|
|
Income (loss) from discontinued operations
|
|
|
0.50
|
|
|
|
0.03
|
|
|
|
0.41
|
|
|
|
(0.21
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
0.51
|
|
|
$
|
0.09
|
|
|
$
|
2.47
|
|
|
$
|
(0.13
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The Company has excluded convertible subordinated notes and
convertible notes, as well as certain outstanding warrants,
restricted stock and stock options, from the calculation of
diluted income (loss) per common share during the periods in
which such securities were anti-dilutive. The following table
presents the total number of shares that could potentially
dilute income (loss) per common share in the future that were
not included in the computation of diluted income (loss) per
common share during the periods presented (shares in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
Options, restricted stock and warrants
|
|
|
28,806
|
|
|
|
21,054
|
|
|
|
32,879
|
|
|
|
20,175
|
|
Convertible notes
|
|
|
42,015
|
|
|
|
42,015
|
|
|
|
|
|
|
|
42,015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
70,821
|
|
|
|
63,069
|
|
|
|
32,879
|
|
|
|
62,190
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income
Taxes
The income tax provision of $7,679 and $34,623 for the three and
nine months ended September 30, 2008, respectively, and
$2,977 and $4,404 for the three and nine months ended
September 30, 2007, respectively, represents taxes for
federal, state and other jurisdictions. The Company recorded an
income tax provision related to discontinued operations of
$8,813 and $8,143 for the three and nine months ended
September 30, 2008, respectively, and an income tax
provision of $823 and $1,461 for the three and nine months ended
September 30, 2007, respectively, included in loss from
discontinued operations, net of tax in the accompanying
consolidated statements of operations. While the majority of the
gain on the 2008 EBSCo Sale (as defined in Note 3) was
offset by net operating loss (NOL) carryforwards,
certain alternative minimum tax and other state taxes were not
offset resulting in a provision of approximately $24,000 for the
nine months ended September 30, 2008. The income tax
provision for the nine months ended September 30, 2008
excludes a benefit for the impairment of auction rate
securities, as it is currently not deductible for tax purposes.
Recent
Accounting Pronouncements
On May 9, 2008, the Financial Accounting Standards Board
(FASB) issued FASB Staff Position (FSP)
Accounting Principles Board (APB) Opinion
No. 14-1,
Accounting for Convertible Debt Instruments That May Be
Settled in Cash upon Conversion (Including Partial Cash
Settlement) (FSP APB
14-1).
The FSP will require cash settled convertible debt to be
separated into debt and equity components at issuance and a
value to be assigned to each. The value assigned to the debt
component will be the estimated fair value, as of the issuance
date, of a similar bond without the conversion feature. The
difference between the bond cash proceeds and this estimated
fair value will be recorded as a debt discount and amortized to
interest expense over the life of the bond. Although FSP APB
14-1 would
have no impact on the Companys actual past or future cash
flows, it will require the Company to record a significant
amount of non-cash interest expense as the debt discount is
amortized. As a result, there will be a material adverse impact
on the results of operations and earnings per share. In
addition, if the convertible debt is redeemed or converted prior
to maturity, any unamortized debt discount will result in a loss
on extinguishment. FSP APB
14-1 will
become effective January 1, 2009, and will require
retrospective application.
On April 25, 2008, the FASB issued FSP
FAS 142-3,
Determination of the Useful Life of Intangible
Assets. This FSP amends the factors that should be
considered in developing renewal or extension assumptions used
to determine the useful life of a recognized intangible asset
under SFAS No. 142, Goodwill and Other
Intangible Assets (SFAS 142). The intent
of this FSP is to improve the consistency between the useful
life of a recognized intangible asset under SFAS 142 and
the period of expected cash flows used to measure the fair value
of the asset under SFAS No. 141 (Revised 2007),
Business Combinations, and other U.S. GAAP.
This FSP is effective for financial statements issued for fiscal
years beginning after December 15,
10
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
2008, and interim periods within those fiscal years. Early
adoption is prohibited. The Company is currently evaluating the
impact that this FSP will have on its operations, financial
position and cash flows.
In December 2007, the FASB issued SFAS No. 141
(Revised 2007), Business Combinations
(SFAS 141R), a replacement of
SFAS No. 141. SFAS 141R is effective for fiscal
years beginning on or after December 15, 2008 and applies
to all business combinations. SFAS 141R provides that, upon
initially obtaining control, an acquirer shall recognize
100 percent of the fair values of acquired assets,
including goodwill, and assumed liabilities, with only limited
exceptions, even if the acquirer has not acquired
100 percent of its target. As a consequence, the current
step acquisition model will be eliminated. Additionally,
SFAS 141R changes current practice, in part, as follows:
(1) contingent consideration arrangements will be fair
valued at the acquisition date and included on that basis in the
purchase price consideration; (2) transaction costs will be
expensed as incurred, rather than capitalized as part of the
purchase price; (3) pre-acquisition contingencies, such as
legal issues, will generally have to be accounted for in
purchase accounting at fair value; and (4) in order to
accrue for a restructuring plan in purchase accounting, the
requirements in SFAS No. 146, Accounting for
Costs Associated with Exit or Disposal Activities, would
have to be met at the acquisition date. While there is no
expected impact to the Companys consolidated financial
statements on the accounting for acquisitions completed prior to
December 31, 2008, the adoption of SFAS 141R on
January 1, 2009 could materially change the accounting for
business combinations consummated subsequent to that date and
for tax matters relating to prior acquisitions settled
subsequent to December 31, 2008.
In December 2007, the FASB issued SFAS No. 160,
Noncontrolling Interests in Consolidated Financial
Statements An Amendment of ARB No. 51
(SFAS 160). SFAS 160 requires the
recognition of a noncontrolling interest (minority interest) as
equity in the financial statements and separate from the
parents equity. The amount of net income attributable to
the noncontrolling interest will be included in consolidated net
income on the face of the results of operations. SFAS 160
clarifies that changes in a parents ownership interest in
a subsidiary that do not result in deconsolidation are equity
transactions if the parent retains its controlling financial
interest. In addition, this statement requires that a parent
recognize a gain or loss in net income when a subsidiary is
deconsolidated. Such gain or loss will be measured using the
fair value of the noncontrolling equity investment on the
deconsolidation date. SFAS 160 also includes expanded
disclosure requirements regarding the interests of the parent
and its noncontrolling interest. SFAS 160 is effective for
financial statements issued for fiscal years beginning after
December 15, 2008 and is to be applied prospectively as of
the beginning of the fiscal year in which the statement is
applied. Early adoption is not permitted. The Company is
currently evaluating the impact that SFAS 160 will have on
its operations, financial position and cash flows.
|
|
2.
|
Discontinued
Operations
|
In November 2007, the Company announced its intention to explore
potential sales transactions for its ViPS and Porex businesses
and in February 2008, the Company announced its intention to
divest these segments. As a result, the financial information
has been reclassified to discontinued operations in the
accompanying consolidated financial statements.
11
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Porex
Summarized operating results for Porex for the three and nine
months ended September 30, 2008 and 2007 are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
Statement of Operations Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
23,131
|
|
|
$
|
21,867
|
|
|
$
|
71,518
|
|
|
$
|
69,579
|
|
Earnings before taxes
|
|
|
5,001
|
|
|
|
4,820
|
|
|
|
13,002
|
|
|
|
15,587
|
|
The major classes of assets and liabilities of Porex as of
September 30, 2008 and December 31, 2007 are as
follows:
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
Assets of discontinued operations:
|
|
|
|
|
|
|
|
|
Accounts receivable, net
|
|
$
|
12,955
|
|
|
$
|
12,922
|
|
Inventory
|
|
|
12,121
|
|
|
|
11,772
|
|
Property and equipment, net
|
|
|
22,231
|
|
|
|
21,176
|
|
Goodwill
|
|
|
42,960
|
|
|
|
43,283
|
|
Intangible assets, net
|
|
|
24,750
|
|
|
|
24,872
|
|
Deferred tax asset
|
|
|
1,420
|
|
|
|
1,420
|
|
Other assets
|
|
|
3,454
|
|
|
|
3,554
|
|
|
|
|
|
|
|
|
|
|
Total Assets
|
|
$
|
119,891
|
|
|
$
|
118,999
|
|
|
|
|
|
|
|
|
|
|
Liabilities of discontinued operations:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
1,983
|
|
|
$
|
1,533
|
|
Accrued expenses
|
|
|
6,587
|
|
|
|
7,684
|
|
Deferred tax liability
|
|
|
24,583
|
|
|
|
24,375
|
|
Other long-term liabilities
|
|
|
|
|
|
|
101
|
|
|
|
|
|
|
|
|
|
|
Total Liabilities
|
|
$
|
33,153
|
|
|
$
|
33,693
|
|
|
|
|
|
|
|
|
|
|
ViPS
On July 22, 2008, the Company completed the sale of its
ViPS segment (ViPS Sale) to an affiliate of General
Dynamics Corporation (General Dynamics) for $224,842
in cash, which reflects the effect of a preliminary estimate of
the amount of a customary working capital adjustment to the
contractual purchase price of $225,000 in cash. The actual
amount of the working capital adjustment has not yet been
determined. The Company incurred approximately $1,337 of
professional fees and other expenses associated with the ViPS
Sale during the three months ended September 30, 2008. In
connection with the sale, the Company recognized a pre-tax gain
of $96,566, which is included in income from discontinued
operations in the accompanying consolidated statements of
operations during the three months ended
September 30, 2008.
12
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Summarized operating results for ViPS for the periods
July 1, 2008 through July 22, 2008, January 1,
2008 through July 22, 2008 and the three and nine months
ended September 30, 2007 are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Period
|
|
|
|
|
|
For the Period
|
|
|
|
|
|
|
July 1, 2008 to
|
|
|
Three Months Ended
|
|
|
January 1, 2008 to
|
|
|
Nine Months Ended
|
|
|
|
July 22, 2008
|
|
|
September 30, 2007
|
|
|
July 22, 2008
|
|
|
September 30, 2007
|
|
|
Statement of Operations Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
5,292
|
|
|
$
|
24,307
|
|
|
$
|
57,497
|
|
|
$
|
76,851
|
|
Earnings before taxes
|
|
|
270
|
|
|
|
1,412
|
|
|
|
8,121
|
|
|
|
4,211
|
|
The major classes of assets and liabilities of ViPS as of
December 31, 2007 are as follows:
|
|
|
|
|
|
Assets of discontinued operations:
|
|
|
|
|
Accounts receivable, net
|
|
$
|
17,240
|
|
Property and equipment, net
|
|
|
4,020
|
|
Goodwill
|
|
|
71,253
|
|
Intangible assets, net
|
|
|
47,815
|
|
Deferred tax asset
|
|
|
804
|
|
Other assets
|
|
|
2,833
|
|
|
|
|
|
|
Total Assets
|
|
$
|
143,965
|
|
|
|
|
|
|
Liabilities of discontinued operations:
|
|
|
|
|
Accounts payable
|
|
$
|
1,599
|
|
Accrued expenses and other
|
|
|
4,370
|
|
Deferred revenue
|
|
|
10,982
|
|
Deferred tax liability
|
|
|
16,924
|
|
|
|
|
|
|
Total Liabilities
|
|
$
|
33,875
|
|
|
|
|
|
|
ACS/ACP
Business
As of December 31, 2007, the Company, through WHC, entered
into an Asset Sale Agreement and completed the sale of certain
assets and certain liabilities of its medical reference
publications business, including the publications ACP
Medicine and ACS Surgery: Principles and Practice.
The assets and liabilities sold are referred to below as the
ACS/ACP Business. ACP Medicine and ACS
Surgery are official publications of the American College of
Physicians and the American College of Surgeons, respectively.
As a result of the sale, the historical financial information of
the ACS/ACP Business has been reclassified as discontinued
operations in the accompanying consolidated financial statements
for the prior year period. The Company will receive net cash
proceeds of $2,809, consisting of $1,734 received during the
quarter ended March 31, 2008 and the remaining $1,075 to be
received during the quarter ending December 31, 2008. The
Company incurred approximately $800 of professional fees and
other expenses associated with the sale of the ACS/ACP Business.
In connection with the sale, the Company recognized a gain of
$3,394 in the three months ended December 31, 2007.
Summarized operating results for the discontinued operations of
the ACS/ACP Business for the three and nine months ended
September 30, 2007 were as follows:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30, 2007
|
|
|
September 30, 2007
|
|
|
Statement of Operations Data:
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
1,100
|
|
|
$
|
3,327
|
|
(Loss) earnings before taxes
|
|
|
(10
|
)
|
|
|
210
|
|
13
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
EPS
On September 14, 2006, the Company completed the sale (the
EPS Sale) of Emdeon Practice Services, Inc.
(together with its subsidiaries, EPS) to Sage
Software, Inc. (Sage Software). The Company has
certain indemnity obligations to advance amounts for reasonable
defense costs for initially ten, and now eight, former officers
and directors of EPS, who were indicted in connection with the
previously disclosed investigation by the United States Attorney
for the District of South Carolina (the
Investigation), which is more fully described in
Note 12, Commitments and Contingencies. In
connection with the EPS Sale, the Company agreed to indemnify
Sage Software relating to these indemnity obligations. During
the quarter ended June 30, 2007, based on information it
had recently received at that time, the Company determined a
reasonable estimate of the range of probable costs with respect
to its indemnification obligation and accordingly, recorded a
pre-tax charge of $57,774, which represented the Companys
estimate of the low end of the probable range of costs related
to this matter. The Company had reserved the low end of the
probable range of costs because no estimate within the range was
a better estimate than any other amount. That estimate included
assumptions as to the duration of the trial and pre-trial
periods, and the defense costs to be incurred during these
periods. During the quarter ended December 31, 2007 and
again during the quarter ended June 30, 2008, the Company
updated the estimated range of its indemnification obligation
based on new information received during those periods, and as a
result, recorded additional pre-tax charges of $15,573 and
$16,980, respectively, each of which reflected the increases in
the low end of the probable range of costs related to this
matter. The probable range of future costs with respect to this
matter is estimated to be approximately $47,400 to $70,400, as
of September 30, 2008 which includes costs that have been
incurred prior to, but were not yet paid, as of
September 30, 2008. The ultimate outcome of this matter is
still uncertain, and the estimate of future costs includes
assumptions as to the duration of the trial and the defense
costs to be incurred during the remainder of the pre-trial
period and during the trial period. Accordingly, the amount of
cost the Company may ultimately incur could be substantially
more than the reserve the Company has currently provided. If the
recorded reserves are insufficient to cover the ultimate cost of
this matter, the Company will need to record additional charges
to its consolidated statement of operations in future periods.
The accrual related to this obligation was $47,399 and $55,563
as of September 30, 2008 and December 31, 2007,
respectively, and is included within liabilities of discontinued
operations in the accompanying consolidated balance sheets.
Also included within liabilities of discontinued operations
related to this matter is $19,912 which represents
reimbursements received from the Companys insurance
carriers between July 31, 2008 and September 30, 2008.
The Company deferred recognizing these insurance reimbursements
within the statement of operations given the pending Coverage
Litigation. For more information regarding the Coverage
Litigation, see Note 12.
|
|
3.
|
Emdeon
Business Services
|
On November 16, 2006, the Company completed the sale of a
52% interest in its Emdeon Business Services segment (2006
EBS Sale) to an affiliate of General Atlantic LLC
(GA). The 2006 EBS Sale was structured so that the
Company and GA each own interests in a limited liability
company, EBS Master LLC (EBSCo), which owns the
entities comprising EBS through a wholly owned limited liability
company, Emdeon Business Services LLC. During the three months
ended June 30, 2007, the Company recognized a gain of $399
which related to the finalization of the working capital
adjustment in connection with the 2006 EBS Sale.
Beginning on November 17, 2006, the Companys
remaining 48% ownership interest in EBSCo was reflected as an
investment in the Companys consolidated financial
statements, accounted for under the equity method and the
Companys share of EBSCos net earnings was reported
as equity in earnings of EBS Master LLC in the accompanying
consolidated statements of operations through February 8,
2008.
14
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
On February 8, 2008, the Company entered into a Securities
Purchase Agreement and simultaneously completed the sale of its
48% minority ownership interest in EBSCo (the 2008 EBSCo
Sale) for $575,000 in cash to an affiliate of GA and
affiliates of Hellman & Friedman, LLC. In connection
with the 2008 EBSCo Sale, the Company recognized a pre-tax gain
of $538,024. The Company expects to utilize a portion of its
federal NOL carryforwards to offset a portion of the tax
liability that would otherwise result from the 2008 EBSCo Sale.
The Companys share of EBSCos net earnings is
reported as equity in earnings of EBS Master LLC in the
accompanying consolidated statements of operations for the three
and nine months ended September 30, 2007 and for the period
January 1, 2008 through February 8, 2008, the closing
date of the 2008 EBSCo Sale. The difference between the equity
in earnings of EBS Master LLC in the accompanying consolidated
statements of operations and 48% of the net income of EBSCo is
principally due to the amortization of the excess of the fair
value of EBSCos net assets as adjusted for in purchase
accounting, over the carryover basis of the Companys
investment in EBSCo. The following is summarized financial
information of EBSCo for the period January 1, 2008 through
February 8, 2008 and for the three and nine months ended
September 30, 2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Period
|
|
|
|
|
|
|
|
|
|
January 1, 2008 to
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
February 8, 2008
|
|
|
September 30, 2007
|
|
|
September 30, 2007
|
|
|
Statement of Operations Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
94,481
|
|
|
$
|
202,954
|
|
|
$
|
602,589
|
|
Cost of operations
|
|
|
44,633
|
|
|
|
94,712
|
|
|
|
280,786
|
|
Net income
|
|
|
5,551
|
|
|
|
9,999
|
|
|
|
26,798
|
|
|
|
4.
|
Termination
of Proposed Merger with WHC
|
On February 20, 2008, the Company and WHC entered into an
Agreement and Plan of Merger (the Merger Agreement),
pursuant to which the Company would merge into WHC (the
WHC Merger), with WHC continuing as the surviving
corporation. The Merger Agreement was amended on May 6,
2008 and September 12, 2008. Pursuant to the terms of a
Termination Agreement entered into on October 19, 2008 (the
Termination Agreement), the Company and WHC mutually
agreed, in light of recent turmoil in financial markets, to
terminate the Merger Agreement. The termination was by mutual
agreement of the companies and was unanimously approved by the
Board of Directors of each of the companies and by a special
committee of independent directors of WHC. The Termination
Agreement maintains the Companys obligation, under the
terms of the Merger Agreement, to pay the expenses of WHC
incurred in connection with the merger. Under the Termination
Agreement, the Company and WHC also agreed to amend the Amended
and Restated Tax Sharing Agreement, dated as of
February 15, 2006, between them (the Tax Sharing
Agreement) so that, for tax years beginning after
December 31, 2007, the Company will no longer be required
to reimburse WHC for use of NOL carryforwards attributable to
WHC that may result from certain extraordinary transactions by
the Company. The Tax Sharing Agreement has not, other than with
respect to certain extraordinary transactions by the Company,
required either the Company or WHC to reimburse the other party
for any net tax savings realized by the consolidated group as a
result of the groups utilization of WHCs or the
Companys NOL carryforwards during the period of
consolidation, and that will continue following the amendment.
The Termination Agreement also provided for the Company to
assign to WHC the Amended and Restated Data License Agreement,
dated as of February 8, 2008, among the Company, EBSCo and
certain affiliated companies.
15
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Gain
Upon Sale of WHC Class A Common Stock
The Companys WHC subsidiary issues its Class A Common
Stock in various transactions from time to time, which result in
the dilution of the Companys percentage ownership in WHC.
The Company accounts for the issuance of WHC Class A Common
Stock in accordance with the SECs Staff Accounting
Bulletin No. 51, Accounting for Sales of Stock
by a Subsidiary. The issuances of WHC Class A Common
Stock resulted in an aggregate gain to equity of $1,768 and
$3,715 during the three and nine months ended September 30,
2008, respectively, related to the exercise of stock options and
the release of restricted stock awards. As a result, the
Companys ownership in WHC decreased to 83.1% as of
September 30, 2008, from 83.5% as of December 31, 2007
(after accounting for the impact of certain WHC shares to be
issued pursuant to the purchase agreement for the acquisition of
Subimo, LLC).
Segment information has been prepared in accordance with
SFAS No. 131, Disclosures about Segments of an
Enterprise and Related Information
(SFAS 131). The accounting policies of the
segments are the same as the accounting policies for the
consolidated Company. Inter-segment revenue represents certain
services provided by the WebMD Online Services segment and WebMD
Publishing and Other Services segment (which we refer to,
together, as the WebMD Segments or, sometimes, as
WebMD) to the Corporate segment. The performance of
the Companys business is monitored based on earnings
before interest, taxes, non-cash and other items. Other items
include: legal expenses incurred by the Company, which reflect
costs and expenses related to the investigation by the United
States Attorney for the District of South Carolina and the SEC;
income related to the reduction of certain sales and use tax
contingencies; professional fees in 2008, primarily consisting
of legal, accounting and financial advisory services related to
the terminated WHC Merger; the gain on the 2008 EBSCo Sale; the
gain recognized in connection with the working capital
adjustment associated with the 2006 EBS Sale; and the impairment
charge related to the Companys auction rate securities.
Reclassification of Segment Information. As a
result of the Companys intention to divest the Porex
segment and due to the ViPS Sale and the December 31, 2007
sale of WHCs ACS/ACP business, the financial information
for these businesses has been reclassified to discontinued
operations for the current and prior year periods. As a result
of the discontinued operations presentation for ViPS and Porex,
the Companys only remaining operating segment would have
been WebMD. Accordingly, the Company expanded its segment
disclosure for WebMD to provide additional information related
to the WebMD Online Services segment and the WebMD Publishing
and Other Services segment. This additional information for
WebMD has been provided for all periods presented.
The WebMD Segments and Corporate segment are described as
follows:
|
|
|
|
|
WebMD Online Services provides health information
services to consumers, physicians, healthcare professionals,
employees and health plans through its public and private online
portals. The public portals for consumers enable them to obtain
health and wellness information (including information on
specific diseases and conditions), check symptoms, locate
physicians, store individual healthcare information, receive
periodic
e-newsletters
on topics of individual interest, enroll in interactive courses
and participate in online communities with peers and experts.
The public portals for physicians and healthcare professionals
make it easier for them to access clinical reference sources,
stay abreast of the latest clinical information, learn about new
treatment options, earn continuing medical education credit and
communicate with peers. The private portals enable employers and
health plans to provide their employees and plan members with
access to personalized health and benefit information and
decision-support technology that helps them make more informed
benefit, provider and treatment choices.
|
16
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
WebMD Online Services provides related services for use by such
employees and members, including lifestyle education and
personalized telephonic health coaching. WebMD Online Services
also provides
e-detailing
promotion and physician recruitment services for use by
pharmaceutical, medical device and healthcare companies.
|
|
|
|
|
|
WebMD Publishing and Other Services publishes The
Little Blue Book, a physician directory, and WebMD the
Magazine, a consumer magazine distributed to physician
office waiting rooms. The Company also published medical
reference textbooks until it divested this business on
December 31, 2007. See Note 2 for further details.
|
|
|
|
Corporate includes personnel costs and other expenses
related to functions that are not directly managed by one of the
Companys segments or by the Porex and ViPS businesses
included in discontinued operations. The personnel costs include
executive personnel, legal, accounting, tax, internal audit,
risk management, human resources and certain information
technology functions. Other corporate costs and expenses include
professional fees including legal and audit services, insurance,
costs of leased property and facilities, telecommunication costs
and software maintenance expenses. Corporate expenses are net of
$838 and $2,572 for the three and nine months ended
September 30, 2008, respectively, and $845 and $2,470 for
the three and nine months ended September 30, 2007,
respectively, which are costs allocated to WebMD for services
provided by the Corporate segment. In connection with the 2006
EBS Sale, EPS Sale and the ViPS Sale, the Company entered into
transition services agreements whereby the Company provided
ViPS, EBSCo, and Sage Software certain administrative services,
including payroll, accounting, purchasing and procurement, tax,
and human resource services, as well as information technology
support. Additionally, EBSCo provided certain administrative
services to the Company. These services were provided through
the Corporate segment, and the related transition services fees
that the Company charged to ViPS, EBSCo, and Sage Software, net
of the fee the Company paid to EBSCo, were also included in the
Corporate segment, which were intended to approximate the cost
of providing these services. The transition services agreement
with Sage Software was terminated on December 31, 2007 and,
therefore, net transition services fees are solely for services
related to EBSCo and ViPS for the three and nine months ended
September 30, 2008.
|
17
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Summarized financial information for the WebMD Segments and
Corporate segment and a reconciliation to income from continuing
operations are presented below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
WebMD Online Services:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advertising and sponsorship
|
|
$
|
72,046
|
|
|
$
|
59,087
|
|
|
$
|
190,494
|
|
|
$
|
158,944
|
|
Licensing
|
|
|
22,139
|
|
|
|
20,001
|
|
|
|
65,928
|
|
|
|
59,915
|
|
Content syndication and other
|
|
|
392
|
|
|
|
490
|
|
|
|
1,154
|
|
|
|
2,027
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total WebMD Online Services
|
|
|
94,577
|
|
|
|
79,578
|
|
|
|
257,576
|
|
|
|
220,886
|
|
WebMD Publishing and Other Services
|
|
|
5,810
|
|
|
|
6,520
|
|
|
|
13,669
|
|
|
|
14,426
|
|
Inter-segment eliminations
|
|
|
(20
|
)
|
|
|
(64
|
)
|
|
|
(60
|
)
|
|
|
(200
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
100,367
|
|
|
$
|
86,034
|
|
|
$
|
271,185
|
|
|
$
|
235,112
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before interest, taxes, non-cash and other items
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
WebMD Online Services
|
|
$
|
25,956
|
|
|
$
|
21,948
|
|
|
$
|
61,287
|
|
|
$
|
48,982
|
|
WebMD Publishing and Other Services
|
|
|
1,212
|
|
|
|
2,138
|
|
|
|
1,485
|
|
|
|
2,643
|
|
Corporate
|
|
|
(4,679
|
)
|
|
|
(5,811
|
)
|
|
|
(15,311
|
)
|
|
|
(18,874
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22,489
|
|
|
|
18,275
|
|
|
|
47,461
|
|
|
|
32,751
|
|
Interest, taxes, non-cash and other items
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
9,386
|
|
|
|
10,864
|
|
|
|
29,384
|
|
|
|
30,638
|
|
Interest expense
|
|
|
(4,636
|
)
|
|
|
(4,660
|
)
|
|
|
(13,871
|
)
|
|
|
(13,985
|
)
|
Income tax provision
|
|
|
(7,679
|
)
|
|
|
(2,977
|
)
|
|
|
(34,623
|
)
|
|
|
(4,404
|
)
|
Depreciation and amortization
|
|
|
(7,265
|
)
|
|
|
(7,390
|
)
|
|
|
(21,468
|
)
|
|
|
(20,954
|
)
|
Non-cash stock-based compensation
|
|
|
(6,531
|
)
|
|
|
(9,285
|
)
|
|
|
(18,974
|
)
|
|
|
(26,246
|
)
|
Non-cash advertising
|
|
|
(178
|
)
|
|
|
(169
|
)
|
|
|
(1,736
|
)
|
|
|
(2,489
|
)
|
Minority interest in WHC income (loss)
|
|
|
(1,845
|
)
|
|
|
(1,800
|
)
|
|
|
929
|
|
|
|
(2,758
|
)
|
Equity in earnings of EBS Master LLC
|
|
|
|
|
|
|
8,005
|
|
|
|
4,007
|
|
|
|
22,679
|
|
Gain on sale of EBS Master LLC
|
|
|
|
|
|
|
|
|
|
|
538,024
|
|
|
|
|
|
Impairment of auction rate securities
|
|
|
|
|
|
|
|
|
|
|
(60,108
|
)
|
|
|
|
|
Other (expense) income, net
|
|
|
(1,101
|
)
|
|
|
4
|
|
|
|
(6,012
|
)
|
|
|
358
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
2,640
|
|
|
|
10,867
|
|
|
|
463,013
|
|
|
|
15,590
|
|
Income (loss) from discontinued operations, net of tax
|
|
|
93,241
|
|
|
|
5,704
|
|
|
|
93,159
|
|
|
|
(38,780
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
95,881
|
|
|
$
|
16,571
|
|
|
$
|
556,172
|
|
|
$
|
(23,190
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7.
|
Stock-Based
Compensation
|
The Company has various stock-based compensation plans
(collectively, the Plans) under which directors,
officers and other eligible employees receive awards of options
to purchase HLTH Common Stock and restricted shares of HLTH
Common Stock. Additionally, WHC has two similar stock-based
compensation plans that provide for stock options and restricted
stock awards based on WHC Class A Common Stock. The Company
also maintained an Employee Stock Purchase Plan through
April 30, 2008, which provided
18
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
employees with the ability to buy shares of HLTH Common Stock at
a discount. The following sections of this note summarize the
activity for each of these plans.
HLTH
Plans
The Company had an aggregate of 5,936,018 shares of HLTH
Common Stock available for future grants under the Plans as of
September 30, 2008. In addition to the Plans, the Company
has granted options to certain directors, officers and key
employees pursuant to individual stock option agreements. At
September 30, 2008, there were options to purchase
4,139,881 shares of HLTH Common Stock outstanding to these
individuals. The terms of these grants are similar to the terms
of the options granted under the Plans and accordingly, the
stock option activity of these individuals is included in all
references to the Plans. Beginning in April 2007, shares are
issued from treasury stock when options are exercised or
restricted stock is granted. Prior to this time, new shares were
issued in connection with these transactions.
Stock
Options
Generally, options under the Plans vest and become exercisable
ratably over a three to five year period based on their
individual grant dates subject to continued employment on the
applicable vesting dates. The majority of options granted under
the Plans expire within ten years from the date of grant.
Options are granted at prices not less than the fair market
value of HLTH Common Stock on the date of grant. The following
table summarizes activity for the Plans for the nine months
ended September 30, 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
Average
|
|
|
|
|
|
|
|
|
|
Average
|
|
|
Remaining
|
|
|
Aggregate
|
|
|
|
|
|
|
Exercise Price
|
|
|
Contractual
|
|
|
Intrinsic
|
|
|
|
Shares
|
|
|
Per Share
|
|
|
Life (In Years)
|
|
|
Value (1)
|
|
|
Outstanding at January 1, 2008
|
|
|
47,293,577
|
|
|
$
|
14.35
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
120,000
|
|
|
|
13.40
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(2,339,811
|
)
|
|
|
7.65
|
|
|
|
|
|
|
|
|
|
Cancelled
|
|
|
(1,405,760
|
)
|
|
|
16.88
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at September 30, 2008
|
|
|
43,668,006
|
|
|
$
|
14.63
|
|
|
|
3.0
|
|
|
$
|
33,489
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vested and exercisable at the end of the period
|
|
|
39,218,041
|
|
|
$
|
15.11
|
|
|
|
2.5
|
|
|
$
|
27,417
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
The aggregate intrinsic value is
based on the market price of HLTHs Common Stock on
September 30, 2008, which was $11.43, less the applicable
exercise price of the underlying option. This aggregate
intrinsic value represents the amount that would have been
realized if all of the option holders had exercised their
options on September 30, 2008.
|
19
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The fair value of each option granted is estimated on the date
of grant using the Black-Scholes option pricing model,
considering the assumptions noted in the following table.
Expected volatility is based on implied volatility from traded
options of HLTH Common Stock combined with historical volatility
of HLTH Common Stock. Prior to January 1, 2006, only
historical volatility was considered. The expected term
represents the period of time that options are expected to be
outstanding following their grant date, and was determined using
historical exercise data. The risk-free rate is based on the
U.S. Treasury yield curve for periods equal to the expected
term of the options on the grant date.
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
Expected dividend yield
|
|
|
0
|
%
|
|
|
0
|
%
|
Expected volatility
|
|
|
0.33
|
|
|
|
0.31
|
|
Risk-free interest rate
|
|
|
2.82
|
%
|
|
|
4.67
|
%
|
Expected term (years)
|
|
|
3.81
|
|
|
|
3.94
|
|
Weighted average fair value of options granted during the period
|
|
$
|
3.92
|
|
|
$
|
4.01
|
|
Restricted
Stock Awards
HLTH Restricted Stock consists of shares of HLTH Common Stock
which have been awarded to employees with restrictions that
cause them to be subject to substantial risk of forfeiture and
restrict their sale or other transfer by the employee until they
vest. Generally, HLTH Restricted Stock awards vest ratably over
a three to five year period from their individual award dates
subject to continued employment on the applicable vesting dates.
The following table summarizes the activity of non-vested HLTH
Restricted Stock for the nine months ended September 30,
2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
Average
|
|
|
|
|
|
|
Grant Date
|
|
|
|
Shares
|
|
|
Fair Value
|
|
|
Balance at January 1, 2008
|
|
|
1,240,297
|
|
|
$
|
10.74
|
|
Vested
|
|
|
(181,769
|
)
|
|
|
9.53
|
|
Forfeited
|
|
|
(35,837
|
)
|
|
|
11.26
|
|
|
|
|
|
|
|
|
|
|
Balance at September 30, 2008
|
|
|
1,022,691
|
|
|
$
|
10.94
|
|
|
|
|
|
|
|
|
|
|
Proceeds received from the exercise of options to purchase HLTH
Common Stock were $10,624 and $17,901 for the three and nine
months ended September 30, 2008, respectively, and $8,821
and $107,635 for the three and nine months ended
September 30, 2007, respectively. The intrinsic value
related to the exercise of these stock options, as well as the
fair value of shares of HLTH Restricted Stock that vested was
$6,513 and $11,840 for the three and nine months ended
September 30, 2008, respectively, and $4,703 and $55,635
for the three and nine months ended September 30, 2007,
respectively.
WebMD
Plans
During September 2005, WHC adopted the 2005 Long-Term Incentive
Plan (the WHC Plan). In connection with the
acquisition of Subimo, LLC, in December 2006, WHC adopted the
WebMD Health Corp. Long-Term Incentive Plan for Employees of
Subimo, LLC (the Subimo Plan). The terms of the
Subimo Plan are similar to the terms of the WHC Plan but it has
not been approved by WHC stockholders. Awards under the Subimo
Plan were made on the date of the Companys acquisition of
Subimo, LLC in reliance on the NASDAQ Global Select Market
exception to shareholder approval for equity grants to new
hires. No additional grants will be made under the Subimo Plan.
The WHC Plan and the Subimo Plan are included in
20
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
all references as the WebMD Plans. The maximum
number of shares of WHC Class A Common Stock that may be
subject to options or restricted stock awards under the WebMD
Plans is 9,480,574, subject to adjustment in accordance with the
terms of the WebMD Plans. WHC had an aggregate of
2,440,150 shares of Class A Common Stock available for
future grants under the WebMD Plans at September 30, 2008.
Stock
Options
Generally, options under the WebMD Plans vest and become
exercisable ratably over a four year period based on their
individual grant dates subject to continued employment on the
applicable vesting dates. The options granted under the WebMD
Plans expire within ten years from the date of grant. Options
are granted at prices not less than the fair market value of
WHCs Class A Common Stock on the date of grant. The
following table summarizes activity for the WebMD Plans for the
nine months ended September 30, 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
Average
|
|
|
|
|
|
|
|
|
|
Average
|
|
|
Remaining
|
|
|
Aggregate
|
|
|
|
|
|
|
Exercise Price
|
|
|
Contractual
|
|
|
Intrinsic
|
|
|
|
Shares
|
|
|
Per Share
|
|
|
Life (In Years)
|
|
|
Value (1)
|
|
|
Outstanding at January 1, 2008
|
|
|
5,020,551
|
|
|
$
|
27.56
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
609,800
|
|
|
|
32.19
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(196,652
|
)
|
|
|
17.56
|
|
|
|
|
|
|
|
|
|
Cancelled
|
|
|
(373,551
|
)
|
|
|
31.42
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at September 30, 2008
|
|
|
5,060,148
|
|
|
$
|
28.23
|
|
|
|
7.8
|
|
|
$
|
32,163
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vested and exercisable at the end of the period
|
|
|
2,239,061
|
|
|
$
|
22.22
|
|
|
|
7.2
|
|
|
$
|
21,487
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
The aggregate intrinsic value is
based on the market price of WHCs Class A Common
Stock on September 30, 2008, which was $29.74, less the
applicable exercise price of the underlying option. This
aggregate intrinsic value represents the amount that would have
been realized if all of the option holders had exercised their
options on September 30, 2008.
|
The fair value of each option granted is estimated on the date
of grant using the Black-Scholes option pricing model,
considering the assumptions noted in the following table. Prior
to August 1, 2007, expected volatility was based on implied
volatility from traded options of stock of comparable companies
combined with historical stock price volatility of comparable
companies. Beginning on August 1, 2007, expected volatility
is based on implied volatility from traded options of WHC
Class A Common Stock combined with historical volatility of
WHC Class A Common Stock. The expected term represents the
period of time that options are expected to be outstanding
following their grant date, and was determined using historical
exercise data of WHC employees who were previously granted HLTH
stock options. The risk-free rate is based on the
U.S. Treasury yield curve for periods equal to the expected
term of the options on the grant date.
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
Expected dividend yield
|
|
|
0
|
%
|
|
|
0
|
%
|
Expected volatility
|
|
|
0.44
|
|
|
|
0.45
|
|
Risk-free interest rate
|
|
|
2.46
|
%
|
|
|
4.65
|
%
|
Expected term (years)
|
|
|
3.25
|
|
|
|
3.34
|
|
Weighted average fair value of options granted during the period
|
|
$
|
10.75
|
|
|
$
|
18.16
|
|
21
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Restricted
Stock Awards
WHC Restricted Stock consists of shares of WHC Class A
Common Stock which have been awarded to employees with
restrictions that cause them to be subject to substantial risk
of forfeiture and restrict their sale or other transfer by the
employee until they vest. Generally, WHC Restricted Stock awards
vest ratably over a four year period from their individual award
dates subject to continued employment on the applicable vesting
dates. The following table summarizes the activity of non-vested
WHC Restricted Stock for the nine months ended
September 30, 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
Average
|
|
|
|
|
|
|
Grant Date
|
|
|
|
Shares
|
|
|
Fair Value
|
|
|
Balance at January 1, 2008
|
|
|
307,722
|
|
|
$
|
29.46
|
|
Granted
|
|
|
19,000
|
|
|
|
28.32
|
|
Vested
|
|
|
(90,687
|
)
|
|
|
21.59
|
|
Forfeited
|
|
|
(12,500
|
)
|
|
|
21.86
|
|
|
|
|
|
|
|
|
|
|
Balance at September 30, 2008
|
|
|
223,535
|
|
|
$
|
32.98
|
|
|
|
|
|
|
|
|
|
|
Proceeds received from the exercise of options to purchase WHC
Class A Common Stock were $1,061 and $3,453 for the three
and nine months ended September 30, 2008, respectively, and
$2,767 and $8,490 for the three and nine months ended
September 30, 2007, respectively. The intrinsic value
related to the exercise of these stock options, as well as the
fair value of shares of WHC Restricted Stock that vested was
$3,299 and $5,769 for the three and nine months ended
September 30, 2008, respectively, and $8,203 and $15,291
for the three and nine months ended September 30, 2007,
respectively.
Employee
Stock Purchase Plan
The Companys 1998 Employee Stock Purchase Plan, as amended
from time to time (the ESPP), allowed eligible
employees the opportunity to purchase shares of HLTH Common
Stock through payroll deductions, up to 15% of a
participants annual compensation with a maximum of
5,000 shares available per participant during each purchase
period. The purchase price of the stock was 85% of the fair
market value on the last day of each purchase period. The ESPP
provided for annual increases equal to the lesser of
1,500,000 shares, 0.5% of the outstanding common shares, or
a lesser amount determined by the Board of Directors. There were
49,125 and 34,610 shares issued under the ESPP during the
nine months ended September 30, 2008 and 2007,
respectively. The ESPP was terminated after the purchase period
that ended on April 30, 2008.
Other
At the time of the WHC initial public offering and each year on
the anniversary of the initial public offering, WHC issued
shares of WHC Class A Common Stock to each non-employee
director with a value equal to their annual board and committee
retainers. The Company recorded stock-based compensation expense
of $85 during the three months ended September 30, 2008 and
2007 and $255 during the nine months ended September 30,
2008 and 2007 in connection with these issuances.
Additionally, the Company recorded stock-based compensation
expense of $279 for the three months ended September 30,
2008 and 2007, and $837 and $815 for the nine months ended
September 30, 2008 and 2007, respectively, in connection
with a stock transferability right for shares required to be
issued in connection with the acquisition of Subimo, LLC by WHC.
22
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Summary
of Stock-Based Compensation Expense
The following table summarizes the components and classification
of stock-based compensation expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
HLTH Plans:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options
|
|
$
|
2,127
|
|
|
$
|
2,791
|
|
|
$
|
5,743
|
|
|
$
|
9,040
|
|
Restricted stock
|
|
|
1,525
|
|
|
|
1,633
|
|
|
|
4,253
|
|
|
|
4,759
|
|
WHC Plans:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options
|
|
|
2,682
|
|
|
|
4,295
|
|
|
|
7,858
|
|
|
|
11,587
|
|
Restricted stock
|
|
|
456
|
|
|
|
820
|
|
|
|
1,260
|
|
|
|
2,429
|
|
Employee Stock Purchase Plan
|
|
|
|
|
|
|
42
|
|
|
|
51
|
|
|
|
127
|
|
Other
|
|
|
372
|
|
|
|
375
|
|
|
|
1,097
|
|
|
|
1,081
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stock-based compensation expense
|
|
$
|
7,162
|
|
|
$
|
9,956
|
|
|
$
|
20,262
|
|
|
$
|
29,023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Included in:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of operations
|
|
$
|
1,005
|
|
|
$
|
1,597
|
|
|
$
|
2,950
|
|
|
$
|
4,159
|
|
Sales and marketing
|
|
|
1,222
|
|
|
|
1,252
|
|
|
|
3,624
|
|
|
|
3,889
|
|
General and administrative
|
|
|
4,304
|
|
|
|
6,436
|
|
|
|
12,400
|
|
|
|
18,198
|
|
Equity in earnings of EBS Master LLC
|
|
|
|
|
|
|
240
|
|
|
|
|
|
|
|
1,039
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
6,531
|
|
|
|
9,525
|
|
|
|
18,974
|
|
|
|
27,285
|
|
Income from discontinued operations
|
|
|
631
|
|
|
|
431
|
|
|
|
1,288
|
|
|
|
1,738
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stock-based compensation expense
|
|
$
|
7,162
|
|
|
$
|
9,956
|
|
|
$
|
20,262
|
|
|
$
|
29,023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of September 30, 2008, approximately $13,035 and $31,887
of unrecognized stock-based compensation expense related to
unvested awards (net of estimated forfeitures) is expected to be
recognized over a weighted-average period of approximately
0.7 years and 1.5 years, related to the HLTH Plans and
the WebMD Plans, respectively.
Pending
Tender Offer
On October 27, 2008, the Company commenced a tender offer
to purchase up to 80,000,000 shares of its Common Stock at
a price of $8.80 per share (the Pending Tender
Offer). The Pending Tender Offer is expected to be
completed in November 2008, subject to a number of terms and
conditions, including that a minimum of 40,000,000 shares
be properly tendered and not withdrawn in the offer.
Stock
Repurchase Program
In December 2006, the Company announced the authorization of a
stock repurchase program (the Program), at which
time the Company was authorized to use up to $100,000 to
purchase shares of HLTH Common Stock from time to time beginning
on December 19, 2006, subject to market conditions. As of
September 30, 2008 and 2007, respectively, the Company had
repurchased 4,280,931 and 4,268,895 shares at an aggregate
cost of approximately $58,447 and $58,444 under the Program. No
shares were repurchased during the nine months ended
September 30, 2008. Repurchased shares are recorded under
the cost method and are reflected as treasury stock in the
accompanying consolidated balance sheets.
23
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
9.
|
Fair
Value of Financial Instruments and Credit Facilities
|
Effective January 1, 2008, the Company adopted
SFAS No. 157, Fair Value Measurements
(SFAS 157), for assets and liabilities measured
at fair value on a recurring basis. SFAS 157 establishes a
common definition for fair value to be applied to existing GAAP
that require the use of fair value measurements, establishes a
framework for measuring fair value and expands disclosure about
such fair value measurements. The adoption of SFAS 157 did
not have an impact on the Companys financial position or
operating results, but did expand certain disclosures.
SFAS 157 defines fair value as the price that would be
received to sell an asset or paid to transfer a liability in an
orderly transaction between market participants at the
measurement date. Additionally, SFAS 157 requires the use
of valuation techniques that maximize the use of observable
inputs and minimize the use of unobservable inputs. These inputs
are prioritized below:
|
|
|
|
Level 1:
|
Observable inputs such as quoted market prices in active markets
for identical assets or liabilities, such as the Companys
equity securities reflected in the table below.
|
|
|
Level 2:
|
Observable market-based inputs or unobservable inputs that are
corroborated by market data.
|
|
|
Level 3:
|
Unobservable inputs for which there is little or no market data,
which require the use of the reporting entitys own
assumptions.
|
The Company did not have any Level 2 assets as of
September 30, 2008. The following table sets forth the
Companys Level 1 and Level 3 financial assets
that were measured at fair value as of September 30, 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 1
|
|
Level 3
|
|
Total
|
|
Auction rate securities
|
|
$
|
|
|
|
$
|
284,408
|
|
|
$
|
284,408
|
|
Equity securities
|
|
|
2,175
|
|
|
|
|
|
|
|
2,175
|
|
The following table reconciles the beginning and ending balances
of the Companys Level 3 assets which consist of the
Companys ARS:
|
|
|
|
|
Balance as of January 1, 2008
|
|
$
|
|
|
Transfers to Level 3
|
|
|
363,700
|
|
Redemptions
|
|
|
(7,900
|
)
|
Impariment charge included in earnings
|
|
|
(60,108
|
)
|
Interest accretion included in earnings
|
|
|
632
|
|
Unrealized loss included in other comprehensive income
|
|
|
(11,916
|
)
|
|
|
|
|
|
Fair Value as of September 30, 2008
|
|
$
|
284,408
|
|
|
|
|
|
|
The Company holds investments in action rate securities
(ARS) which have been classified as Level 3
assets as described above. The types of ARS holdings the Company
owns are backed by student loans, 97% of which are guaranteed
under the Federal Family Education Loan Program (FFELP), and all
had credit ratings of AAA or Aaa when purchased. Historically,
the fair value of the Companys ARS holdings approximated
face value due to the frequent auction periods, generally every
7 to 28 days, which provided liquidity to these
investments. However, since February 2008, virtually all
auctions involving these securities have failed. The result of a
failed auction is that these ARS holdings will continue to pay
interest in accordance with their terms at each respective
auction date; however, liquidity of the securities will be
limited until there is a successful auction, the issuer redeems
the securities, the securities mature or until such time as
other markets for these ARS holdings develop. During the three
months ended March 31, 2008, the Company concluded that the
estimated fair value of the ARS holdings no longer approximated
the face value due to the lack of liquidity. The securities have
been classified within Level 3 as their valuation requires
substantial judgment
24
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
and estimation of factors that are not currently observable in
the market due to the lack of trading in the securities.
The Company estimated the fair value of its ARS holdings using
an income approach valuation technique. Using this approach,
expected future cash flows were calculated over the expected
life of each security and were discounted to a single present
value using a market required rate of return. Some of the more
significant assumptions made in the present value calculations
were (i) the estimated weighted average lives for the loan
portfolios underlying each individual ARS, which range from 4 to
14 years and (ii) the required rates of return used to
discount the estimated future cash flows over the estimated life
of each security, which considered both the credit quality for
each individual ARS and the market liquidity for these
investments. As of March 31, 2008, the Company concluded
the fair value of its ARS holdings was $302,842 (of which
$141,044 relates to WHC), compared to a face value of $362,950
(of which $168,450 relates to WHC). The impairment in value, or
$60,108 (of which $27,406 relates to WHC), was considered to be
other-than-temporary and, accordingly, was recorded as an
impairment charge within the statement of operations during the
three months ended March 31, 2008.
In making the determination that the impairment was
other-than-temporary, the Company considered (i) the
current market liquidity for ARS, particularly student loan
backed ARS, (ii) the long-term maturities of the loan
portfolios underlying each ARS owned by the Company which, on a
weighted average basis, extend to as many as 14 years and
(iii) the ability and intent of the Company to hold its ARS
investments until sufficient liquidity returns to the auction
rate market to enable the sale of these securities or until the
investments mature.
During the three and nine months ended September 30, 2008,
the Company received $5,100 (of which $2,000 relates to WHC) and
$7,900 (of which $3,700 relates to WHC), respectively,
associated with the partial redemption of certain of its ARS
holdings, which represented 100% of their face value. As a
result, as of September 30, 2008, the total face value of
the Companys ARS holdings was $355,800, of which $165,500
relates to WHC. During the three months ended June 30, 2008
and September 30, 2008, the Company reduced the carrying
value of its ARS holdings by $3,019 and $8,897, respectively.
The Company assessed these declines in fair market value to be
temporary as they resulted from fluctuations in interest rate
assumptions and, therefore, recorded these declines as an
unrealized loss in other comprehensive income in the
accompanying consolidated balance sheet.
The Company continues to monitor the market for ARS as well as
the individual ARS holdings it owns. The Company may be required
to record additional losses in future periods if the fair value
of its ARS holdings deteriorates further.
Credit
Facilities
On May 6, 2008, the Company and WHC each entered into a
non-recourse credit facility (each a Credit
Facility) with Citigroup that is secured by their
respective ARS holdings (including, in some circumstances,
interest payable on the ARS holdings), that will allow the
Company and WHC to borrow up to 75% of the face amount of the
ARS holdings pledged as collateral under the respective Credit
Facilities. The Credit Facilities are each governed by a loan
agreement, dated as of May 6, 2008, containing customary
representations and warranties of the borrower and certain
affirmative covenants and negative covenants relating to the
pledged collateral. Under each of the loan agreements, the
borrower and the lender may, in certain circumstances, cause the
pledged collateral to be sold, with the proceeds of any such
sale required to be applied in full immediately to repayment of
amounts borrowed. No borrowings have been made under either
Credit Facility to date. The Company and WHC can each make
borrowings under the Credit Facility until May 2009. The
interest rate applicable to such borrowings will be one-month
LIBOR plus 250 basis points. Any borrowings outstanding
under the Credit Facility after March 2009 become demand loans,
subject to 60 days notice, with recourse only to the
pledged collateral.
25
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
10.
|
Comprehensive
Income (Loss)
|
Comprehensive income (loss) is comprised of net income (loss)
and other comprehensive (loss) income. Other comprehensive
(loss) income includes foreign currency translation adjustments
and certain changes in equity that are excluded from net income
(loss), such as changes in unrealized holding gains and losses
on available-for-sale marketable securities and 48% of the
comprehensive income (loss) of EBSCo. The following table
presents the components of comprehensive income (loss):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
Foreign currency translation (losses) gains
|
|
$
|
(4,488
|
)
|
|
$
|
1,554
|
|
|
$
|
(1,200
|
)
|
|
$
|
2,391
|
|
Unrealized holding (losses) gains on securities
|
|
|
(8,564
|
)
|
|
|
(532
|
)
|
|
|
(11,193
|
)
|
|
|
2
|
|
EBSCo interest rate swap agreement
|
|
|
|
|
|
|
(5,918
|
)
|
|
|
7,326
|
|
|
|
(2,429
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive loss
|
|
|
(13,052
|
)
|
|
|
(4,896
|
)
|
|
|
(5,067
|
)
|
|
|
(36
|
)
|
Net income (loss)
|
|
|
95,881
|
|
|
|
16,571
|
|
|
|
556,172
|
|
|
|
(23,190
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income (loss)
|
|
$
|
82,829
|
|
|
$
|
11,675
|
|
|
$
|
551,105
|
|
|
$
|
(23,226
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Included in comprehensive income (loss) for the three and nine
months ended September 30, 2007 is the Companys share
of unrealized gains on the fair value of EBSCos interest
rate swap agreements, and for the nine months ended
September 30, 2008 is the reversal, in connection with the
2008 EBSCo Sale, of the net cumulative loss related to these
agreements.
Deferred taxes are not included within accumulated other
comprehensive income because a valuation allowance was
maintained for substantially all net deferred tax assets.
Accumulated other comprehensive income includes:
|
|
|
|
|
|
|
|
|
|
|
September 30, 2008
|
|
|
December 31, 2007
|
|
|
Unrealized holding (losses) gains on securities
|
|
$
|
(10,283
|
)
|
|
$
|
910
|
|
Foreign currency translation gains
|
|
|
11,069
|
|
|
|
12,269
|
|
Comprehensive loss of EBSCo
|
|
|
|
|
|
|
(7,326
|
)
|
|
|
|
|
|
|
|
|
|
Total accumulated other comprehensive income
|
|
$
|
786
|
|
|
$
|
5,853
|
|
|
|
|
|
|
|
|
|
|
|
|
11.
|
Goodwill
and Other Intangible Assets
|
The changes in the carrying amount of goodwill for the year
ended December 31, 2007 and the nine months ended
September 30, 2008 are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
WebMD
|
|
|
|
|
|
|
WebMD
|
|
|
Publishing
|
|
|
|
|
|
|
Online
|
|
|
and Other
|
|
|
|
|
|
|
Services
|
|
|
Services
|
|
|
Total
|
|
|
Balance as of January 1, 2007
|
|
$
|
212,439
|
|
|
$
|
11,045
|
|
|
$
|
223,484
|
|
Reversal of income tax valuation allowance
|
|
|
(2,793
|
)
|
|
|
|
|
|
|
(2,793
|
)
|
Adjustments to finalize purchase price allocations
|
|
|
(3,368
|
)
|
|
|
|
|
|
|
(3,368
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2008
|
|
|
206,278
|
|
|
|
11,045
|
|
|
|
217,323
|
|
Reversal of income tax valuation allowance
|
|
|
(5,761
|
)
|
|
|
|
|
|
|
(5,761
|
)
|
Adjustments to finalize purchase price allocations
|
|
|
(148
|
)
|
|
|
|
|
|
|
(148
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of September 30, 2008
|
|
$
|
200,369
|
|
|
$
|
11,045
|
|
|
$
|
211,414
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Intangible assets subject to amortization consist of the
following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2008
|
|
|
December 31, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
Gross
|
|
|
|
|
|
|
|
|
Average
|
|
|
Gross
|
|
|
|
|
|
|
|
|
Average
|
|
|
|
Carrying
|
|
|
Accumulated
|
|
|
|
|
|
Remaining
|
|
|
Carrying
|
|
|
Accumulated
|
|
|
|
|
|
Remaining
|
|
|
|
Amount
|
|
|
Amortization
|
|
|
Net
|
|
|
Useful Life (a)
|
|
|
Amount
|
|
|
Amortization
|
|
|
Net
|
|
|
Useful Life (a)
|
|
|
Content
|
|
$
|
15,954
|
|
|
$
|
(14,051
|
)
|
|
$
|
1,903
|
|
|
|
1.7
|
|
|
$
|
15,954
|
|
|
$
|
(12,581
|
)
|
|
$
|
3,373
|
|
|
|
2.1
|
|
Customer relationships
|
|
|
33,191
|
|
|
|
(12,798
|
)
|
|
|
20,393
|
|
|
|
8.8
|
|
|
|
33,191
|
|
|
|
(10,183
|
)
|
|
|
23,008
|
|
|
|
9.2
|
|
Technology and patents
|
|
|
14,967
|
|
|
|
(12,844
|
)
|
|
|
2,123
|
|
|
|
0.9
|
|
|
|
14,967
|
|
|
|
(10,126
|
)
|
|
|
4,841
|
|
|
|
1.5
|
|
Trade names
|
|
|
7,817
|
|
|
|
(3,319
|
)
|
|
|
4,498
|
|
|
|
7.1
|
|
|
|
7,817
|
|
|
|
(2,725
|
)
|
|
|
5,092
|
|
|
|
7.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
71,929
|
|
|
$
|
(43,012
|
)
|
|
$
|
28,917
|
|
|
|
7.5
|
|
|
$
|
71,929
|
|
|
$
|
(35,615
|
)
|
|
$
|
36,314
|
|
|
|
7.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
|
The calculation of the weighted
average remaining useful life is based on the net book value and
the remaining amortization period (reflected in years) of each
respective intangible asset.
|
Amortization expense was $2,406 and $7,397 for the three and
nine months ended September 30, 2008, respectively, and
$3,320 and $9,853 for the three and nine months ended
September 30, 2007, respectively. Aggregate amortization
expense for intangible assets is estimated to be:
|
|
|
|
|
Years Ending December 31:
|
|
|
|
|
2008 (October 1st to December 31st)
|
|
$
|
2,318
|
|
2009
|
|
|
6,401
|
|
2010
|
|
|
3,337
|
|
2011
|
|
|
2,464
|
|
2012
|
|
|
2,464
|
|
Thereafter
|
|
|
11,933
|
|
|
|
12.
|
Commitments
and Contingencies
|
Investigations
by United States Attorney for the District of South Carolina and
the SEC
As previously disclosed, the United States Attorney for the
District of South Carolina is conducting an investigation of the
Company, which the Company first learned about on
September 3, 2003. Based on the information available to
the Company, it believes that the investigation relates
principally to issues of financial accounting improprieties
relating to Medical Manager Corporation, a predecessor of the
Company (by its merger into the Company in September 2000), and,
more specifically, its Medical Manager Health Systems, Inc.
subsidiary. Medical Manager Health Systems was a predecessor to
Emdeon Practice Services, Inc., a subsidiary that the Company
sold to Sage Software in September 2006. The Company has been
cooperating and intends to continue to cooperate fully with the
U.S. Attorneys Office. As previously reported, the
Board of Directors of the Company has formed a special committee
consisting solely of independent directors to oversee this
matter with the sole authority to direct the Companys
response to the allegations that have been raised. As previously
disclosed, the Company understands that the SEC is also
conducting a formal investigation into this matter. In
connection with the EPS Sale, the Company agreed to indemnify
Sage Software with respect to this matter.
The United States Attorney for the District of South Carolina
announced on January 10, 2005, that three former employees
of Medical Manager Health Systems each had agreed to plead
guilty to one count of mail fraud and that one such employee had
agreed to plead guilty to one count of tax evasion for acts
committed while they were employed by Medical Manager Health
Systems. The three former employees include a Vice President of
Medical Manager Health Systems responsible for acquisitions who
was terminated for cause in January 2003; an executive who
served in various accounting roles at Medical Manager Health
Systems until his resignation in March 2002; and a former
independent Medical Manager dealer who was a paid consultant to
Medical Manager Health Systems until the termination of his
services in 2002. According to the
27
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Informations, Plea Agreements and Factual Summaries filed by the
United States Attorney in, and available from, the District
Court of the United States for the District of South
Carolina Beaufort Division, on January 7, 2005,
the three former employees and other then unnamed co-schemers
were engaged in schemes between 1997 and 2002 that included
causing companies acquired by Medical Manager Health Systems to
pay the former vice president in charge of acquisitions and
co-schemers kickbacks which were funded through increases in the
purchase price paid by Medical Manager Health Systems to the
acquired companies and that included fraudulent accounting
practices to artificially inflate the quarterly revenues and
earnings of Medical Manager Health Systems when it was an
independent public company called Medical Manager Corporation
from 1997 through 1999, when and after it was acquired by
Synetic, Inc. in July 1999 and when and after it became a
subsidiary of the Company in September 2000. A fourth former
officer of Medical Manager Health Systems pled guilty to similar
activities later in 2005.
The fraudulent accounting practices cited by the government in
the January 7, 2005 District Court filings included:
causing companies acquired by Medical Manager Health Systems to
reclassify previously recognized sales revenue as deferred
income so that such deferred income could subsequently be
reported as revenue by Medical Manager Health Systems and its
parents in later periods; fabricating deferred revenue entries
which could be used to inflate earnings when Medical Manager
Health Systems acquired companies; causing companies acquired by
Medical Manager Health Systems to inflate reserve accounts so
that these reserves could be reversed in later reporting periods
in order to artificially inflate earnings for Medical Manager
Health Systems and its parents; accounting for numerous
acquisitions through the pooling of interests method in order to
fraudulently inflate Medical Manager Health Systems
quarterly earnings, when the individuals involved knew the
transactions failed to qualify for such treatment; causing
companies acquired by Medical Manager Health Systems to enter
into sham purchases of software from Medical Manager Health
Systems in connection with the acquisition which purchases were
funded by increasing the purchase price paid by Medical Manager
Health Systems to the acquired company and using these
round trip sales to create fraudulent revenue for
Medical Manager Health Systems and its parents; and causing
Medical Manager Health Systems to book and record sales and
training revenue before the revenue process was complete in
accordance with GAAP and thereby fraudulently inflating Medical
Manager Health Systems reported revenues and earnings. According
to the Informations to which the former employees have pled
guilty, the fraudulent accounting practices resulted in the
reported revenues of Medical Manager Health Systems and its
parents being overstated materially between June 1997 and at
least December 31, 2001, and reported quarterly earnings
being overstated by at least one cent per share in every quarter
during that period.
The documents filed by the United States Attorney in January
2005 stated that the former employees engaged in their
fraudulent conduct in concert with senior
management, and at the direction of senior Medical
Manager officers. In its statement at that time, the
United States Attorney for the District of South Carolina stated
that the senior management and officers referred to in the
Court documents were members of senior management of the Medical
Manager subsidiary during the relevant time period.
On December 15, 2005, the United States Attorney announced
indictments of the following former officers and employees of
Medical Manager Health Systems: Ted W. Dorman, a former Regional
Vice President of Medical Manager Health Systems, who was
employed until March 2003; Charles L. Hutchinson, a former
Controller of Medical Manager Health Systems, who was employed
until June 2001; Maxie L. Juzang, a former Vice President of
Medical Manager Health Systems, who was employed until August
2005; John H. Kang, a former President of Medical Manager Health
Systems, who was employed until May 2001; Frederick B.
Karl, Jr., a former General Counsel of Medical Manager
Health Systems, who was employed until April 2000; Franklyn B.
Krieger, a former Associate General Counsel of Medical Manager
Health Systems, who was employed until February 2002; Lee A.
Robbins, a former Vice President and Chief Financial Officer of
Medical Manager Health Systems, who was employed until September
2000; John P. Sessions, a former President and Chief Operating
Officer of Medical Manager Health Systems, who was employed
until September 2003; Michael A. Singer, a former Chief
Executive Officer of Medical Manager
28
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Health Systems and a former director of the Company, who was
most recently employed by the Company as its Executive Vice
President, Physician Software Strategies until February 2005;
and David Ward, a former Vice President of Medical Manager
Health Systems, who was employed until June 2005. The indictment
charges the persons listed above with conspiracy to commit mail,
wire and securities fraud, a violation of Title 18, United
States Code, Section 371 and conspiracy to commit money
laundering, a violation of Title 18, United States Code,
Section 1956(h). The indictment charges
Messrs. Sessions and Ward with substantive counts of money
laundering, violations of Title 18, United States Code,
Section 1957. The allegations set forth in the indictment
describe activities that are substantially similar to those
described above with respect to the January 2005 plea agreements.
On February 27, 2007, the United States Attorney filed a
Second Superseding Indictment with respect to the former
officers and employees of Medical Manager Health Systems charged
under the prior Indictment, other than Mr. Juzang. The
allegations set forth in the Second Superseding Indictment are
substantially similar to those described above. The trial of the
indicted former officers and directors of Medical Manager Health
Systems has been scheduled for February 2, 2009.
Mr. Robbins passed away on September 27, 2008 and on
October 15, 2008 the court granted a motion to dismiss
Mr. Robbins from the Second Superseding Indictment.
Based on the information it has obtained to date, including that
contained in the court documents filed by the United States
Attorney in South Carolina, the Company does not believe that
any member of its senior management whose duties were not
primarily related to the operations of Medical Manager Health
Systems during the relevant time periods engaged in any of the
violations or improprieties described in those court documents.
The Company understands, however, that in light of the nature of
the allegations involved, the U.S. Attorneys office
has been investigating all levels of the Companys
management. The Company has not uncovered information that it
believes would require a restatement for any of the years
covered by its financial statements. In addition, the Company
believes that the amounts of the kickback payments referred to
in the court documents have already been reflected in the
financial statements of the Company to the extent required.
The Company has certain indemnity obligations to advance amounts
for reasonable defense costs for the initial ten, and now eight,
former officers and directors of EPS. During the year ended
December 31, 2007, the Company recorded a pre-tax charge of
$73,347, related to its estimated liability with respect to
these indemnity obligations. During the three months ended
June 30, 2008, the Company recorded an additional pre-tax
charge of $16,980 which reflects an increase to the
Companys estimated liability related to this matter. See
Note 2 for a more detailed discussion regarding this charge.
Directors &
Officers Liability Insurance Coverage Litigation
On July 23, 2007, the Company commenced litigation (the
Coverage Litigation) in the Court of Chancery of the
State of Delaware in and for New Castle County against ten
insurance companies in which the Company is seeking to compel
the defendant companies (collectively, the
Defendants) to honor their obligations under certain
directors and officers liability insurance policies (the
Policies). The Company is seeking an order requiring
the Defendants to advance
and/or
reimburse expenses that the Company has incurred and expects to
continue to incur for the advancement of the reasonable defense
costs of initially ten, and now eight, former officers and
directors of the Companys former EPS subsidiary who were
indicted in connection with the Investigation described above in
this Note 12. The Company subsequently has settled with two
of the insurance companies during January 2008, through which
the Company received an aggregate amount of $14,625. This amount
was included within (loss) income from discontinued operations
in the statement of operations during the three months ended
December 31, 2007 and was included within prepaid expenses
and other current assets in the accompanying consolidated
balance sheet as of December 31, 2007.
Pursuant to a stipulation among the parties, the Coverage
Litigation was transferred on September 13, 2007 to the
Superior Court of the State of Delaware in and for New Castle
County. The Policies were issued to the Company and to EPS, a
former subsidiary of the Company, which is a co-plaintiff with
the Company in the Coverage Litigation (collectively, the
Plaintiffs). EPS was sold in September 2006 to Sage
Software and
29
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
has changed its name to Sage Software Healthcare, Inc.
(SSHI). In connection with the Companys sale
of EPS to Sage Software, the Company retained certain
obligations relating to the Investigation and agreed to
indemnify Sage Software and SSHI with respect to certain
expenses in connection with the Investigation. The Company
retained the right to assert claims and recover proceeds under
the Policies on behalf of SSHI.
The Policies at issue in the Coverage Litigation consist of two
separate groups of insurance policies. Each group of policies
consists of several layers of coverage, with different insurers
having agreed to provide specified amounts of coverage at
various levels. The first group of policies was issued to EPS in
the amount of $20,000 (the EPS Policies) and the
second group of policies was issued to Synetic, Inc. (the former
parent of EPS, which merged into the Company) in the amount of
$100,000, of which approximately $3,600 was paid by the primary
carrier with respect to another unrelated matter (the
Synetic Policies). As of September 30, 2008,
$50,950 has been paid by insurance companies representing the
EPS Policies and the Synetic Policies through a combination of
payment under the terms of the Policies, payment under
reservation of rights and settlement. Of this amount, $19,912
has been reimbursed by the insurance companies subsequent to the
Courts order on July 31, 2008 (described in more
detail below). The Company has deferred recognizing this amount
as income given the fact that the Coverage Litigation is ongoing
and accordingly this amount has been deferred on the balance
sheet as of September 30, 2008 within Liabilities of
Discontinued Operations. As a result of these payments, the
Company has exhausted its coverage under the EPS Policies and
has remaining coverage under the Synetic Policies of
approximately $60,000.
The carrier with the third level of coverage in the Synetic
Policies filed a motion for summary judgment in the Coverage
Litigation, which most of the carriers who have issued the
Synetic policies joined, which sought summary judgment that any
liability to pay defense costs should be allocated among the
three sets of policies available to the Company (including the
policies with respect to which the Coverage Litigation relates
and a third set of policies the issuers of which had not yet
been named by the Company) such that the Synetic Policies would
only be liable to pay about $23,000 of the $96,400 total
coverage available under such policies. The Company filed its
opposition to the motion together with its motion for summary
judgment against such carrier and several other carriers who
have issued the Synetic Policies seeking to require such
carriers to advance payment of the defense costs that the
Company is obligated to pay while the Coverage Litigation is
pending. On July 31, 2008, the Superior Court for the State
of Delaware denied the motion filed by the carriers seeking
allocation and granted the Companys motion for partial
summary judgment to enforce the duty of such carriers to advance
and reimburse these costs. Pursuant to the Courts order
the issuers of the Synetic Policies have been reimbursing the
Company for its costs. Unless the carriers ultimately prevail in
the Coverage Litigation or obtain an interim ruling from the
court to the contrary, the Company expects to collect from the
remaining carriers under the Synetic Policies who are subject to
the Courts order the costs that it is obligated to pay
subject to the limits of each carriers policy. The
Companys insurance policies provide that under certain
circumstances, amounts advanced by the insurance companies in
connection with the defense costs of the indicted individuals,
may have to be repaid by the Company, although the $14,625 that
the Company has received in settlement from certain carriers is
not subject to being repaid. The Company has obtained an
undertaking from each indicted individual pursuant to which,
under certain circumstances, such individual has agreed to repay
defense costs advanced on such individuals behalf.
On October 29, 2008 the Company filed a Motion for Leave to
File a Second Amended Complaint with the Superior Court. The
Second Amended Complaint would add four new insurance companies
as defendants in the Coverage Action. These carriers are the
issuers of a third set of policies (the Emdeon
Policies) that provide coverage with respect to the
Companys indemnification obligations to the former
officers and directors of the Companys former EPS
subsidiary who were indicted in connection with the
Investigation described above in this Note 12.
Additionally, the Second Amended Complaint would add back as a
defendant in the Coverage Action the issuer of one of the EPS
Policies with whom the Company settled who is also the issuer of
the eighth level of coverage under the Synetic Policies. At the
time of that settlement the Company dismissed the eighth level
carrier without prejudice with respect to that Synetic Policy
and based upon the
30
HLTH
CORPORATION
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
current estimate of the anticipated costs of its indemnification
obligations the Company has determined that it is necessary to
add back the carrier with respect to the Synetic Policy.
Although the Company believes that such eighth level carrier is
situated similarly to the other Synetic Policies, the eighth
level carrier indicated on September 9, 2008 its position
that it was not bound by the Courts July 31, 2008
order regarding the duty of the Synetic carriers to advance and
reimburse defense costs. This resulted in the Company including
the eighth level carrier in the Motion for Leave to File a
Second Amended Complaint, described above.
Notwithstanding the fact that the Company has prevailed in the
summary judgment motions described above, there can be no
assurance that the Company will ultimately prevail in the
Coverage Litigation or that the Defendants will be required to
provide funding on an interim basis pending the resolution of
the Coverage Litigation. The Company intends to continue to
satisfy its legal obligations to the indicted individuals with
respect to advancement of amounts for their defense costs.
Other
In the normal course of business, the Company and its
subsidiaries are involved in various other claims and legal
proceedings. While the ultimate resolution of these matters has
yet to be determined, including those discussed in Note 12
to the Consolidated Financial Statements included in the
Companys Current Report on
Form 8-K
filed with the SEC on June 27, 2008 and in Note 12 to
the Consolidated Financial Statements included in the
Companys Form
10-Q for the
quarterly period ended June 30, 2008, the Company does not
believe that their outcome will have a material adverse effect
on the Companys consolidated financial position, results
of operations or liquidity.
|
|
13.
|
Other
(Expense) Income, Net
|
Other (expense) income, net consists of the following items:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
Transition service fees (a)
|
|
$
|
104
|
|
|
$
|
985
|
|
|
$
|
205
|
|
|
$
|
4,909
|
|
Reduction of tax contingencies (b)
|
|
|
437
|
|
|
|
377
|
|
|
|
1,311
|
|
|
|
1,123
|
|
Legal expense (c)
|
|
|
(403
|
)
|
|
|
(373
|
)
|
|
|
(1,164
|
)
|
|
|
(1,164
|
)
|
Gain on 2006 EBS Sale (d)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
399
|
|
Advisory expense (e)
|
|
|
(1,135
|
)
|
|
|
|
|
|
|
(6,159
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (expense) income, net
|
|
$
|
(997
|
)
|
|
$
|
989
|
|
|
$
|
(5,807
|
)
|
|
$
|
5,267
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
|
Represents the net fees received
from ViPS, Sage Software and EBSCo in relation to their
respective transition services agreements.
|
|
(b)
|
|
Represents the reduction of certain
sales and use tax contingencies resulting from the expiration of
various statutes.
|
|
(c)
|
|
Represents the costs and expenses
incurred by the Company related to the investigation by the
United States Attorney for the District of South Carolina and
the SEC.
|
|
(d)
|
|
Represents a gain recognized in
connection with the working capital adjustment associated with
the 2006 EBS Sale on November 16, 2006.
|
|
(e)
|
|
Represents professional fees,
primarily consisting of legal, accounting and financial advisory
services incurred by the Company related to the potential merger
of HLTH into WHC.
|
|
|
14.
|
Pending
Marketing Technology Solutions Inc. Acquisition
|
On September 15, 2008, WHC announced that it had entered
into a definitive agreement to acquire QualityHealth.com and its
owner, Marketing Technology Solutions Inc. (MTS).
MTS provides on-line performance-based marketing and media
programs directed at pharmaceutical and other healthcare related
advertisers. The purchase price for MTS is $50 million in
cash, payable at closing, and WHC has agreed to pay up to an
additional $25 million in cash if certain performance
thresholds are achieved relating to calendar year 2009.
31
|
|
ITEM 2.
|
Managements
Discussion and Analysis of Financial Condition and Results of
Operations
|
This Item 2 contains forward-looking statements with
respect to possible events, outcomes or results that are, and
are expected to continue to be, subject to risks, uncertainties
and contingencies, including those identified in this Item. See
Forward-Looking Statements on page 3.
Overview
Managements discussion and analysis of financial condition
and results of operations, or MD&A, is provided as a
supplement to the Consolidated Financial Statements and notes
thereto included elsewhere in this Quarterly Report and to
provide an understanding of our results of operations, financial
condition and changes in financial condition. Our MD&A is
organized as follows:
|
|
|
|
|
Introduction. This section provides a general
description of our company, a brief discussion of our operating
segments, a description of the termination of our proposed
merger with WHC, a description of pending transactions and other
recent transactions, other significant developments and trends,
and a discussion on how our business is impacted by seasonality.
|
|
|
|
Critical Accounting Policies and
Estimates. This section discusses those
accounting policies that both are considered important to our
financial condition and results of operations, and require us to
exercise subjective or complex judgments in making estimates and
assumptions. In addition, all of our significant accounting
policies, including our critical accounting policies, are
summarized in Note 1 to the Consolidated Financial
Statements contained in our Current Report on Form
8-K filed
with the SEC on June 27, 2008.
|
|
|
|
Recent Accounting Pronouncements. This section
provides a summary of the most recent authoritative accounting
standards and guidance that have either been recently adopted or
may be adopted in the future.
|
|
|
|
Results of Operations and Results of Operations by Operating
Segment. These sections provide our analysis and
outlook for the significant line items on our consolidated
statements of operations, as well as other information that we
deem meaningful to understand our results of operations on both
a company-wide and a
segment-by-segment
basis.
|
|
|
|
Liquidity and Capital Resources. This section
provides an analysis of our liquidity and cash flows and
discussions of our contractual obligations and commitments, as
well as our outlook on our available liquidity as of
September 30, 2008.
|
|
|
|
Factors That May Affect Our Future Financial Condition or
Results of Operations. This section describes
circumstances or events that could have a negative effect on our
financial condition or results of operations, or that could
change, for the worse, existing trends in some or all of our
businesses. The factors discussed in this section are in
addition to factors that may be described elsewhere in this
Quarterly Report.
|
In this MD&A, dollar amounts are in thousands, unless
otherwise noted.
Introduction
Our
Company
HLTH Corporation is a Delaware corporation that was incorporated
in December 1995 and commenced operations in January 1996 as
Healtheon Corporation. We changed our name to Healtheon/WebMD
Corporation in November 1999, to WebMD Corporation in September
2000, to Emdeon Corporation in October 2005 and to HLTH
Corporation in May 2007. Our common stock began trading on the
Nasdaq National Market under the symbol HLTH on
February 11, 1999 and now trades under that symbol on the
Nasdaq Global Select Market.
As of September 30, 2008, we owned 83.1% of the aggregate
amount of outstanding shares of WebMD Health Corp. (which we
refer to as WHC) Class A Common Stock (after accounting for
the impact of certain WHC shares to be issued pursuant to the
purchase agreement for the acquisition of Subimo, LLC) and
Class B
32
Common Stock and, accordingly, our consolidated financial
statements reflect the minority shareholders 16.9% share
of equity and net income (loss) of WHC.
HLTHs 48% ownership in EBS Master LLC (which we refer to
as EBSCo) was accounted for under the equity method through
February 8, 2008, the date of the sale of our investment in
EBS Master LLC. See Other Recent
Transactions Sale of EBSCo below.
Segments
As a result of our intentions to sell our Porex segment and due
to the sale of our ViPS segment, see Pending
Transactions and Other Recent
Transactions below, our remaining operating segments are
WebMD Online Services and WebMD Publishing and Other Services
(which we refer to together, as our WebMD Segments or,
sometimes, as WebMD). The following is a description of each of
our operating segments and our corporate segment:
|
|
|
|
|
WebMD Online Services. This segment owns and
operates both public and private online portals. The public
portals enable consumers to become more informed about
healthcare choices and assist them in playing an active role in
managing their health. The public portals also enable physicians
and other healthcare professionals to improve their clinical
knowledge and practice of medicine, as well as their
communication with patients. The public portals generate revenue
primarily through the sale of advertising and sponsorship
products, including continuing medical education (which we refer
to as CME) services. Our sponsors and advertisers include
pharmaceutical, biotechnology, medical device and consumer
products companies. Through our private portals for employers
and health plans, we provide information and services that
enable their employees and members, respectively, to make more
informed benefit, treatment and provider decisions. We also
provide related services for use by such employees and members,
including lifestyle education and personalized telephonic health
coaching. We generate revenue from our private portals through
the licensing of these portals to employers and health plans
either directly or through distributors, as well as through the
fees charged for our coaching services. We also distribute
online content and services to other entities and generate
revenue from these arrangements through the sale of advertising
and sponsorship products and content syndication fees. We also
provide
e-detailing
promotion and physician recruitment services for use by
pharmaceutical, medical device and healthcare companies.
|
|
|
|
WebMD Publishing and Other Services. This
segment provides offline products and services, including:
The Little Blue Book, a physician directory; and WebMD
the Magazine, a consumer-targeted publication that WebMD
distributes free of charge to physician office waiting rooms. We
generate revenue from sales of The Little Blue Book
directories and advertisements in those directories, and
sales of advertisements in WebMD the Magazine. Until
December 31, 2007, we published ACP Medicine and
ACS Surgery: Principles of Practice, its medical
reference textbooks. We sold this business in 2007 and it has
now been reflected as a discontinued operation in our financial
statements. The WebMD Publishing and Other Services segment
complements the WebMD Online Services segment and extends the
reach of the WebMD brand and our influence among health-involved
consumers and clinically-active physicians.
|
|
|
|
Corporate. Corporate includes personnel costs
and other expenses related to functions that are not directly
managed by one of our segments, or by the ViPS and Porex
businesses which are reflected within discontinued operations.
The personnel costs include executive personnel, legal,
accounting, tax, internal audit, risk management, human
resources and certain information technology functions. Other
corporate costs and expenses include professional fees including
legal and audit services, insurance, costs of leased property
and facilities, telecommunication costs and software maintenance
expenses. Corporate expenses are net of $838 and $2,572 for the
three and nine months ended September 30, 2008,
respectively, and $845 and $2,470 for the three and nine months
ended September 30, 2007, respectively, which are costs
allocated to WebMD for services provided by the Corporate
segment. In connection with the sale of our Emdeon Business
Services (which we refer to as EBS) and Emdeon Practice Services
(which we refer to as EPS) segments during the second half of
2006 and the sale of
|
33
|
|
|
|
|
our ViPS segment during the three months ended
September 30, 2008, we entered into transition services
agreements whereby we provided EBSCo, Sage Software, Inc. (which
we refer to as Sage Software) and ViPS certain administrative
services, including payroll, accounting, purchasing and
procurement, tax, and human resource services, as well as
information technology support. Additionally, EBSCo provides us
certain administrative services, including telecommunication
infrastructure and management services, data center support and
purchasing and procurement services. Some of the services
provided by EBSCo to HLTH are, in turn, used to fulfill
HLTHs obligations to provide transition services to Sage
Software. These services are provided through the Corporate
segment, and the related transition services fees we charge to
EBSCo, Sage Software and ViPS, net of the fee we pay to EBSCo,
are also included in the Corporate segment, which were intended
to approximate the cost of providing these services. The
transition services agreement with Sage Software was terminated
on December 31, 2007 and, therefore, net transition
services fees are for services related to EBSCo and ViPS for the
three and nine months ended September 30, 2008.
|
Termination
of Proposed Merger with WHC
On October 19, 2008, pursuant to the terms of a termination
agreement (which we refer to as the Termination Agreement), HLTH
and WHC mutually agreed, in light of recent turmoil in financial
markets, to terminate the Agreement and Plan of Merger, dated as
of February 20, 2008, between HLTH and WHC, as amended by
Amendment No. 1, dated as of May 6, 2008, and
Amendment No. 2, dated as of September 12, 2008 (which
we refer to as the Merger Agreement). The Merger Agreement
resulted from negotiations between HLTH and a Special Committee
of the Board of Directors of WHC during late 2007 and early
2008. HLTHs Board of Directors had initiated the process
leading to the entry into the Merger Agreement with WHC because
it believed that the primary reason of many of the holders of
HLTH Common Stock for owning those shares was HLTHs
controlling interest in WHC and that the value of HLTHs
other businesses was not adequately reflected in the trading
price of HLTH Common Stock. In connection with the entry by HLTH
and WHC into the Merger Agreement, the HLTH Board made a
determination to divest Porex and ViPS (which divestitures were
not, however, dependent on the merger occurring). See
Pending Transactions Proposed
Divestiture of Porex and Other Recent
Transactions ViPS Sale below. The decisions
relating to the divestitures of ViPS, Porex and HLTHs 48%
interest in EBS (see Other Recent
Transactions Sale of EBSCo below) were based
on the corporate strategic considerations described above and
not the performance of, or underlying business conditions
affecting, the respective businesses.
The termination of the Merger Agreement was by mutual agreement
of the companies and was unanimously approved by the Board of
Directors of each of the companies and by a special committee of
independent directors of WHC. The Boards determined that both
HLTH, as controlling stockholder of WHC, and the public
stockholders of WHC would benefit from WHC continuing as a
publicly-traded subsidiary with no long-term debt and
approximately $340,000 in cash and investments. The Boards
concluded that, by terminating the merger, HLTH and WHC would
retain financial flexibility and be in a position to pursue
potential acquisition opportunities expected to be available to
companies with significant cash resources in a period of
financial market uncertainty.
The Termination Agreement maintains HLTHs obligation,
under the terms of the Merger Agreement, to pay the expenses of
WHC incurred in connection with the merger. Under the
Termination Agreement, HLTH and WHC have also agreed to amend
the Amended and Restated Tax Sharing Agreement, dated as of
February 15, 2006, between them (which we refer to as the
Tax Sharing Agreement) so that, for tax years beginning after
December 31, 2007, HLTH will no longer be required to
reimburse WHC for use of net operating loss (which we refer to
as NOL) carryforwards attributable to WebMD that may result from
certain extraordinary transactions by HLTH. The Tax Sharing
Agreement has not, other than with respect to certain
extraordinary transactions by HLTH, required either HLTH or WHC
to reimburse the other party for any net tax savings realized by
the consolidated group as a result of the groups
utilization of WHCs or HLTHs NOL carryforwards
during the period of consolidation, and that will continue
following the amendment. The Termination Agreement also provided
for HLTH to assign to WHC the Amended and Restated Data License
Agreement, dated as of February 8, 2008, among HLTH, EBSCo
and certain affiliated companies.
34
Pending
Transactions
Pending Tender Offer. On October 27,
2008, we commenced a tender offer to purchase up to
80,000,000 shares of our common stock at a price of $8.80
per share (which we refer to as the Pending Tender Offer). The
Pending Tender Offer is expected to be completed in November
2008, subject to a number of terms and conditions. Under the
Merger Agreement, holders of HLTH Common Stock would have
received merger consideration consisting of 0.1979 shares
of WHC Common Stock and approximately $6.63 in cash (subject to
increase up to $6.89 per share in cash in certain
circumstances). In deciding to make the Pending Tender Offer,
our Board of Directors considered that, following the
termination of the Merger Agreement, some holders of HLTH common
stock might wish to have the opportunity to sell some or all of
their holdings for cash. In addition, our Board of Directors
believes that investing in our shares through the Pending Tender
Offer is an attractive use of our cash and investments on hand
and an efficient means to provide value to our stockholders. The
Pending Tender Offer represents an opportunity for us to return
capital to our stockholders who elect to tender their shares.
Additionally, stockholders who do not participate in the Pending
Tender Offer will automatically increase their relative
percentage interest in us and our future operations at no
additional cost to them. We anticipate that we will pay for the
shares tendered in the Pending Tender Offer and all expenses
applicable to the Pending Tender Offer from cash and investments
on hand. The Pending Tender Offer is not conditioned upon the
receipt of financing.
Proposed Divestiture of Porex. On
February 21, 2008, we announced our intention to divest our
Porex segment. As a result of our intention to divest this
segment and our expectation that the divestiture would be
completed within one year, we reflected this segment as a
discontinued operation within the consolidated financial
statements contained elsewhere in this Quarterly Report.
Pending Acquisition of Marketing Technology Solutions
Inc. On September 15, 2008, WHC announced
that it had entered into a definitive agreement to acquire
QualityHealth.com and its owner, Marketing Technology Solutions
Inc. (which we refer to as MTS). MTS provides on-line
performance-based marketing and media programs directed at
pharmaceutical and other healthcare related advertisers. The
purchase price for MTS is $50,000 in cash, payable at closing,
and WHC has agreed to pay up to an additional $25,000 in cash if
certain performance thresholds are achieved relating to calendar
year 2009.
Other
Recent Transactions
ViPS Sale. On February 21, 2008, we
announced our intention to divest our ViPS segment. On
June 3, 2008, we entered into a stock purchase agreement
for the sale of our ViPS segment to an affiliate of General
Dynamics Corporation. On July 22, 2008, we completed the
sale of our ViPS business (which we refer to as the ViPS Sale).
The purchase price was approximately $224,842 in cash, which
reflects the effect of a preliminary estimate of the amount of
a customary working capital adjustment to the contractual
purchase price of $225,000 in cash. We have reflected ViPS as a
discontinued operation within the consolidated financial
statements contained elsewhere in this Quarterly Report.
Sale of EBSCo. On February 8, 2008, we
entered into a Securities Purchase Agreement and simultaneously
completed the sale of our 48% minority ownership interest in
EBSCo (which we refer to as the 2008 EBSCo Sale) for $575,000 in
cash to an affiliate of General Atlantic LLC and affiliates of
Hellman & Friedman, LLC.
Sale of ACP Medicine and ACS Surgery. As of
December 31, 2007, through our WebMD Publishing and Other
Services segment, WHC entered into an Asset Sale Agreement and
completed the sale of certain assets and certain liabilities of
our medical reference publications business, including the
publications ACP Medicine and ACS Surgery: Principles
and Practice (which we collectively refer to as the ACS/ACP
Business). ACP Medicine and ACS Surgery are
official publications of the American College of Physicians and
the American College of Surgeons, respectively. WebMD received
net cash proceeds of $2,809, consisting of $1,734 received
during the three months ended March 31, 2008 and the
remaining $1,075 to be received in the quarter ending
December 31, 2008. WebMD incurred approximately $800 of
professional fees and other expenses associated with the sale of
the ACS/ACP Business. In connection with the sale, WebMD
recognized a gain of $3,394 as of December 31, 2007. The
decision to divest ACS/ACP Business was made because management
determined that it was not a good fit with WebMDs core
business.
35
Other
Significant Developments and Trends
Auction Rate Securities; Non-Recourse Credit
Facilities. We hold investments in auction rate
securities (which we refer to as ARS) backed by student loans,
97% of which are guaranteed under the Federal Family Education
Loan Program (FFELP), and all had credit ratings of AAA or Aaa
when purchased. Historically, the fair value of our ARS holdings
approximated face value due to the frequent auction periods,
generally every 7 to 28 days, which provided liquidity to
these investments. However, since February 2008, virtually all
auctions involving these securities have failed. The result of a
failed auction is that these ARS holdings will continue to pay
interest in accordance with their terms at each respective
auction date; however, liquidity of the securities will be
limited until there is a successful auction, the issuer redeems
the securities, the securities mature or until such time as
other markets for these ARS holdings develop. During the three
months ended March 31, 2008, we concluded that the
estimated fair value of the ARS holdings no longer approximated
the face value due to the lack of liquidity.
As of March 31, 2008, we concluded the fair value of our
ARS holdings was $302,842 (of which $141,044 related to WHC),
compared to a face value of $362,950 (of which $168,450 related
to WHC). The impairment in value, or $60,108 (of which $27,406
related to WHC), was considered to be other-than-temporary and,
accordingly, was recorded as an impairment charge within the
statement of operations during the three months ended
March 31, 2008. During the three and nine months ended
September 30, 2008, we received $5,100 (of which $2,000
relates to WHC) and $7,900 (of which $3,700 relates to WHC),
respectively, associated with the partial redemption of certain
of our ARS holdings which represented 100% of their face value.
During the three months ended June 30, 2008 and
September 30, 2008, we reduced the carrying value of our
ARS holdings by $3,019 and $8,897, respectively. We assessed
these declines in fair market value to be temporary as they
resulted from fluctuations in interest rate assumptions and,
therefore, recorded these declines as an unrealized loss in our
stockholders equity. As a result of the above activity, as
of September 30, 2008, the total face value of our ARS holdings
was $355,800, of which $165,500 relates to WHC, compared to a
fair value of $284,408, of which $132,848 relates to WHC.
HLTH and WHC have each entered into a non-recourse credit
facility (which we refer to as the Credit Facilities) with
Citigroup that is secured by their respective ARS holdings
(including, in some circumstances, interest payable on the ARS
holdings), that will allow HLTH and WHC to borrow up to 75% of
the face amount of the ARS holdings pledged as collateral under
the respective Credit Facilities. The Credit Facilities are each
governed by a loan agreement, dated as of May 6, 2008,
containing customary representations and warranties of the
borrower and certain affirmative covenants and negative
covenants relating to the pledged collateral. Under each of the
loan agreements, the borrower and the lender may, in certain
circumstances, cause the pledged collateral to be sold, with the
proceeds of any such sale required to be applied in full
immediately to repayment of amounts borrowed.
No borrowings have been made under either of the Credit
Facilities to date. HLTH and WHC can each make borrowings under
their respective Credit Facilities until May 2009. The interest
rate applicable to such borrowings will be one-month LIBOR plus
250 basis points. Any borrowings outstanding under the
respective Credit Facilities after March 2009 become demand
loans, subject to 60 days notice, with recourse only to the
pledged collateral.
We continue to monitor the market for ARS as well as the
individual ARS holdings we own. We may be required to record
additional losses in future periods if the fair value of our ARS
holdings deteriorates further.
Directors & Officers Liability Insurance Coverage
Litigation. On July 23, 2007, we commenced
litigation (which we refer to as the Coverage Litigation) in the
Court of Chancery of the State of Delaware in and for New Castle
County against ten insurance companies in which we are seeking
to compel the defendant companies (which we refer to
collectively as the Defendants) to honor their obligations under
certain directors and officers liability insurance policies
(which we refer to as the Policies). We are seeking an order
requiring the Defendants to advance
and/or
reimburse expenses that we have incurred and expect to continue
to incur for the advancement of the reasonable defense costs of
initially ten, and now eight, former officers and directors of
our former EPS subsidiary who were indicted in connection with
the previously disclosed investigation by the United States
Attorney for the District of South Carolina (which we refer to
as the
36
Investigation) described in Note 12, Commitments and
Contingencies located in the Notes to the Consolidated
Financial Statements elsewhere in this Quarterly Report. We
subsequently settled with two of the insurance companies during
January 2008, through which we received an aggregate amount of
$14,625. This amount was included within (loss) income from
discontinued operations in the accompanying statement of
operations during the three months ended December 31, 2007
and is included within prepaid expenses and other current assets
in our consolidated balance sheet as of December 31, 2007.
Pursuant to a stipulation among the parties, the Coverage
Litigation was transferred on September 13, 2007 to the
Superior Court of the State of Delaware in and for New Castle
County. The Policies were issued to our company and to EPS, our
former subsidiary, which is our co-plaintiff in the Coverage
Litigation (which we refer to collectively as the Plaintiffs).
EPS was sold in September 2006 to Sage Software and has changed
its name to Sage Software Healthcare, Inc. (which we refer to as
SSHI). In connection with our sale of EPS to Sage Software, we
retained certain obligations relating to the Investigation and
agreed to indemnify Sage Software and SSHI with respect to
certain expenses in connection with the Investigation. We
retained the right to assert claims and recover proceeds under
the Policies on behalf of SSHI.
The Policies at issue in the Coverage Litigation consist of two
separate groups of insurance policies. Each group of policies
consists of several layers of coverage, with different insurers
having agreed to provide specified amounts of coverage at
various levels. The first group of policies was issued to EPS in
the amount of $20,000 (which we refer to as the EPS Policies)
and the second group of policies was issued to Synetic, Inc.
(the former parent of EPS, which merged into HLTH) in the amount
of $100,000, of which approximately $3,600 was paid by the
primary carrier with respect to another unrelated matter (which
we refer to as the Synetic Policies). As of September 30,
2008, $50,950 has been paid by insurance companies representing
the EPS Policies and the Synetic Policies through a combination
of payment under the terms of the Policies, payment under
reservation of rights and settlement. Of this amount, $19,912
has been reimbursed by the insurance companies subsequent to the
Courts order on July 31, 2008 (described in more
detail below). We have deferred recognizing this amount as
income given the fact that the Coverage Litigation is ongoing
and accordingly this amount has been deferred on the balance
sheet as of September 30, 2008 within liabilities of
discontinued operations. As a result of these payments, we have
exhausted our coverage under the EPS Policies and have remaining
coverage under the Synetic Policies of approximately $60,000.
The carrier with the third level of coverage in the Synetic
Policies filed a motion for summary judgment in the Coverage
Litigation, which most of the carriers who have issued the
Synetic policies joined, which sought summary judgment that any
liability to pay defense costs should be allocated among the
three sets of policies available to our company (including the
policies with respect to which the Coverage Litigation relates
and a third set of policies the issuers of which had not yet
been named by our company) such that the Synetic Policies would
only be liable to pay about $23,000 of the $96,400 total
coverage available under such policies. We filed our opposition
to the motion together with our motion for summary judgment
against such carrier and several other carriers who have issued
the Synetic Policies seeking to require such carriers to advance
payment of the defense costs that we are obligated to pay while
the Coverage Litigation is pending. On July 31, 2008 the
Superior Court for the State of Delaware denied the motion filed
by the carriers seeking allocation and granted HLTHs
motion for partial summary judgment to enforce the duty of such
carriers to advance and reimburse these costs. Pursuant to the
Courts order the issuers of the Synetic Policies have been
reimbursing us for our costs. Unless the carriers ultimately
prevail in the Coverage Litigation or obtain an interim ruling
from the court to the contrary, we expect to collect from the
remaining carriers under the Synetic Policies who are subject to
the Courts order the costs that it is obligated to pay
subject to the limits of each carriers policy. Our
insurance policies provide that under certain circumstances,
amounts advanced by the insurance companies in connection with
the defense costs of the indicted individuals, may have to be
repaid by us, although the $14,625 that we have received in
settlement from certain carriers is not subject to being repaid.
We have obtained an undertaking from each indicted individual
pursuant to which, under certain circumstances, such individual
has agreed to repay defense costs advanced on such
individuals behalf.
On October 29, 2008, we filed a Motion for Leave to File a
Second Amended Complaint with the Superior Court. The Second
Amended Complaint would add four new insurance companies as
defendants in the Coverage Action. These carriers are the
issuers of a third set of policies (which we refer to as Emdeon
37
Policies) that provide coverage with respect to our
indemnification obligations to the former officers and directors
of our former EPS subsidiary who were indicted in connection
with the Investigation described in Note 12,
Commitments and Contingencies located in the Notes
to the Consolidated Financial Statements elsewhere in this
Quarterly Report. Additionally, the Second Amended Complaint
would add back as a defendant in the Coverage Action the issuer
of one of the EPS Policies with whom we settled who is also the
issuer of the eighth level of coverage under the Synetic
Policies. At the time of that settlement we dismissed the eighth
level carrier without prejudice with respect to that Synetic
Policy and based upon the current estimate of the anticipated
costs of its indemnification obligations we have determined that
it is necessary to add back the carrier with respect to the
Synetic Policy. Although we believe that such eighth level
carrier is situated similarly to the other Synetic Policies, the
eighth level carrier indicated on September 9, 2008 its
position that it was not bound by the Courts July 31,
2008 order regarding the duty of the Synetic carriers to advance
and reimburse defense costs. This resulted in us including the
eighth level carrier in the Motion for Leave to File a Second
Amended Complaint, described above.
Notwithstanding the fact that we have prevailed in the summary
judgment motions described above, there can be no assurance that
we will ultimately prevail in the Coverage Litigation or that
the Defendants will be required to provide funding on an interim
basis pending the resolution of the Coverage Litigation. We
intend to continue to satisfy our legal obligations to the
indicted individuals with respect to advancement of amounts for
their defense costs.
Indemnification Obligations. We have certain
indemnity obligations to advance amounts for reasonable defense
costs for initially ten, and now eight, former officers and
directors of EPS, who were indicted in connection with the
Investigation. In connection with the sale of EPS, we agreed to
indemnify Sage Software relating to these indemnity obligations.
During the quarter ended June 30, 2007, based on
information we had recently received at that time, we determined
a reasonable estimate of the range of probable costs with
respect to our indemnification obligation and recorded a pre-tax
charge of $57,774, which represented our estimate of the low end
of the probable range of costs related to this matter. We
reserved the low end of the probable range of costs because no
estimate within the range was a better estimate than any other
amount. That estimate included assumptions as to the duration of
the trial and pre-trial periods, and the defense costs to be
incurred during these periods. During the quarter ended
December 31, 2007 and again during the quarter ended
June 30, 2008, we updated the estimated range of our
indemnification obligation based on new information received
during those periods, and as a result, recorded additional
pre-tax charges of $15,573 and $16,980, respectively, each of
which reflected the increases in the low end of the probable
range of costs related to this matter. The probable range of
future costs with respect to this matter is estimated to be
approximately $47,400 to $70,400, as of September 30, 2008,
which includes costs that have been incurred prior to, but not
yet paid, as of September 30, 2008. The ultimate outcome of
this matter is still uncertain, and the estimate of future costs
includes assumptions as to the duration of the trial and the
defense costs to be incurred during the remainder of the
pre-trial period and during the trial period. Accordingly, the
amount of cost we may ultimately incur could be substantially
more than the reserve we have currently provided. If the
recorded reserves are insufficient to cover the ultimate cost of
this matter, we will need to record additional charges to our
consolidated statement of operations in future periods. The
accrual related to this obligation was $47,399 and $55,563 as of
September 30, 2008 and December 31, 2007,
respectively, and is included within liabilities of discontinued
operations in our consolidated financial statements.
Use of the Internet by Consumers and
Physicians. The Internet has emerged as a major
communications medium and has already fundamentally changed many
sectors of the economy, including the marketing and sales of
financial services, travel, and entertainment, among others. The
Internet is also changing the healthcare industry and has
transformed how consumers and physicians find and utilize
healthcare information. As consumers are required to assume
greater financial responsibility for rising healthcare costs,
the Internet serves as a valuable resource by providing them
with immediate access to searchable and dynamic interactive
content to check symptoms, assess risks, understand diseases,
find providers and evaluate treatment options. The Internet has
also become a primary source of information for physicians
seeking to improve clinical practice and is growing relative to
traditional information sources, such as conferences, meetings
and offline journals.
38
Increased Online Marketing and Education Spending for
Healthcare Products. Pharmaceutical,
biotechnology and medical device companies spend large amounts
each year marketing their products and educating consumers and
physicians about them; however, only a small portion of this
amount is currently spent on online services. We believe that
these companies, which comprise the majority of the advertisers
and sponsors for our WebMD Online Services segment, are becoming
increasingly aware of the effectiveness of the Internet relative
to traditional media in providing health, clinical and
product-related information to consumers and physicians, and
this increasing awareness will result in increasing demand for
our services. However, notwithstanding our general expectation
for increased demand, our advertising and sponsorship revenue
may vary significantly from quarter to quarter due to a number
of factors, many of which are not in our control, and some of
which may be difficult to forecast accurately, including the
following:
|
|
|
|
|
The majority of our advertising and sponsorship contracts are
for terms of approximately four to twelve months. We have
relatively few longer term advertising and sponsorship
contracts. In addition, we have noted a trend this year, among
some of its advertisers and sponsors, of seeking to enter into
shorter term contracts than they had entered into in the past.
|
|
|
|
The time between the date of initial contact with a potential
advertiser or sponsor regarding a specific program and the
execution of a contract with the advertiser or sponsor for that
program may be subject to delays over which we have little or no
control, including as a result of budgetary constraints of the
advertiser or sponsor or their need for internal approvals.
|
Other factors that may affect the timing of contracting for
specific programs with advertisers and sponsors, or receipt of
revenue under such contracts, include: the timing of FDA
approval for new products or for new approved uses for existing
products; the timing of FDA approval of generic products that
compete with existing brand name products; the timing of
withdrawals of products from the market; seasonal factors
relating to the prevalence of specific health conditions and
other seasonal factors that may affect the timing of promotional
campaigns for specific products; and the scheduling of
conferences for physicians and other healthcare professionals.
Changes in Health Plan Design; Health Management
Initiatives. In a healthcare market where a
greater share of the responsibility for healthcare costs and
decision-making has been increasingly shifting to consumers, use
of information technology (including personal health records) to
assist consumers in making informed decisions about healthcare
has also increased. We believe that, through the WebMD Health
and Benefits Manager tools of the private portals of our WebMD
Online Services segment, including the personal health record
application, we are well positioned to play a role in this
consumer-directed healthcare environment, and these services
will be a significant driver for the growth of our private
portals during the next several years. However, our growth
strategy depends, in part, on increasing usage of our private
portal services by our employer and health plan clients
employees and members, respectively. Increasing usage of these
services requires us to continue to deliver and improve the
underlying technology and develop new and updated applications,
features and services. In addition, we face competition in the
area of healthcare decision-support tools and online health
management applications and health information services. Many of
our competitors have greater financial, technical, product
development, marketing and other resources than we do, and may
be better known than we are. We also expect that, for clients
and potential clients in the industries most seriously affected
by recent adverse changes in general economic conditions
(including those in the financial services industry), we may
experience some reductions in initial contracts, contract
expansions and contract renewals for our private portal services.
The healthcare industry in the United States and relationships
among healthcare payers, providers and consumers are very
complicated. In addition, the Internet and the market for online
services are relatively new and still evolving. Accordingly,
there can be no assurance that the trends identified above will
continue or that the expected benefits to our WebMD Online
Services segment from our responses to those trends will be
achieved. In addition, the market for healthcare information
services is highly competitive and not only are our existing
competitors seeking to benefit from these same trends, but the
trends may also attract additional competitors.
39
Seasonality
The timing of our revenue is affected by seasonal factors. The
advertising and sponsorship revenue within the WebMD Online
Services segment is seasonal, primarily due to the annual budget
approval process of the advertising and sponsorship clients of
our public portals. This portion of our revenue is usually the
lowest in the first quarter of each calendar year, and increases
during each consecutive quarter throughout the year. Our private
portal licensing revenue is historically highest in the second
half of the year as new customers are typically added during
this period in conjunction with their annual open enrollment
periods for employee benefits. Additionally, the annual
distribution cycle within the WebMD Publishing and Other
Services segment results in a significant portion of the revenue
in this segment being recognized in the second and third quarter
of each calendar year. The timing of revenue in relation to the
expenses of the WebMD Segments, much of which do not vary
directly with revenue, has an impact on cost of operations,
sales and marketing and general and administrative expenses as a
percentage of revenue in each calendar quarter.
Critical
Accounting Policies and Estimates
Our discussion and analysis of our financial condition and
results of operations are based upon our Consolidated Financial
Statements and Notes to Consolidated Financial Statements,
contained elsewhere in this Quarterly Report, which were
prepared in conformity with U.S. generally accepted
accounting principles. The preparation of financial statements
requires us to make certain estimates and assumptions that
affect the amounts reported in the consolidated financial
statements and accompanying notes. We base our estimates on
historical experience, current business factors, and various
other assumptions that we believe are necessary to consider in
order to form a basis for making judgments about the carrying
values of assets and liabilities, the recorded amounts of
revenue and expenses, and disclosure of contingent assets and
liabilities. We are subject to uncertainties such as the impact
of future events, economic, environmental and political factors,
and changes in our business environment; therefore, actual
results could differ from these estimates. Accordingly, the
accounting estimates used in preparation of our financial
statements will change as new events occur, as more experience
is acquired, as additional information is obtained and as our
operating environment changes. Changes in estimates are made
when circumstances warrant. Such changes in estimates and
refinements in estimation methodologies are reflected in
reported results of operations; if material, the effects of
changes in estimates are disclosed in the notes to our
consolidated financial statements.
We evaluate our estimates on an ongoing basis, including those
related to revenue recognition, investments in auction rate
securities, income taxes and tax contingencies, collectibility
of customer receivables, long-lived assets including goodwill
and other intangible assets, software and Web site development
costs, prepaid advertising services, certain accrued expenses,
contingencies, litigation and related legal accruals and the
value attributed to employee stock options and other stock-based
awards.
We believe the following reflects our critical accounting
policies and our more significant judgments and estimates used
in the preparation of our consolidated financial statements:
|
|
|
|
|
Revenue Recognition Revenue from advertising
is recognized as advertisements are delivered or as publications
are distributed. Revenue from sponsorship arrangements, content
syndication and distribution arrangements, and licenses of
healthcare management tools and private portals as well as
related health coaching services are recognized ratably over the
term of the applicable agreement. Revenue from the sponsorship
of CME is recognized over the period WebMD substantially
completes its contractual deliverables as determined by the
applicable agreements. When contractual arrangements contain
multiple elements, revenue is allocated to each element based on
its relative fair value determined using prices charged when
elements are sold separately. In certain instances where fair
value does not exist for all the elements, the amount of revenue
allocated to the delivered elements equals the total
consideration less the fair value of the undelivered elements.
In instances where fair value does not exist for the undelivered
elements, revenue is recognized when the last element is
delivered.
|
|
|
|
Long-Lived Assets Our long-lived assets
consist of property and equipment, goodwill and other intangible
assets. Goodwill and other intangible assets arise from the
acquisitions we have made. The amount assigned to intangible
assets is subjective and based on our estimates of the future
benefit of
|
40
|
|
|
|
|
the intangible assets using accepted valuation techniques, such
as discounted cash flow and replacement cost models. Our
long-lived assets, excluding goodwill, are amortized over their
estimated useful lives, which we determine based on the
consideration of several factors, including the period of time
the asset is expected to remain in service. We evaluate the
carrying value and remaining useful lives of long-lived assets,
excluding goodwill, whenever indicators of impairment are
present. We evaluate the carrying value of goodwill annually, or
whenever indicators of impairment are present. We use a
discounted cash flow approach to determine the fair value of
goodwill. Long-lived assets held for sale are reported at the
lower of cost or fair value less cost to sell. There was no
impairment of goodwill noted as a result of our impairment
testing in 2007.
|
|
|
|
|
|
Fair Value of Investments We hold investments
in ARS which are backed by student loans, 97% of which are
guaranteed under the Federal Family Education Loan Program
(FFELP), and all of which had credit ratings of AAA or Aaa when
purchased. Historically, the fair value of our ARS holdings
approximated face value due to the frequent auction periods,
generally every 7 to 28 days, which provided liquidity to
these investments. However, since February 2008, virtually all
auctions involving these securities have failed. The result of a
failed auction is that these ARS will continue to pay interest
in accordance with their terms at each respective auction date;
however, liquidity of the securities will be limited until there
is a successful auction, the issuer redeems the securities, the
securities mature or until such time as other markets for these
ARS develop. We cannot be certain regarding the amount of time
it will take for an auction market or other markets to develop.
Accordingly, during the three months ended March 31, 2008,
we concluded that the estimated fair value of the ARS holdings
no longer approximated the face value due to the lack of
liquidity.
|
We estimated the fair value of our ARS holdings using an income
approach valuation technique. Using this approach, expected
future cash flows were calculated over the expected life of each
security and were discounted to a single present value using a
market required rate of return. Some of the more significant
assumptions made in the present value calculations include
(i) the estimated weighted average lives for the loan
portfolios underlying each individual ARS, which range from 4 to
14 years and (ii) the required rates of return used to
discount the estimated future cash flows over the estimated life
of each security, which considered both the credit quality for
each individual ARS and the market liquidity for these
investments. As of March 31, 2008, we concluded the fair
value of our ARS holdings was $302,842 (of which $141,044
related to WHC), compared to a face value of $362,950 (of which
$168,450 related to WHC). The impairment in value, or $60,108
(of which $27,406 related to WHC), was considered to be
other-than-temporary, and accordingly, was recorded as an
impairment charge within the statement of operations during the
three months ended March 31, 2008. During the three and
nine months ended September 30, 2008, we received $5,100
(of which $2,000 relates to WHC) and $7,900 (of which $3,700
relates to WHC), respectively, associated with the partial
redemption of certain of our ARS holdings which represented 100%
of their face value. Also during the three months ended
June 30, 2008 and September 30, 2008, we reduced the
carrying value of our ARS holdings by $3,019 and $8,897. We
assessed these declines in fair market value to be temporary as
they resulted from fluctuations in interest rate assumptions
and, therefore, recorded these declines as an unrealized loss in
other comprehensive income within stockholders equity.
Our ARS have been classified as Level 3 assets in
accordance with Statement of Financial Accounting Standards
(which we refer to as SFAS) No. 157, Fair Value
Measurements, as their valuation requires substantial
judgment and estimation of factors that are not currently
observable in the market due to the lack of trading in the
securities. If different assumptions were used for the various
inputs to the valuation approach including, but not limited to,
assumptions involving the estimated lives of the ARS
investments, the estimated cash flows over those estimated
lives, and the estimated discount rates applied to those cash
flows, the estimated fair value of these investments could be
significantly higher or lower than the fair value we determined.
We continue to monitor the market for ARS as well as the
individual ARS investments we own. We may be required to record
additional losses in future periods if the fair value of our ARS
deteriorate further.
41
|
|
|
|
|
Sale of Subsidiary Stock Our WHC subsidiary
issues its Class A Common Stock in various transactions,
which results in a dilution of our percentage ownership in WHC.
We account for the sale of WHC Class A Common Stock in
accordance with the SECs Staff Accounting
Bulletin No. 51, Accounting for Sales of Stock by a
Subsidiary. The difference between the carrying amount of
our investment in WHC before and after the issuance of WHC
Class A Common Stock is considered either a gain or loss
and is reflected as a component of our stockholders
equity. During the three and nine months ended
September 30, 2008, WHC stock options were exercised and
restricted stock awards were released in accordance with
WHCs equity plans. The issuance of these shares resulted
in an aggregate gain of $1,768 and $3,715 during the three and
nine months ended September 30, 2008, respectively, and our
ownership in WHC decreased to 83.1% as of September 30,
2008 from 83.5% as of December 31, 2007 (after accounting
for the impact of certain WHC shares to be issued pursuant to
the purchase agreement for the acquisition of Subimo, LLC). We
expect to continue to record gains in the future related to
future issuances of WHC Class A Common Stock.
|
|
|
|
Stock-Based Compensation On January 1,
2006, we adopted SFAS No. 123, (Revised 2004):
Share-Based Payment (which we refer to as SFAS 123R),
which replaces SFAS No. 123, Accounting for
Stock-Based Compensation (which we refer to as
SFAS 123) and supersedes Accounting Principles Board
(which we refer to as APB) Opinion No. 25, Accounting
for Stock Issued to Employees (which we refer to as APB
25). SFAS 123R requires all share-based payments to
employees, including grants of employee stock options, to be
recognized as compensation expense over the service period
(generally the vesting period) in the consolidated financial
statements based on their fair values. We elected to use the
modified prospective transition method. Under the modified
prospective transition method, awards that were granted or
modified on or after January 1, 2006 are measured and
accounted for in accordance with SFAS 123R. Unvested stock
options and restricted stock awards that were granted prior to
January 1, 2006 will continue to be accounted for in
accordance with SFAS 123, using the same grant date fair
value and same expense attribution method used under SFAS 123,
except that all awards are recognized in the results of
operations over the remaining vesting periods. The impact of
forfeitures that may occur prior to vesting is also estimated
and considered in the amount recognized for all stock-based
compensation beginning January 1, 2006. As of
September 30, 2008, approximately $13,035 and $31,887 of
unrecognized stock-based compensation expense related to
unvested awards (net of estimated forfeitures) is expected to be
recognized over a weighted-average period of approximately
0.7 years and 1.5 years, related to the HLTH and WHC
stock-based compensation plans, respectively. The total
recognition period for the remaining unrecognized stock-based
compensation expense for both the HLTH and WHC stock-based
compensation plans is approximately four years; however, the
majority of this cost will be recognized over the next two
years, in accordance with our vesting provisions.
|
The fair value of each option granted is estimated on the date
of grant using the Black-Scholes option pricing model. The
assumptions used in this model are expected dividend yield,
expected volatility, risk-free interest rate and expected term.
The expected volatility for stock options to purchase HLTH
Common Stock is based on implied volatility from traded options
of HLTH Common Stock combined with historical volatility of HLTH
Common Stock. Prior to August 1, 2007, the expected
volatility for stock options to purchase WHC Class A Common
Stock was based on implied volatility from traded options of
stock of comparable companies combined with historical stock
price volatility of comparable companies. Beginning on
August 1, 2007, expected volatility is based on implied
volatility from traded options of WHC Class A Common Stock
combined with historical volatility of WHC Class A Common
Stock.
|
|
|
|
|
Deferred Taxes Our deferred tax assets are
comprised primarily of NOL carryforwards. At December 31,
2007, we had NOL carryforwards of approximately
$1.3 billion, which expire at varying dates from 2011
through 2028. These NOL carryforwards may be used to offset
taxable income in future periods, reducing the amount of taxes
we might otherwise be required to pay. Based on information
available at the time of this filing, we currently estimate that
the NOL carryforwards that were available as of
December 31, 2007 will be reduced by an aggregate of
approximately $550,000 as a result of offsetting our gains on
the sale of ViPS on July 22, 2008 and the 2008 EBSCo Sale
on February 8, 2008. Approximately $120,000 of this
|
42
|
|
|
|
|
amount will be NOL carryforwards attributable to WHC. These
estimates are based on various assumptions and are subject to
material change. The actual amount of the NOL carryforwards we
utilize, including the portion attributable to WHC, will not be
finalized until we complete the calculation of our 2008 federal
income taxes.
|
Substantially all of our NOL carryforwards are reserved for by a
valuation allowance. In determining the need for a valuation
allowance, management determined the probability of realizing
deferred tax assets, taking into consideration factors including
historical operating results, expectations of future earnings
and taxable income. Management will continue to evaluate the
need for a valuation allowance, and in the future, should
management determine that realization of the net deferred tax
asset is more likely than not, some or all of the remaining
valuation allowance will be reversed, and our effective tax rate
may be reduced by such reversal.
|
|
|
|
|
Tax Contingencies Our tax contingencies are
recorded to address potential exposures involving tax positions
we have taken that could be challenged by tax authorities. These
potential exposures result from applications of various
statutes, rules, regulations and interpretations. Our estimates
of tax contingencies reflect assumptions and judgments about
potential actions by taxing jurisdictions. We believe that these
assumptions and judgments are reasonable; however, our accruals
may change in the future due to new developments in each matter
and the ultimate resolution of these matters may be greater or
less than the amount that we have accrued. Consistent with our
historical financial reporting, we have elected to reflect
interest and penalties related to uncertain tax positions as
part of the income tax provision.
|
Recent
Accounting Pronouncements
On May 9, 2008, the FASB issued FSP APB Opinion
No. 14-1,
Accounting for Convertible Debt Instruments That May Be
Settled in Cash upon Conversion (Including Partial Cash
Settlement) (which we refer to as FSP APB
14-1). The
FSP will require cash settled convertible debt to be separated
into debt and equity components at issuance and a value to be
assigned to each. The value assigned to the debt component will
be the estimated fair value, as of the issuance date, of a
similar bond without the conversion feature. The difference
between the bond cash proceeds and this estimated fair value
will be recorded as a debt discount and amortized to interest
expense over the life of the bond. Although FSP APB
14-1 would
have no impact on our actual past or future cash flows, it will
require us to record a significant amount of non-cash interest
expense as the debt discount is amortized. As a result, there
will be a material adverse impact on the results of operations
and earnings per share. In addition, if the convertible debt is
redeemed or converted prior to maturity, any unamortized debt
discount will result in a loss on extinguishment. FSP APB
14-1 will
become effective January 1, 2009, and will require
retrospective application.
On April 25, 2008, the FASB issued FSP
FAS 142-3,
Determination of the Useful Life of Intangible
Assets. This FSP amends the factors that should be
considered in developing renewal or extension assumptions used
to determine the useful life of a recognized intangible asset
under SFAS No. 142, Goodwill and Other
Intangible Assets (which we refer to as SFAS 142).
The intent of this FSP is to improve the consistency between the
useful life of a recognized intangible asset under SFAS 142
and the period of expected cash flows used to measure the fair
value of the asset under SFAS No. 141 (Revised 2007),
Business Combinations, and other U.S. GAAP.
This FSP is effective for financial statements issued for fiscal
years beginning after December 15, 2008, and interim
periods within those fiscal years. Early adoption is prohibited.
We are currently evaluating the impact that this FSP will have
on our operations, financial position and cash flows.
In December 2007, the FASB issued SFAS No. 141
(Revised 2007), Business Combinations (which we
refer to as SFAS 141R), a replacement of
SFAS No. 141. SFAS 141R is effective for fiscal
years beginning on or after December 15, 2008 and applies
to all business combinations. SFAS 141R provides that, upon
initially obtaining control, an acquirer shall recognize
100 percent of the fair values of acquired assets,
including goodwill, and assumed liabilities, with only limited
exceptions, even if the acquirer has not acquired
100 percent of its target. As a consequence, the current
step acquisition model will be eliminated. Additionally,
43
SFAS 141R changes current practice, in part, as follows:
(1) contingent consideration arrangements will be fair
valued at the acquisition date and included on that basis in the
purchase price consideration; (2) transaction costs will be
expensed as incurred, rather than capitalized as part of the
purchase price; (3) pre-acquisition contingencies, such as
legal issues, will generally have to be accounted for in
purchase accounting at fair value; and (4) in order to
accrue for a restructuring plan in purchase accounting, the
requirements in SFAS No. 146, Accounting for
Costs Associated with Exit or Disposal Activities, would
have to be met at the acquisition date. While there is no
expected impact to our consolidated financial statements on the
accounting for acquisitions completed prior to December 31,
2008, the adoption of SFAS 141R on January 1, 2009
could materially change the accounting for business combinations
consummated subsequent to that date and for tax matters relating
to prior acquisitions settled subsequent to December 31,
2008.
In December 2007, the FASB issued SFAS No. 160,
Noncontrolling Interests in Consolidated Financial
Statements An Amendment of ARB No. 51
(which we refer to as SFAS 160). SFAS 160 requires the
recognition of a noncontrolling interest (minority interest) as
equity in the financial statements and separate from the
parents equity. The amount of net income attributable to
the noncontrolling interest will be included in consolidated net
income on the face of the results of operations. SFAS 160
clarifies that changes in a parents ownership interest in
a subsidiary that do not result in deconsolidation are equity
transactions if the parent retains its controlling financial
interest. In addition, this statement requires that a parent
recognize a gain or loss in net income when a subsidiary is
deconsolidated. Such gain or loss will be measured using the
fair value of the noncontrolling equity investment on the
deconsolidation date. SFAS 160 also includes expanded
disclosure requirements regarding the interests of the parent
and its noncontrolling interest. SFAS 160 is effective for
financial statements issued for fiscal years beginning after
December 15, 2008 and is to be applied prospectively as of
the beginning of the fiscal year in which the statement is
applied. Early adoption is not permitted. We are currently
evaluating the impact that SFAS 160 will have on our
operations, financial position and cash flows.
44
Results
of Operations
The following table sets forth our consolidated statements of
operations data and expresses that data as a percentage of
revenue for the periods presented (amounts in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30,
|
|
|
Nine Months Ended September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
$
|
|
|
%
|
|
|
$
|
|
|
%
|
|
|
$
|
|
|
%
|
|
|
$
|
|
|
%
|
|
|
Revenue
|
|
$
|
100,367
|
|
|
|
100.0
|
|
|
$
|
86,034
|
|
|
|
100.0
|
|
|
$
|
271,185
|
|
|
|
100.0
|
|
|
$
|
235,112
|
|
|
|
100.0
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of operations
|
|
|
35,322
|
|
|
|
35.2
|
|
|
|
30,021
|
|
|
|
34.9
|
|
|
|
99,655
|
|
|
|
36.7
|
|
|
|
87,636
|
|
|
|
37.3
|
|
Sales and marketing
|
|
|
26,441
|
|
|
|
26.4
|
|
|
|
22,459
|
|
|
|
26.1
|
|
|
|
77,731
|
|
|
|
28.7
|
|
|
|
67,258
|
|
|
|
28.6
|
|
General and administrative
|
|
|
22,928
|
|
|
|
22.9
|
|
|
|
25,718
|
|
|
|
29.8
|
|
|
|
67,253
|
|
|
|
24.8
|
|
|
|
81,111
|
|
|
|
34.5
|
|
Depreciation and amortization
|
|
|
7,265
|
|
|
|
7.2
|
|
|
|
7,390
|
|
|
|
8.6
|
|
|
|
21,468
|
|
|
|
7.9
|
|
|
|
20,954
|
|
|
|
8.9
|
|
Interest income
|
|
|
9,386
|
|
|
|
9.4
|
|
|
|
10,864
|
|
|
|
12.6
|
|
|
|
29,384
|
|
|
|
10.8
|
|
|
|
30,638
|
|
|
|
13.0
|
|
Interest expense
|
|
|
4,636
|
|
|
|
4.6
|
|
|
|
4,660
|
|
|
|
5.4
|
|
|
|
13,871
|
|
|
|
5.1
|
|
|
|
13,985
|
|
|
|
5.9
|
|
Gain on sale of EBS Master LLC
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
538,024
|
|
|
|
198.4
|
|
|
|
|
|
|
|
|
|
Impairment of auction rate securities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60,108
|
|
|
|
22.2
|
|
|
|
|
|
|
|
|
|
Other (expense) income, net
|
|
|
(997
|
)
|
|
|
(1.0
|
)
|
|
|
989
|
|
|
|
1.1
|
|
|
|
(5,807
|
)
|
|
|
(2.1
|
)
|
|
|
5,267
|
|
|
|
2.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before income tax provision
|
|
|
12,164
|
|
|
|
12.1
|
|
|
|
7,639
|
|
|
|
8.9
|
|
|
|
492,700
|
|
|
|
181.7
|
|
|
|
73
|
|
|
|
0.0
|
|
Income tax provision
|
|
|
7,679
|
|
|
|
7.7
|
|
|
|
2,977
|
|
|
|
3.5
|
|
|
|
34,623
|
|
|
|
12.8
|
|
|
|
4,404
|
|
|
|
1.8
|
|
Minority interest in WHC income (loss)
|
|
|
1,845
|
|
|
|
1.8
|
|
|
|
1,800
|
|
|
|
2.1
|
|
|
|
(929
|
)
|
|
|
(0.3
|
)
|
|
|
2,758
|
|
|
|
1.2
|
|
Equity in earnings of EBS Master LLC
|
|
|
|
|
|
|
|
|
|
|
8,005
|
|
|
|
9.3
|
|
|
|
4,007
|
|
|
|
1.5
|
|
|
|
22,679
|
|
|
|
9.6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
2,640
|
|
|
|
2.6
|
|
|
|
10,867
|
|
|
|
12.6
|
|
|
|
463,013
|
|
|
|
170.7
|
|
|
|
15,590
|
|
|
|
6.6
|
|
Income (loss) from discontinued operations, net of tax
|
|
|
93,241
|
|
|
|
92.9
|
|
|
|
5,704
|
|
|
|
6.7
|
|
|
|
93,159
|
|
|
|
34.4
|
|
|
|
(38,780
|
)
|
|
|
(16.5
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
95,881
|
|
|
|
95.5
|
|
|
$
|
16,571
|
|
|
|
19.3
|
|
|
$
|
556,172
|
|
|
|
205.1
|
|
|
$
|
(23,190
|
)
|
|
|
(9.9
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue is derived from the WebMD Segments. The WebMD Online
Services segment derives revenue from advertising, sponsorship
(including online CME services),
e-detailing
promotion and physician recruitment services, content
syndication and distribution, and licenses of private online
portals to employers, healthcare payers and others, along with
related services including lifestyle education and personalized
telephonic coaching. The WebMD Publishing and Other Services
segment derives revenue from sales of, and advertising in, its
physician directories, and advertisements in WebMD the
Magazine. Additionally, WebMD sold its ACS/ACP Business as
of December 31, 2007 and the revenue and expenses of this
business are shown as discontinued operations for the three and
nine months ended September 30, 2007.
WebMDs customers include pharmaceutical, biotechnology,
medical device and consumer products companies, as well as
employers and health plans. WebMDs customers also include
physicians and other healthcare providers who buy its physician
directories.
Cost of operations consists of costs related to services and
products WebMD provides to customers and costs associated with
the operation and maintenance of WebMDs public and private
portals. These costs relate to editorial and production
operations, Web site operations, non-capitalized Web site
development costs, and costs related to the production and
distribution of WebMDs publications. These costs consist
of expenses related to salaries and related expenses, non-cash
stock-based compensation, creating and licensing content,
telecommunications, leased properties, printing and distribution.
Sales and marketing expense consists primarily of advertising,
product and brand promotion, salaries and related expenses, and
non-cash stock-based compensation. These expenses include items
related to salaries and related expenses of account executives,
account management and marketing personnel, costs and expenses
for marketing programs, and fees for professional marketing and
advertising services. Also included in sales and marketing
expense are the non-cash advertising expenses, which are
discussed below.
45
General and administrative expense consists primarily of
salaries, non-cash stock-based compensation and other
salary-related expenses of administrative, finance, legal,
information technology, human resources and executive personnel.
These expenses include costs of general insurance and costs of
accounting and internal control systems to support our
operations.
Our discussions throughout this MD&A make references to
certain non-cash expenses. We consider non-cash expenses to be
those expenses that result from the issuance of our equity
instruments. The following is a summary of our principal
non-cash expenses:
|
|
|
|
|
Non-cash advertising expense. Expense related
to the use of WebMDs prepaid advertising inventory that
WHC received from News Corporation in exchange for equity
instruments we issued in connection with an agreement we entered
into with News Corporation in 1999 and subsequently amended in
2000. This non-cash advertising expense is included in cost of
operations when WebMD utilizes this advertising inventory in
conjunction with offline advertising and sponsorship programs
and is included in sales and marketing expense when WebMD uses
the asset for promotion of WebMDs brand.
|
|
|
|
Non-cash stock-based compensation
expense. Expense related to the awards of all
share-based payments to employees and non-employee directors,
including grants of employee stock options, to be recognized as
compensation expense over the service period (generally the
vesting period) in the consolidated financial statements based
on their fair values. Non-cash stock-based compensation expense
is reflected in the same expense captions as the related salary
cost of the respective employee.
|
The following table is a summary of our non-cash expenses
included in the respective statements of operations captions.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months
|
|
|
|
Three Months Ended
|
|
|
Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
Advertising expense included in:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales and marketing
|
|
$
|
178
|
|
|
$
|
169
|
|
|
$
|
1,736
|
|
|
$
|
2,489
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation expense included in:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of operations
|
|
$
|
1,005
|
|
|
$
|
1,597
|
|
|
$
|
2,950
|
|
|
$
|
4,159
|
|
Sales and marketing
|
|
|
1,222
|
|
|
|
1,252
|
|
|
|
3,624
|
|
|
|
3,889
|
|
General and administrative
|
|
|
4,304
|
|
|
|
6,436
|
|
|
|
12,400
|
|
|
|
18,198
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
6,531
|
|
|
$
|
9,285
|
|
|
$
|
18,974
|
|
|
$
|
26,246
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three
and Nine Months Ended September 30, 2008 and
2007
The following discussion is a comparison of our results of
operations on a consolidated basis for the three and nine months
ended September 30, 2008 and 2007.
Revenue
Our total revenue increased 16.7% and 15.3% to $100,367 and
$271,185 for the three and nine months ended September 30,
2008 from $86,034 and $235,112 in the prior year periods. These
increases were primarily due to higher advertising and
sponsorship revenue from WebMDs public portals. WebMD
Online Services accounted for $14,999 and $36,690 of the revenue
increases for the three and nine months ended September 30,
2008, partially offset by decreases of $710 and $757 for the
three and nine months ended September 30, 2008 within the
WebMD Publishing and Other Services. A more detailed discussion
regarding changes in revenue is included below under
Results of Operations by Operating
Segment.
Costs and
Expenses
Cost of Operations. Cost of operations was
$35,322 and $99,655 for the three and nine months ended
September 30, 2008, compared to $30,021 and $87,636 in the
prior year periods. Our cost of operations
46
represented 35.2% and 36.7% of revenue for the three and nine
months ended September 30, 2008, compared to 34.9% and
37.3% of revenue in the prior year periods. Included in cost of
operations are non-cash expenses related to stock-based
compensation of $1,005 and $2,950 for the three and nine months
ended September 30, 2008, compared to $1,597 and $4,159 in
the prior year periods. These decreases in non-cash stock-based
compensation expense for the three and nine months ended
September 30, 2008, compared to the prior year periods were
primarily related to the graded vesting methodology used in
determining stock-based compensation expense relating to
WebMDs stock options and restricted stock awards granted
at the time of its initial public offering.
Cost of operations, excluding the non-cash stock-based
compensation expense discussed above, was $34,317 and $96,705,
or 34.2% and 35.7% of revenue, for the three and nine months
ended September 30, 2008, compared to $28,424 and $83,477,
or 33.0% and 35.5% of revenue, in the prior year periods. These
increases in absolute dollars, as well as the increases as a
percentage of revenue, were primarily attributable to increases
in compensation-related costs due to higher staffing levels
relating to WebMDs Web site operations and development.
Sales and Marketing. Sales and marketing
expense was $26,441 and $77,731 for the three and nine months
ended September 30, 2008, compared to $22,459 and $67,258
in the prior year periods. Our sales and marketing expense
represented 26.4% and 28.7% of revenue for the three and nine
months ended September 30, 2008, compared to 26.1% and
28.6% of revenue in the prior year periods. Included in sales
and marketing expense were non-cash expenses related to
advertising of $178 and $1,736 for the three and nine months
ended September 30, 2008, compared to $169 and $2,489 in
the prior year periods. Non-cash advertising expense decreased
during the nine months ended September 30, 2008, compared
to the prior year period, due to lower utilization of
WebMDs prepaid advertising inventory. Also included in
sales and marketing expense were non-cash expenses related to
stock-based compensation of $1,222 and $3,624 for the three and
nine months ended September 30, 2008, compared to $1,252
and $3,889 in the prior year periods. The decreases in non-cash
stock-based compensation expense were primarily related to the
graded vesting methodology used in determining stock-based
compensation expense relating to WebMDs stock options and
restricted stock awards granted at the time of its initial
public offering.
Sales and marketing expense, excluding the non-cash expenses
discussed above, was $25,041 and $72,371, or 24.9% and 26.7% of
revenue, for the three and nine months ended September 30,
2008, compared to $21,038 and $60,880, or 24.5% and 25.9% of
revenue in the prior year periods. The increases in absolute
dollars, as well the increases as a percentage of revenue, were
primarily attributable to increases of approximately $2,800 and
$8,200 for the three and nine months ended September 30,
2008 in compensation-related costs due to increased staffing and
sales commissions related to higher revenue.
General and Administrative. General and
administrative expense was $22,928 and $67,253 for the three and
nine months ended September 30, 2008, compared to $25,718
and $81,111 in the prior year periods. Our general and
administrative expenses represented 22.9% and 24.8% of revenue
for the three and nine months ended September 30, 2008,
compared to 29.8% and 34.5% of revenue in the prior year
periods. Included in general and administrative expense was
non-cash stock-based compensation expense of $4,304 and $12,400
for the three and nine months ended September 30, 2008,
compared to $6,436 and $18,198 in the prior year periods.
Non-cash stock-based compensation expense was lower for the
three and nine months ended September 30, 2008, when
compared to the prior year periods, in our WebMD Segments by
approximately $1,500 and $3,300, respectively, due to the graded
vesting methodology used in determining stock-based compensation
expense relating to WebMDs stock options and restricted
stock awards granted at the time of its initial public offering,
as well as lower non-cash stock-based compensation expense of
approximately $600 and $2,500, respectively, in our Corporate
segment.
General and administrative expense, excluding the non-cash
stock-based compensation expense discussed above, was $18,624
and $54,853, or 18.6% and 20.2% of revenue for the three and
nine months ended September 30, 2008, compared to $19,282
and $62,913, or 22.4% and 26.8% of revenue in the prior year
periods. The decreases in absolute dollars were primarily
attributable to lower costs in our Corporate segment as a result
of the sales of EPS and EBS during the latter part of 2006,
partially offset by a net reduction of $881 and $4,704 in
transition services income during the three and nine months
ended September 30, 2008
47
and by approximately $1,000 in higher compensation related costs
due to increased staffing in our WebMD Segments for the three
months ended September 30, 2008, as compared to the prior
year periods. In the aggregate, expenses related to the
Corporate segment, net of the transition services income,
represented approximately $2,000 and $8,100 of the
year-over-year decrease for the three and nine months ended
September 30, 2008.
Depreciation and Amortization. Depreciation
and amortization expense was $7,265 and $21,468, or 7.2% and
7.9% of revenue for the three and nine months ended
September 30, 2008, compared to $7,390 and $20,954, or 8.6%
and 8.9% of revenue, in the prior year periods. The decrease for
the three months ended September 30, 2008, as compared to
the prior year period, was due to approximately $1,000 in lower
amortization expense resulting from certain WHC intangible
assets becoming fully amortized, partially offset by
approximately $1,000 in depreciation expense resulting from WHC
capital expenditures made in 2007 and 2008. The increase for the
nine months ended September 30, 2008, as compared to the
prior year period, was primarily due to approximately $3,500 in
depreciation expense resulting from WHCs capital
expenditures in 2007 and 2008, which was partially offset by a
decrease in amortization expense of approximately $2,400
resulting from certain WHC intangible assets becoming fully
amortized, and lower depreciation expense of approximately $500
in our Corporate segment as a result of certain information
technology systems being written off during 2007 as a result of
the sales of EBS and EPS.
Interest Income. Interest income was $9,386
and $29,384 for the three and nine months ended
September 30, 2008, compared to $10,864 and $30,638 in the
prior year periods. These decreases for the three and nine
months ended September 30, 2008, primarily relate to a
decrease in the average rates of return for the period,
partially offset by higher average investment balances.
Interest Expense. Interest expense of $4,636
and $13,871 for the three and nine months ended
September 30, 2008 was consistent with interest expense of
$4,660 and $13,985 in the prior year periods. Interest expense
in the three and nine months ended September 30, 2008 and
2007 primarily included the interest expense and the
amortization of debt issuance costs for our $350,000 of
1.75% Convertible Subordinated Notes due 2023 and our
$300,000 of
31/8% Convertible
Notes due 2025.
Gain on Sale of EBS Master LLC. The gain on
sale of EBS Master LLC of $538,024 represented a pre-tax gain
recognized in connection with the 2008 EBSCo Sale on
February 8, 2008. See
Introduction Other Recent
Transactions Sale of EBSCo with respect to
this matter.
Impairment of Auction Rate
Securities. Impairment of auction rate securities
represents a charge of $60,108 related to an
other-than-temporary reduction of the fair value of our ARS
holdings during the three months ended March 31, 2008. For
additional information, see
Introduction Other Significant
Developments and Trends Impairment of Auction Rate
Securities; Non-Recourse Credit Facilities above.
Other (Expense) Income, Net. For the three and
nine months ended September 30, 2008, other expense, net
was $997 and $5,807 compared to other income, net of $989 and
$5,267 in the prior year periods. Other (expense) income, net
for the three and nine months ended September 30, 2008
includes $1,135 and $6,159 of advisory expenses for professional
fees, primarily consisting of legal, accounting and financial
advisory services related to the terminated merger transaction
with WHC . See Introduction
Termination of Proposed Merger with WHC for more
information. Also included in other (expense) income, net was
$403 and $1,164 for the three and nine months ended
September 30, 2008, compared to $373 and $1,164 in the
prior year periods of external legal costs and expenses we
incurred related to the investigation by the United States
Attorney for the District of South Carolina and the SEC.
Transition services income of $104 and $205 for the three and
eight months ended September 30, 2008, compared to $985 and
$4,909 in the prior year periods, represents amounts earned from
the service fee charged to EBSCo, Sage Software and ViPS, net of
services EBSCo provides to us, for services rendered under each
of their respective transition services agreements. The
transition services agreement with Sage Software was terminated
during the fourth quarter of 2007 and the transition services
agreement for ViPS began during the third quarter of 2008.
Therefore, net transition services fees for the three and nine
months ended September 30, 2008 are for services related to
EBSCo and ViPS, while transition services fees for the three and
nine months ended September 30, 2007 are for services
related to EBSCo and Sage Software.
48
Income Tax Provision. The income tax provision
of $7,679 and $34,623 for the three and nine months ended
September 30, 2008, respectively, and $2,977 and $4,404 for
the three and nine months ended September 30, 2007,
respectively, represents taxes related to federal, state and
other jurisdictions. While the majority of the gain on the 2008
EBSCo Sale was offset by NOL carryforwards, certain alternative
minimum tax and other state taxes were not offset resulting in a
provision of approximately $24,000 for the nine months ended
September 30, 2008. The income tax provision for the nine
months ended September 30, 2008 excludes a benefit for the
impairment of ARS, as it is currently not deductible for tax
purposes.
Minority Interest in WHC Income
(Loss). Minority interest expense of $1,845 and
income of $929 for the three and nine months ended
September 30, 2008, compared to expense of $1,800 and
$2,758 in the prior year periods represents the minority
stockholders proportionate share of net income or loss for
WHC. The ownership interest of minority shareholders fluctuates
based on the net income or loss reported by WHC, combined with
changes in the percentage ownership of WHC held by the minority
interest shareholders. The minority interest shareholders
percentage ownership changes as a result of the issuance of WHC
Class A Common Stock for the exercise of stock options and
the release of restricted awards.
Income (Loss) from Discontinued Operations, Net of
Tax. Income from discontinued operations, net of
tax, was $93,241 and $93,159 for the three and nine months ended
September 30, 2008, compared to income of $5,704 and a loss
of $38,780 in the prior year periods. Included in income (loss)
from discontinued operations, net of tax, is a pre-tax gain of
$96,566 from the ViPS Sale. In addition, income from
discontinued operations includes the aggregate pre-tax operating
results of our ViPS and Porex segments of $5,271 and $21,123 for
the three and nine months ended September 30, 2008, and
$6,232 and $19,798 for the three and nine months ended
September 30, 2007. Also included in loss from discontinued
operations are pre-tax charges of approximately $16,980 for the
nine months ended September 30, 2008 and $57,774 for the
nine months ended September 30, 2007 related to our
indemnity obligations to advance amounts for reasonable defense
costs for initially ten and now eight former officers and
directors of EPS, who were indicted in connection with the
investigation by the United States Attorney for the District of
South Carolina and the SEC.
Results
of Operations by Operating Segment
We monitor the performance of our business based on earnings
before interest, taxes, non-cash and other items. Other items
include: legal expenses we incurred, which reflect costs and
expenses related to the investigation by the United States
Attorney for the District of South Carolina and the SEC; income
related to the reduction of certain sales and use tax
contingencies; professional fees in 2008, primarily consisting
of legal, accounting and financial advisory services, related to
the terminated WHC Merger; the gain on the 2008 EBSCo Sale; the
gain recognized in connection with the working capital
adjustment associated with the EBS sale during the second half
of 2006; and the impairment charge related to our ARS.
Inter-segment revenue primarily represents certain services
provided by our WebMD Segments to our Corporate segment.
Reclassification of Segment Information. As a
result of our intention to divest the Porex segment and due to
the ViPS Sale and the December 31, 2007 sale of WHCs
ACS/ACP business, the financial information for these businesses
has been reclassified to discontinued operations for the current
and prior year periods. As a result of the discontinued
operations presentation for ViPS and Porex, our only remaining
operating segment is WebMD. We expanded our segment disclosure
for WebMD to provide additional information related to the WebMD
Online Services segment and the WebMD Publishing and Other
Services segment. This additional information for WebMD has been
provided for all periods presented.
49
Summarized financial information for our WebMD Segments and
Corporate segment and a reconciliation to income from continuing
operations are presented below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
WebMD Online Services:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advertising and sponsorship
|
|
$
|
72,046
|
|
|
$
|
59,087
|
|
|
$
|
190,494
|
|
|
$
|
158,944
|
|
Licensing
|
|
|
22,139
|
|
|
|
20,001
|
|
|
|
65,928
|
|
|
|
59,915
|
|
Content syndication and other
|
|
|
392
|
|
|
|
490
|
|
|
|
1,154
|
|
|
|
2,027
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total WebMD Online Services
|
|
|
94,577
|
|
|
|
79,578
|
|
|
|
257,576
|
|
|
|
220,886
|
|
WebMD Publishing and Other Services
|
|
|
5,810
|
|
|
|
6,520
|
|
|
|
13,669
|
|
|
|
14,426
|
|
Inter-segment eliminations
|
|
|
(20
|
)
|
|
|
(64
|
)
|
|
|
(60
|
)
|
|
|
(200
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
100,367
|
|
|
$
|
86,034
|
|
|
$
|
271,185
|
|
|
$
|
235,112
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before interest, taxes, non-cash and other items
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
WebMD Online Services
|
|
$
|
25,956
|
|
|
$
|
21,948
|
|
|
$
|
61,287
|
|
|
$
|
48,982
|
|
WebMD Publishing and Other Services
|
|
|
1,212
|
|
|
|
2,138
|
|
|
|
1,485
|
|
|
|
2,643
|
|
Corporate
|
|
|
(4,679
|
)
|
|
|
(5,811
|
)
|
|
|
(15,311
|
)
|
|
|
(18,874
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22,489
|
|
|
|
18,275
|
|
|
|
47,461
|
|
|
|
32,751
|
|
Interest, taxes, non-cash and other items
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
9,386
|
|
|
|
10,864
|
|
|
|
29,384
|
|
|
|
30,638
|
|
Interest expense
|
|
|
(4,636
|
)
|
|
|
(4,660
|
)
|
|
|
(13,871
|
)
|
|
|
(13,985
|
)
|
Income tax provision
|
|
|
(7,679
|
)
|
|
|
(2,977
|
)
|
|
|
(34,623
|
)
|
|
|
(4,404
|
)
|
Depreciation and amortization
|
|
|
(7,265
|
)
|
|
|
(7,390
|
)
|
|
|
(21,468
|
)
|
|
|
(20,954
|
)
|
Non-cash stock-based compensation
|
|
|
(6,531
|
)
|
|
|
(9,285
|
)
|
|
|
(18,974
|
)
|
|
|
(26,246
|
)
|
Non-cash advertising
|
|
|
(178
|
)
|
|
|
(169
|
)
|
|
|
(1,736
|
)
|
|
|
(2,489
|
)
|
Minority interest in WHC income (loss)
|
|
|
(1,845
|
)
|
|
|
(1,800
|
)
|
|
|
929
|
|
|
|
(2,758
|
)
|
Equity in earnings of EBS Master LLC
|
|
|
|
|
|
|
8,005
|
|
|
|
4,007
|
|
|
|
22,679
|
|
Gain on sale of EBS Master LLC
|
|
|
|
|
|
|
|
|
|
|
538,024
|
|
|
|
|
|
Impairment of auction rate securities
|
|
|
|
|
|
|
|
|
|
|
(60,108
|
)
|
|
|
|
|
Other (expense) income, net
|
|
|
(1,101
|
)
|
|
|
4
|
|
|
|
(6,012
|
)
|
|
|
358
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
2,640
|
|
|
|
10,867
|
|
|
|
463,013
|
|
|
|
15,590
|
|
Income (loss) from discontinued operations, net of tax
|
|
|
93,241
|
|
|
|
5,704
|
|
|
|
93,159
|
|
|
|
(38,780
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
95,881
|
|
|
$
|
16,571
|
|
|
$
|
556,172
|
|
|
$
|
(23,190
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following discussion is a comparison of the results of
operations for our WebMD Segments and Corporate segment for the
three and nine months ended September 30, 2008 and 2007.
WebMD Online Services. Revenue was $94,577 and
$257,576 for the three and nine months ended September 30,
2008, an increase of $14,999 or 18.8% and $36,690 or 16.6%,
compared to the prior year periods. Advertising and sponsorship
revenue increased $12,959 or 21.9% and $31,550 or 19.8% for the
three and nine months ended September 30, 2008, compared to
the prior year periods. The increases in advertising and
sponsorship revenue were attributable to an increase in the
number of unique sponsored programs on WebMDs sites,
including both brand sponsorship and educational programs. The
number of such programs grew to approximately 800 compared to
approximately 500 last year. In general, pricing remained
relatively stable for WebMDs advertising and sponsorship
programs and was not a significant source of the revenue
increase. Licensing revenue increased $2,138 or 10.7% and $6,013
or 10.0% for the three and nine months
50
ended September 30, 2008, compared to the prior year
periods. These increases were due to an increase in the number
of companies using WebMDs private portal platform to 129
from 112 last year. In general, pricing remained relatively
stable for WebMDs private portal licenses and was not a
significant source of the revenue increase. WebMD also had
approximately 140 additional customers who purchased stand-alone
decision-support services from them. Content syndication and
other revenue decreased to $392 and $1,154 for the three and
nine months ended September 30, 2008 from $490 and $2,027
in the prior year periods, primarily as a result of the
completion of certain contracts and WebMDs decision not to
seek new content syndication business.
WebMD Online Services earnings before interest, taxes, non-cash
and other items was $25,956 and $61,287 for the three and nine
months ended September 30, 2008, compared to $21,948 and
$48,982 in the prior year periods. As a percentage of revenue,
earnings before interest, taxes, non-cash and other items was
27.4% and 23.8% for the three and nine months ended
September 30, 2008, compared to 27.6% and 22.2% in the
prior year periods. The increase as a percentage of revenue for
the nine months ended September 30, 2008 was due to higher
revenue from the increase in the number of brands and sponsored
programs in WebMDs public portals as well as the increase
in companies using WebMDs private online portal without
incurring a proportionate increase in overall expenses.
WebMD Publishing and Other Services. Revenue
was $5,810 and $13,669 for the three and nine months ended
September 30, 2008, compared to $6,520 and $14,426 in the
prior year periods. The decrease for the three months ended
September 30, 2008 was attributable to $698 of lower
advertising revenue in The Little Blue Book. The decrease
for the nine months ended September 30, 2008 was
attributable to $1,503 of lower advertising in The Little
Blue Book, offset by $746 of higher advertising in WebMD
the Magazine. In general, pricing remained relatively stable
for advertising in both The Little Blue Book and WebMD
the Magazine and was not a significant source for changes in
revenue.
WebMD Publishing and Other Services earnings before interest,
taxes, non-cash and other items was $1,212 and $1,485 for the
three and nine months ended September 30, 2008, compared to
$2,138 and $2,643 in the prior year periods. These decreases
were primarily attributable to lower advertising, as noted above.
Corporate. Corporate includes costs and
expenses for functions not directly managed by one of our
segments, including the Porex and ViPS businesses which are
reflected within discontinued operations. Corporate expenses
decreased to $4,679 or 4.7% of revenue and $15,311 or 5.6% of
revenue for the three and nine months ended September 30,
2008, compared to $5,811 or 6.8% of revenue and $18,874 or 8.0%
of revenue in the prior year periods. These decreases in our
Corporate segment were due to lower personnel and other costs
and expenses associated with our overall management of HLTH and
our subsidiaries, including certain insurance, professional and
information technology costs. These lower costs and expenses
were attributable to the sales of EPS and EBS during the third
and fourth quarters of 2006. Offsetting the reduction in
expenses is a net reduction of transition service income of $881
and $4,704 when comparing the three and nine months ended
September 30, 2008 to the same periods in 2007. The
transition services income is lower for the three and nine
months ended September 30, 2008, as compared to the prior
year periods, as a result of the termination of the transition
services agreement with Sage Software during the fourth quarter
of 2007 as well as fewer services are being performed under the
EBSCo agreement in the current year periods as compared to the
prior year periods.
Inter-Segment Eliminations. Inter-segment
eliminations primarily represents certain services provided by
the WebMD Segments to our Corporate segment.
Liquidity
and Capital Resources
Cash
Flows
Cash provided by operating activities from our continuing
operations was $50,328 for the nine months ended
September 30, 2008, compared to $22,860 for the prior year
period. The $27,468 increase in cash provided by operating
activities from our continuing operations when compared to a
year ago primarily relates to the timing of tax payments for the
sale of our EBS segment in the latter part of 2006 that were
paid during
51
the nine months ended September 30, 2007. In addition, the
period-over-period increase in cash provided by operating
activities from continuing operations is due to the continuing
operating activities of our WebMD Segments in the amount of
$7,943.
Cash provided by investing activities from our continuing
operations was $748,352 for the nine months ended
September 30, 2008, compared to cash used in investing
activities from our continuing operations of $317,971 for the
prior year period. Cash provided by investing activities from
our continuing operations for the nine months ended
September 30, 2008 included $574,617 of net proceeds
received from the 2008 EBSCo Sale, $222,771 of net proceeds
received from the ViPS Sale and $23,333 we received, which was
released from escrow, from the sale of our EPS segment, which
was sold in the latter part of 2006. Also included in cash
provided by investing activities from our continuing operations
for the nine months ended September 30, 2008 are net
purchases of $59,611, net of maturities and sales, of available
for sale securities, compared to net purchases of $338,030, net
of maturities and sales, in the prior year period.
Cash provided by financing activities from our continuing
operations was $21,068 for the nine months ended
September 30, 2008, compared to $71,257 for the prior year
period. Cash provided by financing activities for the nine
months ended September 30, 2008 and 2007 principally
related to proceeds of $20,725 and $114,077, respectively, from
the issuance of HLTH Common Stock and WHC Class A Common
Stock resulting from the exercises of employee stock options,
partially offset by the repurchases of HLTH Common Stock for
$47,120 in the prior year period.
Included in our consolidated statements of cash flows are cash
flows from discontinued operations of the ViPS and Porex
segments and the ACS/ACP Business. Our cash flows provided by
operating activities from discontinued operations for the nine
months ended September 30, 2008 included an aggregate of
$19,104 related to our ViPS and Porex segments while cash flows
provided by operating activities from discontinued operations
for the nine months ended September 30, 2007 primarily
included an aggregate of $33,705 related to our ViPS segment,
Porex segment and the ACS/ACP Business. Also included in cash
flows from discontinued operations provided by operating
activities for the nine months ended September 30, 2008 is
the receipt of $34,537 of insurance settlements related to our
Director & Officer insurance policies, offset by
$25,144 and $9,339 in payments made during the nine months ended
September 30, 2008, and 2007, respectively, in connection
with legal costs and expenses incurred related to the
investigation by the United States Attorney for the District of
South Carolina and the SEC. For additional information, see
Introduction Other Significant Developments
and Trends Directors & Officers Liability
Insurance Coverage Litigation.
Outlook
on Future Liquidity
As of September 30, 2008, we had approximately
$1.38 billion in consolidated cash and cash equivalents,
and we owned investments in ARS with a face value of $355,800
and a fair value of $284,408. While liquidity for our ARS
investments is currently limited, HLTH and WHC entered into
non-recourse credit facilities with Citigroup that will allow
each of us to borrow up to 75% of the face amount of our
respective ARS holdings. See
Introduction Other Significant
Developments and Trends Impairment of Auction Rate
Securities and Related Credit Facilities above. Our
working capital, including discontinued operations, as of
September 30, 2008 was approximately $1.66 billion.
Our liquidity is expected to be significantly impacted as a
result of the Pending Tender Offer. The Pending Tender Offer
could result in the purchase of 80,000,000 shares of our
common stock at a price of $8.80 per share, which would result
in the use of cash of approximately $704,000. In addition, WHC
entered into a definitive agreement to acquire MTS. See
Introduction Pending
Transactions Pending Acquisition of Marketing
Technology Solutions Inc. above. The pending acquisition
will result in $50,000 in cash, payable at closing, and payment
of up to an additional $25,000 in cash if certain performance
thresholds are achieved relating to calendar year 2009.
We believe that our available cash resources and future cash
flow from operations will provide sufficient cash resources to
meet the cash commitments of the Pending Tender Offer, the
pending acquisition of MTS, our $350,000 of
1.75% Convertible Subordinated Notes due 2023, our $300,000
of
31/8% Convertible
Notes
52
due 2025 and to fund our currently anticipated working capital
and capital expenditure requirements, for up to twenty-four
months. Our future liquidity and capital requirements will
depend upon numerous factors, including retention of customers
at current volume and revenue levels, implementation of new or
updated application and service offerings, competing
technological and market developments, and potential future
acquisitions. In addition, our ability to generate cash flow is
subject to numerous factors beyond our control, including
general economic, regulatory and other matters affecting us and
our customers. We plan to continue to enhance our online
services and to continue to invest in acquisitions, strategic
relationships, facilities and technological infrastructure and
product development. We intend to grow each of our existing
businesses and enter into complementary ones through both
internal investments and acquisitions. We may need to raise
additional funds to support expansion, develop new or enhanced
applications and services, respond to competitive pressures,
acquire complementary businesses or technologies or take
advantage of unanticipated opportunities. If required, we may
raise such additional funds through public or private debt or
equity financing, strategic relationships or other arrangements.
We cannot assure that such financing will be available on
acceptable terms, if at all, or that such financing will not be
dilutive to our stockholders. Future indebtedness may impose
various restrictions and covenants on us that could limit our
ability to respond to market conditions, to provide for
unanticipated capital investments or to take advantage of
business opportunities.
Factors
That May Affect Our Future Financial Condition or Results of
Operations
This section describes circumstances or events that could have a
negative effect on our financial results or operations or that
could change, for the worse, existing trends in some or all of
our businesses. The occurrence of one or more of the
circumstances or events described below could have a material
adverse effect on our financial condition, results of operations
and cash flows or on the trading prices of the common stock and
convertible notes that we have issued or securities we may issue
in the future. The risks and uncertainties described in this
Quarterly Report are not the only ones facing us. Additional
risks and uncertainties that are not currently known to us or
that we currently believe are immaterial may also adversely
affect our business and operations.
Risks
Related to WebMD
If WebMD
is unable to provide content and services that attract and
retain users to The WebMD Health Network on a consistent basis,
its advertising and sponsorship revenue could be
reduced
Users of The WebMD Health Network have numerous other
online and offline sources of healthcare information services.
WebMDs ability to compete for user traffic on its public
portals depends upon its ability to make available a variety of
health and medical content, decision-support applications and
other services that meet the needs of a variety of types of
users, including consumers, physicians and other healthcare
professionals, with a variety of reasons for seeking
information. WebMDs ability to do so depends, in turn, on:
|
|
|
|
|
its ability to hire and retain qualified authors, journalists
and independent writers;
|
|
|
|
its ability to license quality content from third
parties; and
|
|
|
|
its ability to monitor and respond to increases and decreases in
user interest in specific topics.
|
We cannot assure you that WebMD will be able to continue to
develop or acquire needed content, applications and tools at a
reasonable cost. In addition, since consumer users of
WebMDs public portals may be attracted to The WebMD
Health Network as a result of a specific condition or for a
specific purpose, it is difficult for WebMD to predict the rate
at which they will return to the public portals. Because WebMD
generates revenue by, among other things, selling sponsorships
of specific pages, sections or events on The WebMD Health
Network, a decline in user traffic levels or a reduction in
the number of pages viewed by users could cause WebMDs
revenue to decrease and could have a material adverse effect on
its results of operations.
53
Developing
and implementing new and updated applications, features and
services for WebMDs public and private portals may be more
difficult than expected, may take longer and cost more than
expected and may not result in sufficient increases in revenue
to justify the costs
Attracting and retaining users of WebMDs public portals
and clients for its private portals requires WebMD to continue
to improve the technology underlying those portals and to
continue to develop new and updated applications, features and
services for those portals. If WebMD is unable to do so on a
timely basis or if WebMD is unable to implement new
applications, features and services without disruption to its
existing ones, it may lose potential users and clients.
WebMD relies on a combination of internal development, strategic
relationships, licensing and acquisitions to develop its portals
and related applications, features and services. WebMDs
development
and/or
implementation of new technologies, applications, features and
services may cost more than expected, may take longer than
originally expected, may require more testing than originally
anticipated and may require the acquisition of additional
personnel and other resources. There can be no assurance that
the revenue opportunities from any new or updated technologies,
applications, features or services will justify the amounts
spent.
WebMD
faces significant competition for its products and
services
The markets in which WebMD operates are intensely competitive,
continually evolving and, in some cases, subject to rapid change.
|
|
|
|
|
WebMDs public portals face competition from numerous other
companies, both in attracting users and in generating revenue
from advertisers and sponsors. WebMD competes for users with
online services and Web sites that provide health-related
information, including commercial sites as well as public sector
and not-for-profit sites. WebMD competes for advertisers and
sponsors with: health-related Web sites; general purpose
consumer Web sites that offer specialized health sub-channels;
other high-traffic Web sites that include both
healthcare-related and non-healthcare-related content and
services; search engines that provide specialized health search;
and advertising networks that aggregate traffic from multiple
sites.
|
|
|
|
WebMDs private portals compete with: providers of
healthcare decision-support tools and online health management
applications; wellness and disease management vendors; and
health information services and health management offerings of
healthcare benefits companies and their affiliates.
|
|
|
|
WebMDs offline publications compete with numerous other
offline publications, some of which have better access to
traditional distribution channels than WebMD has, and also
compete with online information sources.
|
Many of WebMDs competitors have greater financial,
technical, product development, marketing and other resources
than it does. These organizations may be better known than WebMD
and have more customers or users than WebMD does. WebMD cannot
provide assurance that it will be able to compete successfully
against these organizations or any alliances they have formed or
may form. Since there are no substantial barriers to entry into
the markets in which WebMDs public portals participate, we
expect that competitors will continue to enter these markets.
Failure
to maintain and enhance the WebMD brand could have a
material adverse effect on WebMDs business
We believe that the WebMD brand identity that WebMD
has developed has contributed to the success of its business and
has helped it achieve recognition as a trusted source of health
and wellness information. We also believe that maintaining and
enhancing that brand is important to expanding the user base for
WebMDs public portals, to its relationships with sponsors
and advertisers and to its ability to gain additional employer
and healthcare payer clients for our private portals. WebMD has
expended considerable resources on establishing and enhancing
the WebMD brand and its other brands, and it has
developed policies and procedures designed to preserve and
enhance its brands, including editorial procedures designed to
provide
54
quality control of the information it publishes. WebMD expects
to continue to devote resources and efforts to maintain and
enhance its brand. However, WebMD may not be able to
successfully maintain or enhance awareness of its brands and
circumstances or events, including ones outside of its control,
may have a negative effect on its brands. If WebMD is unable to
maintain or enhance awareness of its brand, and do so in a
cost-effective manner, its business could be adversely affected.
WebMDs
online businesses have a limited operating history
WebMDs online businesses have a limited operating history
and participate in relatively new markets. These markets, and
WebMDs online businesses, have undergone significant
changes during their short history and can be expected to
continue to change. Many companies with business plans based on
providing healthcare information and related services through
the Internet have failed to be profitable and some have filed
for bankruptcy
and/or
ceased operations. Even if demand from users exists, we cannot
assure you that WebMDs businesses will continue to be
profitable.
WebMDs
success depends, in part, on its attracting and retaining
qualified executives and employees
The success of WebMD depends, in part, on its ability to attract
and retain qualified executives, writers and editors, software
developers and other technical and professional personnel and
sales and marketing personnel. WebMD anticipates a continuing
need to hire and retain qualified employees in these areas.
Competition for qualified personnel in the healthcare
information technology and healthcare information services
industries is intense, and we cannot assure you that WebMD will
be able to hire or retain a sufficient number of qualified
personnel to meet its requirements, or that it will be able to
do so at salary, benefit and other compensation costs that are
acceptable to it. Failure to do so may have an adverse effect on
its business.
If WebMD
is unable to provide healthcare content for its offline
publications that attracts and retains users, its revenue will
be reduced
Interest in WebMDs offline publications, such as The
Little Blue Book, is based upon WebMDs ability to make
available up-to-date health content that meets the needs of its
physician users. Although WebMD has been able to continue to
update and maintain the physician practice information that it
publishes in The Little Blue Book, if WebMD is unable to
continue to do so for any reason, the value of The Little
Blue Book would diminish and interest in this publication
and advertising in this publication would be adversely affected.
WebMD the Magazine was launched in April 2005 and, as a
result, has a very short operating history. We cannot assure you
that WebMD the Magazine will be able to attract and
retain the advertisers needed to make this publication
successful in the future.
The
timing of WebMDs advertising and sponsorship revenue may
vary significantly from quarter to quarter
WebMDs advertising and sponsorship revenue may vary
significantly from quarter to quarter due to a number of
factors, many of which are not in WebMDs control, and some
of which may be difficult to forecast accurately. The majority
of WebMDs advertising and sponsorship programs are for
terms of approximately four to twelve months. WebMD has
relatively few longer term advertising and sponsorship programs.
In addition, WebMD has noted a trend this year, among some of
its advertisers and sponsors, of seeking to enter into shorter
term contracts than they had entered into in the past. We cannot
assure you that WebMDs current advertisers and sponsors
will continue to use its services beyond the terms of their
existing contracts or that they will enter into any additional
contracts.
In addition, the time between the date of initial contact with a
potential advertiser or sponsor regarding a specific program and
the execution of a contract with the advertiser or sponsor for
that program may be lengthy, especially for larger contracts,
and may be subject to delays over which WebMD has little or no
control, including as a result of budgetary constraints of the
advertiser or sponsor or their need for internal
55
approvals. Other factors that could affect the timing of
contracting for specific programs with advertisers and sponsors,
or receipt of revenue under such contracts, include:
|
|
|
|
|
the timing of FDA approval for new products or for new approved
uses for existing products;
|
|
|
|
the timing of FDA approval of generic products that compete with
existing brand name products;
|
|
|
|
the timing of withdrawals of products from the market;
|
|
|
|
seasonal factors relating to the prevalence of specific health
conditions and other seasonal factors that may affect the timing
of promotional campaigns for specific products; and
|
|
|
|
the scheduling of conferences for physicians and other
healthcare professionals.
|
Lengthy
sales and implementation cycles for WebMDs private online
portals make it difficult to forecast revenues from these
applications and may have an adverse impact on that
business
The period from WebMDs initial contact with a potential
client for a private online portal and the first purchase of its
solution by the client is difficult to predict. In the past,
this period has generally ranged from six to twelve months, but
in some cases has been longer. Potential sales may be subject to
delays or cancellations due to a clients internal
procedures for approving large expenditures and other factors
beyond WebMDs control, including the effect of general
economic conditions on the willingness of potential clients to
commit to licensing our private portals. The time it takes to
implement a private online portal is also difficult to predict
and has lasted as long as six months from contract execution to
the commencement of live operation. Implementation may be
subject to delays based on the availability of the internal
resources of the client that are needed and other factors
outside of WebMDs control. As a result, we have limited
ability to forecast the timing of revenue from new clients.
This, in turn, makes it more difficult to predict WebMDs
financial performance from quarter to quarter.
During the sales cycle and the implementation period, we may
expend substantial time, effort and money preparing contract
proposals, negotiating contracts and implementing the private
online portal without receiving any related revenue. In
addition, many of the expenses related to providing private
online portals are relatively fixed in the short term, including
personnel costs and technology and infrastructure costs. Even if
WebMDs private portal revenue is lower than expected, it
may not be able to reduce related short-term spending in
response. Any shortfall in such revenue would have a direct
impact on its results of operations.
WebMDs
ability to provide comparative information on hospital cost and
quality depends on its ability to obtain the required data on a
timely basis and, if it is unable to do so, its private portal
services would be less attractive to clients
WebMD provides, in connection with its private portal services,
comparative information about hospital cost and quality.
WebMDs ability to provide this information depends on its
ability to obtain comprehensive, reliable data. WebMD currently
obtains this data from a number of public and private sources,
including the Centers for Medicare and Medicaid Services (CMS),
24 individual states and the Leapfrog Group. We cannot provide
assurance that WebMD would be able to find alternative sources
for this data on acceptable terms and conditions. Accordingly,
WebMDs business could be negatively impacted if CMS or
WebMDs other data sources cease to make such information
available or impose terms and conditions for making it available
that are not consistent with WebMDs planned usage. In
addition, the quality of the comparative information services
that WebMD provides depends on the reliability of the
information that it is able to obtain. If the information WebMD
uses to provide these services contains errors or is otherwise
unreliable, WebMD could lose clients and its reputation could be
damaged.
56
WebMDs
ability to renew existing licenses with employers and health
plans will depend, in part, on WebMDs ability to continue
to increase usage of our private portal services by their
employees and plan members
In a healthcare market where a greater share of the
responsibility for healthcare costs and decision-making has been
increasingly shifting to consumers, use of information
technology (including personal health records) to assist
consumers in making informed decisions about healthcare has also
increased. We believe that through WebMDs Health and
Benefits Manager tools, including WebMDs personal health
record application, WebMD is well positioned to play a role in
this consumer-directed healthcare environment, and these
services will be a significant driver for the growth of
WebMDs private portals during the next several years.
However, WebMDs growth strategy depends, in part, on
increasing usage of WebMDs private portal services by
WebMDs employer and health plan clients employees
and members, respectively. Increasing usage of WebMDs
services requires WebMD to continue to deliver and improve the
underlying technology and develop new and updated applications,
features and services. In addition, WebMD faces competition in
the area of healthcare decision-support tools and online health
management applications and health information services. Many of
WebMDs competitors have greater financial, technical,
product development, marketing and other resources than WebMD
does, and may be better known than WebMDs. We cannot
provide assurance that WebMD will be able to meet its
development and implementation goals, nor that WebMD will be
able to compete successfully against other vendors offering
competitive services and, as a result, may experience static or
diminished usage for WebMDs private portal services and
possible non-renewals of WebMDs license agreements.
WebMD may
be unsuccessful in its efforts to increase advertising and
sponsorship revenue from consumer products companies
Most of WebMDs advertising and sponsorship revenue has, in
the past, come from pharmaceutical, biotechnology and medical
device companies. WebMD has been focusing on increasing
sponsorship revenue from consumer products companies that are
interested in communicating health-related or safety-related
information about their products to WebMDs audience.
However, while a number of consumer products companies have
indicated an intent to increase the portion of their promotional
spending used on the Internet, we cannot assure you that these
advertisers and sponsors will find WebMDs consumer Web
sites to be as effective as other Web sites or traditional media
for promoting their products and services. If WebMD encounters
difficulties in competing with the other alternatives available
to consumer products companies, this portion of WebMDs
business may develop more slowly than we expect or may fail to
develop.
WebMD
could be subject to breach of warranty or other claims by
clients of our online portals if the software and systems we use
to provide them contain errors or experience failures
Errors in the software and systems WebMD uses could cause
serious problems for clients of its online portals. WebMD may
fail to meet contractual performance standards or client
expectations. Clients of WebMDs online portals may seek
compensation from WebMD or may seek to terminate their
agreements with WebMD, withhold payments due to WebMD, seek
refunds from WebMD of part or all of the fees charged under
those agreements or initiate litigation or other dispute
resolution procedures. In addition, WebMD could face breach of
warranty or other claims by clients or additional development
costs. WebMDs software and systems are inherently complex
and, despite testing and quality control, we cannot be certain
that they will perform as planned.
WebMD attempts to limit, by contract, its liability to its
clients for damages arising from its negligence, errors or
mistakes. However, contractual limitations on liability may not
be enforceable in certain circumstances or may otherwise not
provide sufficient protection to WebMD from liability for
damages. WebMD maintains liability insurance coverage, including
coverage for errors and omissions. However, it is possible that
claims could exceed the amount of WebMDs applicable
insurance coverage, if any, or that this coverage may not
continue to be available on acceptable terms or in sufficient
amounts. Even if these claims do not result in liability to
WebMD, investigating and defending against them could be
expensive and time consuming and would divert managements
attention away from WebMDs operations. In addition,
negative publicity
57
caused by these events may delay or hinder market acceptance of
WebMDs services, including unrelated services.
Any
service interruption or failure in the systems that WebMD uses
to provide online services could harm WebMDs
business
WebMDs online services are designed to operate
24 hours a day, seven days a week, without interruption.
However, WebMD has experienced and expects that it will in the
future experience interruptions and delays in services and
availability from time to time. WebMD relies on internal systems
as well as third-party vendors, including data center providers
and bandwidth providers, to provide its online services. WebMD
may not maintain redundant systems or facilities for some of
these services. In the event of a catastrophic event with
respect to one or more of these systems or facilities, WebMD may
experience an extended period of system unavailability, which
could negatively impact its relationship with users. To operate
without interruption, both WebMD and its service providers must
guard against:
|
|
|
|
|
damage from fire, power loss and other natural disasters;
|
|
|
|
communications failures;
|
|
|
|
software and hardware errors, failures and crashes;
|
|
|
|
security breaches, computer viruses and similar disruptive
problems; and
|
|
|
|
other potential interruptions.
|
Any disruption in the network access or co-location services
provided by third-party providers to WebMD or any failure by
these third-party providers or WebMDs own systems to
handle current or higher volume of use could significantly harm
WebMDs business. WebMD exercises little control over these
third-party vendors, which increases its vulnerability to
problems with the services they provide.
Any errors, failures, interruptions or delays experienced in
connection with these third-party technologies and information
services or WebMDs own systems could negatively impact
WebMDs relationships with users and adversely affect its
brand and its business and could expose WebMD to liabilities to
third parties. Although WebMD maintains insurance for its
business, the coverage under its policies may not be adequate to
compensate it for all losses that may occur. In addition, we
cannot provide assurance that WebMD will continue to be able to
obtain adequate insurance coverage at an acceptable cost.
WebMDs
online services are dependent on the development and maintenance
of the Internet infrastructure
WebMDs ability to deliver its online services is dependent
on the development and maintenance of the infrastructure of the
Internet by third parties. The Internet has experienced a
variety of outages and other delays as a result of damages to
portions of its infrastructure, and it could face outages and
delays in the future. The Internet has also experienced, and is
likely to continue to experience, significant growth in the
number of users and the amount of traffic. If the Internet
continues to experience increased usage, the Internet
infrastructure may be unable to support the demands placed on
it. In addition, the reliability and performance of the Internet
may be harmed by increased usage or by denial-of-service
attacks. Any resulting interruptions in WebMDs services or
increases in response time could, if significant, result in a
loss of potential or existing users of and advertisers and
sponsors on WebMDs Web sites and, if sustained or
repeated, could reduce the attractiveness of WebMDs
services.
Customers who utilize WebMDs online services depend on
Internet service providers and other Web site operators for
access to WebMDs Web sites. All of these providers have
experienced significant outages in the past and could experience
outages, delays and other difficulties in the future due to
system failures unrelated to WebMDs systems. Any such
outages or other failures on their part could reduce traffic to
WebMDs Web sites.
58
Implementation
of additions to or changes in hardware and software platforms
used to deliver WebMDs online services may result in
performance problems and may not provide the additional
functionality that was expected
From time to time, WebMD implements additions to or changes in
the hardware and software platforms that it uses for providing
its online services. During and after the implementation of
additions or changes, a platform may not perform as expected,
which could result in interruptions in operations, an increase
in response time or an inability to track performance metrics.
In addition, in connection with integrating acquired businesses,
WebMD may move their operations to its hardware and software
platforms or make other changes, any of which could result in
interruptions in those operations. Any significant interruption
in WebMDs ability to operate any of its online services
could have an adverse effect on its relationships with users and
clients and, as a result, on its financial results. WebMD relies
on a combination of purchasing, licensing, internal development,
and acquisitions to develop its hardware and software platforms.
WebMDs implementation of additions to or changes in these
platforms may cost more than originally expected, may take
longer than originally expected, and may require more testing
than originally anticipated. In addition, we cannot provide
assurance that additions to or changes in these platforms will
provide the additional functionality and other benefits that
were originally expected.
If the
systems WebMD uses to provide online portals experience security
breaches or are otherwise perceived to be insecure, WebMDs
business could suffer
WebMD retains and transmits confidential information, including
personal health records, in the processing centers and other
facilities it uses to provide online services. It is critical
that these facilities and infrastructure remain secure and be
perceived by the marketplace as secure. A security breach could
damage WebMDs reputation or result in liability. WebMD may
be required to expend significant capital and other resources to
protect against security breaches and hackers or to alleviate
problems caused by breaches. Despite the implementation of
security measures, this infrastructure or other systems that
WebMD interfaces with, including the Internet and related
systems, may be vulnerable to physical break-ins, hackers,
improper employee or contractor access, computer viruses,
programming errors, denial-of-service attacks or other attacks
by third parties or similar disruptive problems. Any compromise
of WebMDs security, whether as a result of its own systems
or the systems that they interface with, could reduce demand for
its services and could subject WebMD to legal claims from its
clients and users, including for breach of contract or breach of
warranty.
WebMD
faces potential liability related to the privacy and security of
personal information it collects from or on behalf of users of
its services
Privacy of personal health information, particularly personal
health information stored or transmitted electronically, is a
major issue in the United States. The Privacy Standards under
the Health Insurance Portability and Accountability Act of 1996
(or HIPAA) establish a set of basic national privacy standards
for the protection of individually identifiable health
information by health plans, healthcare clearinghouses and
healthcare providers (referred to as covered entities) and their
business associates. Only covered entities are directly subject
to potential civil and criminal liability under the Privacy
Standards. Accordingly, the Privacy Standards do not apply
directly to WebMD. However, portions of WebMDs business,
such as those managing employee or plan member health
information for employers or health plans, are or may be
business associates of covered entities and are bound by certain
contracts and agreements to use and disclose protected health
information in a manner consistent with the Privacy Standards.
Depending on the facts and circumstances, WebMD could
potentially be subject to criminal liability for aiding and
abetting or conspiring with a covered entity to violate the
Privacy Standards. We cannot assure you that WebMD will
adequately address the risks created by the Privacy Standards.
In addition, we are unable to predict what changes to the
Privacy Standards might be made in the future or how those
changes could affect our business. Any new legislation or
regulation in the area of privacy of personal information,
including personal health information, could also affect the way
WebMD operates its business and could harm its business.
In addition, Internet user privacy and the use of consumer
information to track online activities are major issues both in
the United States and abroad. For example, in December 2007, the
Federal Trade Commission
59
(FTC) published for comment proposed principles to govern
tracking of consumers activities online in order to
deliver advertising targeted to the interests of individual
consumers. WebMD has privacy policies posted on its Web sites
that it believes comply with applicable laws requiring notice to
users about WebMDs information collection, use and
disclosure practices. However, whether and how existing privacy
and consumer protection laws in various jurisdictions apply to
the Internet is still uncertain. WebMD also notifies users about
its information collection, use and disclosure practices
relating to data it receives through offline means such as paper
health risk assessments. We cannot assure you that the privacy
policies and other statements WebMD provides to users of its
products and services, or WebMDs practices will be found
sufficient to protect it from liability or adverse publicity in
this area. A determination by a state or federal agency or court
that any of WebMDs practices do not meet applicable
standards, or the implementation of new standards or
requirements, could adversely affect WebMDs business.
Failure
to comply with regulations related to advertising and promotion
may result in enforcement action and loss of
sponsorship
The WebMD Health Network provides services involving
advertising and promotion of prescription and over-the-counter
drugs and medical devices. If the Food and Drug Administration
(FDA) or the FTC finds that any information on The WebMD
Health Network or in WebMD the Magazine violates FDA
or FTC regulations, they may take regulatory or judicial action
against WebMD
and/or the
advertiser or sponsor of that information. State attorneys
general may also take similar action based on their states
consumer protection statutes. Any increase or change in
regulation of drug or medical device advertising and promotion
could make it more difficult for WebMD to contract for
sponsorships and advertising. Members of Congress, physician
groups and others have criticized the FDAs current
policies, and have called for restrictions on advertising of
prescription drugs and medical devices to consumers and
increased FDA enforcement. We cannot predict what actions the
FDA or industry participants may take in response to these
criticisms. It is also possible that new laws will be enacted
that impose restrictions on such advertising and promotion.
WebMDs advertising and sponsorship revenue could be
materially reduced by additional restrictions on the advertising
of prescription drugs and medical devices to consumers, whether
imposed by law or regulation or required under policies adopted
by industry members.
Failure
to maintain its CME accreditation could adversely affect
WebMDs ability to provide online CME offerings
Medscapes continuing medical education (CME) activities
are planned and implemented in accordance with the current
Essential Areas and Policies of the Accreditation Council for
Continuing Medical Education, or ACCME, which oversees providers
of CME credit, and other applicable accreditation standards. In
2007, ACCME revised its standards for commercial support of CME.
The revised standards are intended to ensure, among other
things, that CME activities of ACCME-accredited providers, such
as Medscape, are independent of commercial
interests, which are now defined as entities that produce,
market, re-sell or distribute healthcare goods and services,
excluding certain organizations. Commercial
interests, and entities owned or controlled by
commercial interests, are ineligible for
accreditation by ACCME. The revised standards also provide that
accredited CME providers may not place their CME content on Web
sites owned or controlled by a commercial interest.
In addition, accredited CME providers may no longer ask
commercial interests for speaker or topic
suggestions, and are also prohibited from asking
commercial interests to review CME content prior to
delivery.
As a result of the revised standards, WebMD has made certain
adjustments to its corporate structure, management and
operations intended to ensure that Medscape will continue to
provide CME activities that are developed independently from
those programs developed by its sister companies, which may not
be independent of commercial interests. ACCME
required accredited providers to implement changes relating to
placing CME content on Web sites owned or controlled by
commercial interests by January 1, 2008, and is
requiring accredited providers to implement any corporate
structural changes necessary to meet the revised standards
regarding the definition of commercial interest by
August 2009. We believe that the adjustments that WebMD and
Medscape have made to their structure and operations satisfy the
revised standards.
60
In June 2008, the ACCME announced a
call-for-comments on several ACCME proposals,
including the following:
|
|
|
|
|
Potential New Paradigm for Commercial
Support: The ACCME has stated that it believes
that due consideration should be given to the possibility of
eliminating commercial support of CME. The ACCME has requested
the medical profession, the public and CME providers to weigh in
on the debate on this subject. To frame the debate, the ACCME
has proposed several possible scenarios: (a) maintaining
the current system of commercial support; (b) completely
eliminating commercial support; (c) a new paradigm that
provides for commercial support if the following conditions are
met: (1) educational needs are identified and verified by
organizations that do not receive commercial support and are
free of financial relationships with industry; (2) the CME
addresses a professional practice gap of a particular group of
learners that is corroborated by bona fide performance
measurements of the learners own practice; (3) the
CME content is from a continuing education curriculum specified
by a bona fide organization or entity; and (4) the CME is
verified as free of commercial bias; and (d) an alternative
new paradigm in which the four conditions described above would
provide a basis for a mechanism to distribute commercial support
derived from industry-donated, pooled funds.
|
|
|
|
Defining Appropriate Interactions between ACCME Accredited
Providers and Commercial Supporters. The ACCME
has proposed that (a) accredited providers must not receive
communications from commercial interests announcing or
prescribing any specific content that would be a preferred, or
sought-after, topic for commercially supported CME (e.g.,
therapeutic area, product-line, patho-physiology); and
(b) receiving communications from commercial interests
regarding a commercial interests internal criteria for
providing commercial support would also not be permissible.
|
The ACCME sought comments on the above, and the comment period
ended to end on September 12, 2008. The comments submitted
to the ACCME indicated significant backing from the medical
profession for commercially-supported CME and, accordingly, we
believe that it is unlikely that a proposal for complete
elimination of such support would be adopted. However, we cannot
predict the ultimate outcome of the process, including what
other alternatives may be considered by ACCME as a result of
comments it has received. The elimination of, or restrictions
on, commercial support for CME could adversely affect the volume
of sponsored online CME programs implemented through our Web
sites.
Medscapes current ACCME accreditation expires at the end
of July 2010. In order for Medscape to renew its accreditation,
it will be required to demonstrate to the ACCME that it
continues to meet ACCME requirements. If Medscape fails to
maintain its status as an accredited ACCME provider (whether at
the time of such renewal or at an earlier time as a result of a
failure to comply with existing additional ACCME standards), it
would not be permitted to accredit ACCME activities for
physicians and other healthcare professionals. Instead, it would
be required to use third parties to provide such CME-related
services. That, in turn, could discourage potential sponsors
from engaging Medscape to develop CME or education-related
activities, which could have a material adverse effect on our
business.
Government
regulation and industry initiatives could adversely affect the
volume of sponsored online CME programs implemented through
WebMDs Web sites or require changes to how WebMD offers
CME
CME activities may be subject to government regulation by
Congress, the FDA, the Department of Health and Human Services,
the federal agency responsible for interpreting certain federal
laws relating to healthcare, and by state regulatory agencies.
Medscape
and/or the
sponsors of the CME activities that Medscape accredits may be
subject to enforcement actions if any of these CME activities
are deemed improperly promotional, potentially leading to the
termination of sponsorships.
During the past several years, educational activities, including
CME, directed to physicians have been subject to increased
governmental scrutiny to ensure that sponsors do not influence
or control the content of the activities. In response,
pharmaceutical companies and medical device companies have
developed and implemented internal controls and procedures that
promote adherence to applicable regulations and requirements. In
implementing these controls and procedures, Medscapes
various sponsors may interpret the
61
regulations and requirements differently and may implement
varying procedures or requirements. These controls and
procedures:
|
|
|
|
|
may discourage pharmaceutical companies from providing grants
for independent educational activities;
|
|
|
|
may slow their internal approval for such grants;
|
|
|
|
may reduce the volume of sponsored educational programs that
Medscape produces to levels that are lower than in the past,
thereby reducing revenue; and
|
|
|
|
|
|
may require Medscape to make changes to how it offers or
provides educational programs, including CME.
|
In addition, future changes to laws and regulations, or to the
internal compliance programs of supporters or potential
supporters, may further discourage, significantly limit or
prohibit supporters or potential supporters from engaging in
educational activities with Medscape, or may require Medscape to
make further changes in the way it offers or provides
educational programs.
Risks
Related to Porex
Porexs
success depends upon demand for its products, which in some
cases ultimately depends upon end-user demand for the products
of its customers
Demand for our Porex products may change materially as a result
of economic or market conditions and other trends that affect
the industries in which Porex participates. In addition, because
a significant portion of our Porex products are components that
are eventually integrated into or used with products
manufactured by customers for resale to end-users, the demand
for these product components is dependent on product development
cycles and marketing efforts of these other manufacturers, as
well as variations in their inventory levels, which are factors
that we are unable to control. Accordingly, the amount of
Porexs sales to manufacturer customers can be difficult to
predict and subject to wide quarter-to-quarter variances.
Porexs sales to manufacturer customers that sell products
used by consumers have been adversely affected by economic
conditions during recent months. We cannot predict how long that
adverse effect will continue and it could, depending on future
economic conditions, become worse in future periods.
Porex
faces significant competition for its products
Porex operates in competitive markets and its products are, in
general, used in applications that are affected by technological
change and product obsolescence. The competitors for
Porexs porous plastic products include other producers of
porous plastic materials as well as companies that manufacture
and sell products made from materials other than porous plastics
that can be used for the same purposes as Porexs products.
For example, Porexs porous plastic pen nibs compete with
felt and fiber tips manufactured by a variety of suppliers
worldwide. Other Porex porous plastic products compete,
depending on the application, with membrane material, porous
metals, metal screens, fiberglass tubes, pleated paper,
resin-impregnated felt, ceramics and other substances and
devices. Some of Porexs competitors may have greater
financial, technical, product development, marketing and other
resources than Porex does. We cannot provide assurance that
Porex will be able to compete successfully against these
companies or against particular products they provide or may
provide in the future.
Porexs
product offerings must meet changing customer
requirements
A significant portion of our Porex products are integrated into
end products used by manufacturing companies in various
industries, some of which are characterized by rapidly changing
technology, evolving industry standards and frequent new product
introductions. Accordingly, to satisfy its customers, Porex must
develop and introduce, in a timely manner, products that meet
changing customer requirements at competitive prices. To do
this, Porex must:
|
|
|
|
|
develop new uses of existing porous plastics technologies and
applications;
|
|
|
|
innovate and develop new porous plastics technologies and
applications;
|
62
|
|
|
|
|
commercialize those technologies and applications;
|
|
|
|
manufacture at a cost that allows it to price its products
competitively;
|
|
|
|
manufacture and deliver its products in sufficient volumes and
on time;
|
|
|
|
accurately anticipate customer needs; and
|
|
|
|
differentiate its offerings from those of its competitors.
|
We cannot assure you that Porex will be able to develop new or
enhanced products or that, if it does, those products will
achieve market acceptance. If Porex does not introduce new
products in a timely manner and make enhancements to existing
products to meet the changing needs of its customers, some of
its products could become obsolete over time, in which case
Porexs customer relationships, revenue and operating
results would be negatively impacted.
Potential
new or enhanced Porex products may not achieve sufficient sales
to be profitable or justify the cost of their
development
We cannot be certain, when we engage in Porex research and
development activities, whether potential new products or
product enhancements will be accepted by the customers for whom
they are intended. Achieving market acceptance for new or
enhanced products may require substantial marketing efforts and
expenditure of significant funds to create awareness and demand
by potential customers. In addition, sales and marketing efforts
with respect to these products may require the use of additional
resources for training our existing Porex sales forces and
customer service personnel and for hiring and training
additional salespersons and customer service personnel.
There can be no assurance that the revenue opportunities from
new or enhanced products will justify amounts spent for their
development and marketing. In addition, there can be no
assurance that any pricing strategy that we implement for any
new or enhanced Porex products will be economically viable or
acceptable to the target markets.
Porex may
not be able to source the raw materials it needs or may have to
pay more for those raw materials
Some of Porexs products require high-grade plastic resins
with specific properties as raw materials. While Porex has not
experienced any material difficulty in obtaining adequate
supplies of high-grade plastic resins that meet its
requirements, it relies on a limited number of sources for some
of these plastic resins. If Porex experiences a reduction or
interruption in supply from these sources, it may not be able to
access alternative sources of supply within a reasonable period
of time or at commercially reasonable rates, which could have a
material adverse effect on its business and financial results.
In addition, the prices of some of the raw materials that Porex
uses depend, to a great extent, on the price of petroleum. As a
result, increases in the price of petroleum could have an
adverse effect on Porexs margins and on the ability of
Porexs porous plastics products to compete with products
made from other raw materials.
Disruptions
in Porexs manufacturing operations could have a material
adverse effect on its business and financial results
Any significant disruption in Porexs manufacturing
operations, including as a result of fire, power interruptions,
equipment malfunctions, labor disputes, material shortages,
earthquakes, floods, computer viruses, sabotage, terrorist acts
or other force majeure, could have a material adverse effect on
Porexs ability to deliver products to customers and,
accordingly, its financial results.
63
Porex may
not be able to keep third parties from using technology it has
developed
Porex uses proprietary technology for manufacturing its porous
plastics products and its success is dependent, to a significant
extent, on its ability to protect the proprietary and
confidential aspects of its technology. Although Porex owns
certain patents, it relies primarily on non-patented proprietary
manufacturing processes. To protect its proprietary processes,
Porex relies on a combination of trade secret laws, license
agreements, nondisclosure and other contractual provisions and
technical measures, including designing and manufacturing its
porous molding equipment and most of its molds in-house. Trade
secret laws do not afford the statutory exclusivity possible for
patented processes. There can be no assurance that the legal
protections afforded to Porex or the steps taken by Porex will
be adequate to prevent misappropriation of its technology. In
addition, these protections do not prevent independent
third-party development of competitive products or services.
The
nature of Porexs products exposes it to product liability
claims that may not be adequately covered by indemnity
agreements or insurance
The products sold by Porex, whether sold directly to end-users
or sold to other manufacturers for inclusion in the products
that they sell, expose it to potential risk of product liability
claims, particularly with respect to Porexs life sciences,
clinical, surgical and medical products. In addition, Porex is
subject to the risk that a government authority or third party
may require it to recall one or more of its products. Some of
Porexs products are designed to be permanently implanted
in the human body. Design defects and manufacturing defects with
respect to such products sold by Porex or failures that occur
with the products of Porexs manufacturer customers that
contain components made by Porex could result in product
liability claims
and/or a
recall of one or more of Porexs products. Porex believes
that it carries adequate insurance coverage against product
liability claims and other risks. We cannot assure you, however,
that claims in excess of Porexs insurance coverage will
not arise. In addition, Porexs insurance policies must be
renewed annually. Although Porex has been able to obtain
adequate insurance coverage at an acceptable cost in the past,
we cannot assure you that Porex will continue to be able to
obtain adequate insurance coverage at an acceptable cost.
In most instances, Porex enters into indemnity agreements with
its manufacturing customers. These indemnity agreements
generally provide that these customers would indemnify Porex
from liabilities that may arise from the sale of their products
that incorporate Porex components to, or the use of such
products by, end-users. While Porex generally seeks contractual
indemnification from its customers, any such indemnification is
limited, as a practical matter, to the creditworthiness of the
indemnifying party. If Porex does not have adequate contractual
indemnification available, product liability claims, to the
extent not covered by insurance, could have a material adverse
effect on its business and its financial results.
Porexs
manufacturing of medical devices is subject to extensive
regulation by the U.S. Food and Drug Administration and its
failure to meet strict regulatory requirements could require it
to pay fines, incur other costs or close facilities
Porexs Surgical Products Group manufactures and markets
medical devices, such as reconstructive and aesthetic surgical
implants used in craniofacial applications and post-surgical
drains. In addition, Porex manufactures and markets blood serum
filters as a medical device for use in laboratory applications.
These products are subject to extensive regulation by the FDA
under the FDC Act. The FDAs regulations govern, among
other things, product development, testing, manufacturing,
labeling, storage, premarket clearance (referred to as 510(k)
clearance), premarket approval (referred to as PMA approval),
advertising and promotion, and sales and distribution. In
addition, the Porex facilities and manufacturing techniques used
for manufacturing medical devices generally must conform to
standards that are established by the FDA and other government
agencies, including those of European and other foreign
governments. These regulatory agencies may conduct periodic
audits or inspections of such facilities or processes to monitor
Porexs compliance with applicable regulatory standards. If
the FDA finds that Porex has failed to comply with applicable
regulations, the agency can institute a wide variety of
enforcement actions, including: warning letters or untitled
letters; fines and civil penalties; unanticipated expenditures
to address or defend such actions; delays in clearing or
approving, or refusal to clear or approve, products; withdrawal
or suspension of approval of products; product
64
recall or seizure; orders for physician notification or device
repair, replacement or refund; interruption of production;
operating restrictions; injunctions; and criminal prosecution.
Any adverse action by an applicable regulatory agency could
impair Porexs ability to produce its medical device
products in a cost-effective and timely manner in order to meet
customer demands. Porex may also be required to bear other costs
or take other actions that may have a negative impact on its
future sales of such products and its ability to generate
profits.
Economic,
political and other risks associated with Porexs
international sales and geographically diverse operations could
adversely affect Porexs operations and financial
results
Since Porex sells its products worldwide, its business is
subject to risks associated with doing business internationally.
In addition, Porex has manufacturing facilities in the United
Kingdom, Germany and Malaysia. Accordingly, Porexs
operations and financial results could be harmed by a variety of
factors, including:
|
|
|
|
|
changes in foreign currency exchange rates;
|
|
|
|
changes in a specific countrys or regions political
or economic conditions, particularly in emerging markets;
|
|
|
|
trade protection measures and import or export licensing
requirements;
|
|
|
|
changes in tax laws;
|
|
|
|
differing protection of intellectual property rights in
different countries; and
|
|
|
|
changes in regulatory requirements.
|
Environmental
regulation could adversely affect Porexs
business
Porex is subject to foreign and domestic environmental laws and
regulations and is subject to scheduled and random checks by
environmental authorities. Porexs business involves the
handling, storage and disposal of materials that are classified
as hazardous. Although Porexs safety procedures for
handling, storage and disposal of these materials are designed
to comply with the standards prescribed by applicable laws and
regulations, Porex may be held liable for any environmental
damages that result from Porexs operations. Porex may be
required to pay fines, remediation costs and damages, which
could have a material adverse effect on its results of
operations.
Risks
Related to Providing Products and Services to the Healthcare
Industry
Developments
in the healthcare industry and its funding could adversely
affect our businesses
Most of the revenue of WebMD is derived from healthcare industry
participants and could be affected by changes affecting
healthcare spending. In addition, a significant portion of
Porexs revenue comes from products used in healthcare or
related applications. WebMDs advertising and sponsorship
revenue is particularly dependent on pharmaceutical,
biotechnology and medical device companies. General reductions
in expenditures by healthcare industry participants could result
from, among other things:
|
|
|
|
|
government regulation or private initiatives that affect the
manner in which healthcare providers interact with patients,
payers or other healthcare industry participants, including
changes in pricing or means of delivery of healthcare products
and services;
|
|
|
|
consolidation of healthcare industry participants;
|
|
|
|
reductions in governmental funding for healthcare or in tax
benefits applicable to healthcare expenditures; and
|
|
|
|
adverse changes in business or economic conditions affecting
healthcare payers or providers, pharmaceutical companies,
medical device manufacturers or other healthcare industry
participants.
|
65
Even if general expenditures by healthcare industry participants
remain the same or increase, developments in the healthcare
industry may result in reduced spending in some or all of the
specific markets we serve. For example, use of our products and
services could be affected by:
|
|
|
|
|
changes in the design of health insurance plans;
|
|
|
|
a decrease in the number of new drugs or medical devices coming
to market; and
|
|
|
|
decreases in marketing expenditures by pharmaceutical companies
or medical device manufacturers, including as a result of
governmental regulation or private initiatives that discourage
or prohibit promotional activities by pharmaceutical or medical
device companies.
|
In addition, healthcare industry participants expectations
regarding pending or potential industry developments may also
affect their budgeting processes and spending plans with respect
to products and services of the types we provide.
The healthcare industry has changed significantly in recent
years, and we expect that significant changes will continue to
occur. However, the timing and impact of developments in the
healthcare industry are difficult to predict. We cannot provide
assurance that the markets for our products and services will
continue to exist at current levels or that we will have
adequate technical, financial and marketing resources to react
to changes in those markets.
Government
regulation of healthcare creates risks and challenges with
respect to our compliance efforts and business
strategies
The healthcare industry is highly regulated and is subject to
changing political, legislative, regulatory and other
influences. Existing and new laws and regulations affecting the
healthcare industry could create unexpected liabilities for us,
could cause us to incur additional costs and could restrict our
operations. Many healthcare laws are complex and their
application to specific products and services may not be clear.
In particular, many existing healthcare laws and regulations,
when enacted, did not anticipate the online services that WebMD
provides. However, these laws and regulations may nonetheless be
applied to our products and services. Our failure to accurately
anticipate the application of these laws and regulations, or
other failure to comply, could create liability for us, result
in adverse publicity and negatively affect our businesses. Some
of the risks that we face from healthcare regulation are as
follows:
|
|
|
|
|
because WebMDs public portals business involves
advertising and promotion of prescription and over-the-counter
drugs and medical devices, any increase in regulation of these
areas could make it more difficult for WebMD to contract for
sponsorships and advertising;
|
|
|
|
because WebMD is the leading distributor of online CME to
healthcare professionals, any failure to maintain its status as
an accredited CME provider or any change in government
regulation of CME or in industry practices could adversely
affect WebMDs business;
|
|
|
|
because Porex manufactures medical devices for implantation, it
is subject to extensive FDA regulation, as well as foreign
regulatory requirements;
|
|
|
|
because we provide products and services to healthcare
providers, our sales and promotional practices must comply with
federal and state anti-kickback laws; and
|
|
|
|
in providing health information to consumers, we must not engage
in activities that could be deemed to be practicing medicine and
a violation of applicable laws.
|
66
Risks
Applicable to Our Entire Company and to Ownership of Our
Securities
The
ongoing investigations by the United States Attorney for the
District of South Carolina and the SEC could negatively impact
our company and divert management attention from our business
operations
The United States Attorney for the District of South Carolina is
conducting an investigation of our company. Based on the
information available to HLTH as of the date of this Quarterly
Report on
Form 10-Q,
we believe that the investigation relates principally to issues
of financial accounting improprieties for Medical Manager
Corporation, a predecessor of HLTH (by its merger into HLTH in
September 2000), and Medical Manager Health Systems, a former
subsidiary of HLTH; however, we cannot be sure of the
investigations exact scope or how long it may continue. In
addition, HLTH understands that the SEC is conducting a formal
investigation into this matter. Adverse developments in
connection with the investigations, if any, including as a
result of matters that the authorities or HLTH may discover,
could have a negative impact on our company and on how it is
perceived by investors and potential investors and customers and
potential customers. In addition, the management effort and
attention required to respond to the investigations and any such
developments could have a negative impact on our business
operations.
HLTH intends to continue to fully cooperate with the authorities
in this matter. We believe that the amount of the expenses that
we will incur in connection with the investigations will
continue to be significant and we are not able to determine, at
this time, what portion of those amounts may ultimately be
covered by insurance or may ultimately be repaid to us by
individuals to whom we are advancing amounts for their defense
costs. In connection with the sale of Emdeon Practice Services
to Sage Software, we have agreed to indemnify Sage Software with
respect to this matter.
If
certain transactions occur with respect to our capital stock,
limitations may be imposed on our ability to utilize our net
operating loss carryforwards and tax credits to reduce our
income taxes
As of December 31, 2007, we had net operating loss
carryforwards of approximately $1.3 billion for federal
income tax purposes and federal tax credits of approximately
$35.7 million, which excludes the impact of any
unrecognized tax benefits. Based on information available at the
time of this filing, we currently estimate that the net
operating loss carryforwards that were available as of
December 31, 2007 will be reduced by an aggregate of
approximately $550 million as a result of offsetting our
gains on the sale of our ViPS business on July 22, 2008 and
the February 8, 2008 sale of our 48% interest in Emdeon
Business Services. These estimates are based on various
assumptions and are subject to material change.
If certain transactions occur with respect to our capital stock,
including issuances, redemptions, recapitalizations, exercises
of options, conversions of convertible debt, purchases or sales
by 5%-or-greater shareholders and similar transactions, that
result in a cumulative change of more than 50% of the ownership
of our capital stock, over a three-year period, as determined
under rules prescribed by the U.S. Internal Revenue Code
and applicable Treasury regulations, an annual limitation would
be imposed with respect to our ability to utilize our net
operating loss carryforwards and federal tax credits. The tender
offer being made by HLTH for its Common Stock that began on
October 27, 2008 may result in a cumulative change of
more than 50% of the ownership of our capital, as determined
under rules prescribed by the U.S. Internal Revenue Code
and applicable Treasury regulations. However, we currently are
unable to calculate the annual limitation that would be imposed
on our ability to utilize our net operating loss carryforwards
and federal tax credits if such ownership change were to occur,
which would depend on various factors including the level of
participation in the tender offer. Because substantially all of
our net operating loss carryforwards are reserved for by a
valuation allowance, we would not expect an annual limitation on
the utilization of our net operating loss carryforwards to
significantly reduce our net deferred tax assets, although the
timing of our cash flows may be impacted to the extent any such
annual limitation deferred the utilization of our net operating
loss carryforwards to future tax years.
67
We may
not be successful in protecting our intellectual property and
proprietary rights
Intellectual property and proprietary rights are important to
our businesses. The steps that we take to protect our
intellectual property, proprietary information and trade secrets
may prove to be inadequate and, whether or not adequate, may be
expensive. We rely on a combination of trade secret, patent and
other intellectual property laws and confidentiality procedures
and non-disclosure contractual provisions to protect our
intellectual property. We cannot assure you that we will be able
to detect potential or actual misappropriation or infringement
of our intellectual property, proprietary information or trade
secrets. Even if we detect misappropriation or infringement by a
third party, we cannot assure you that we will be able to
enforce our rights at a reasonable cost, or at all. In addition,
our rights to intellectual property, proprietary information and
trade secrets may not prevent independent third-party
development and commercialization of competing products or
services.
Third
parties may claim that we are infringing their intellectual
property, and we could suffer significant litigation or
licensing expenses or be prevented from selling products or
services
We could be subject to claims that we are misappropriating or
infringing intellectual property or other proprietary rights of
others. These claims, even if not meritorious, could be
expensive to defend and divert managements attention from
our operations. If we become liable to third parties for
infringing these rights, we could be required to pay a
substantial damage award and to develop non-infringing
technology, obtain a license or cease selling the products or
services that use or contain the infringing intellectual
property. We may be unable to develop non-infringing products or
services or obtain a license on commercially reasonable terms,
or at all. We may also be required to indemnify our customers if
they become subject to third-party claims relating to
intellectual property that we license or otherwise provide to
them, which could be costly.
Acquisitions,
business combinations and other transactions may be difficult to
complete and, if completed, may have negative consequences for
our business and our securityholders
We may seek to acquire or to engage in business combinations
with companies engaged in complementary businesses. In addition,
we may enter into joint ventures, strategic alliances or similar
arrangements with third parties. These transactions may result
in changes in the nature and scope of our operations and changes
in our financial condition. Our success in completing these
types of transactions will depend on, among other things, our
ability to locate suitable candidates and negotiate mutually
acceptable terms with them, as well as the availability of
financing. Significant competition for these opportunities
exists, which may increase the cost of and decrease the
opportunities for these types of transactions.
Financing for these transactions may come from several sources,
including:
|
|
|
|
|
cash and cash equivalents on hand and marketable securities;
|
|
|
|
proceeds from the incurrence of indebtedness; and
|
|
|
|
proceeds from the issuance of additional common stock, preferred
stock, convertible debt or other securities.
|
Our issuance of additional securities could:
|
|
|
|
|
cause substantial dilution of the percentage ownership of our
stockholders at the time of the issuance;
|
|
|
|
cause substantial dilution of our earnings per share;
|
|
|
|
subject us to the risks associated with increased leverage,
including a reduction in our ability to obtain financing or an
increase in the cost of any financing we obtain;
|
|
|
|
subject us to restrictive covenants that could limit our
flexibility in conducting future business activities; and
|
|
|
|
adversely affect the prevailing market price for our outstanding
securities.
|
We do not intend to seek securityholder approval for any such
acquisition or security issuance unless required by applicable
law or regulation or the terms of existing securities.
68
Our
business will suffer if we fail to successfully integrate
acquired businesses and technologies or to assess the risks in
particular transactions
We have in the past acquired, and may in the future acquire,
businesses, technologies, services, product lines and other
assets. The successful integration of the acquired businesses
and assets into our operations, on a cost-effective basis, can
be critical to our future performance. The amount and timing of
the expected benefits of any acquisition, including potential
synergies between HLTH and the acquired business, are subject to
significant risks and uncertainties. These risks and
uncertainties include, but are not limited to, those relating to:
|
|
|
|
|
our ability to maintain relationships with the customers of the
acquired business;
|
|
|
|
our ability to cross-sell products and services to customers
with which we have established relationships and those with
which the acquired businesses have established relationships;
|
|
|
|
our ability to retain or replace key personnel;
|
|
|
|
potential conflicts in payer, provider, strategic partner,
sponsor or advertising relationships;
|
|
|
|
our ability to coordinate organizations that are geographically
diverse and may have different business cultures; and
|
|
|
|
compliance with regulatory requirements.
|
We cannot guarantee that any acquired businesses will be
successfully integrated with our operations in a timely or
cost-effective manner, or at all. Failure to successfully
integrate acquired businesses or to achieve anticipated
operating synergies, revenue enhancements or cost savings could
have a material adverse effect on our business, financial
condition and results of operations.
Although our management attempts to evaluate the risks inherent
in each transaction and to value acquisition candidates
appropriately, we cannot assure you that we will properly
ascertain all such risks or that acquired businesses and assets
will perform as we expect or enhance the value of our company as
a whole. In addition, acquired companies or businesses may have
larger than expected liabilities that are not covered by the
indemnification, if any, that we are able to obtain from the
sellers.
We will
incur significant additional non-cash interest expense upon the
adoption of FASB Staff Position No. APB
14-1,
Accounting for Convertible Debt Instruments that May be
Settled in Cash upon Conversion (Including Partial Cash
Settlement)
On May 9, 2008, the Financial Accounting Standard Board (or
FASB) issued FASB Staff Position No. APB
14-1,
Accounting for Convertible Debt Instruments that May be
Settled in Cash upon Conversion (Including Partial Cash
Settlement), which will significantly impact the
accounting for convertible debt when it is adopted during the
first quarter of 2009. The FSP will require cash settled
convertible debt to be separated into debt and equity components
at issuance and a value to be assigned to each. The value
assigned to the debt component will be the estimated fair value,
as of the issuance date, of a similar bond without the
conversion feature. The difference between the bond cash
proceeds and this estimated fair value will be recorded as a
debt discount and amortized to interest expense over the life of
the bond. Although FSP APB
14-1 will
have no impact on our actual past or future cash flows, it will
require us to record a significant amount of non-cash interest
expense as the debt discount is amortized. As a result, there
will be an adverse impact on our results of operations and
earnings per share and that impact could be material.
We may
not be able to raise additional funds when needed for our
business or to exploit opportunities
Our future liquidity and capital requirements will depend upon
numerous factors, including the success of the integration of
our businesses, our existing and new applications and service
offerings, competing technologies and market developments,
potential future acquisitions and dispositions of companies or
businesses, and additional repurchases of our common stock. We
may need to raise additional funds to support expansion, develop
new or enhanced applications and services, respond to
competitive pressures, acquire complementary businesses or
technologies or take advantage of unanticipated opportunities.
If required, we may raise such additional funds through public
or private debt or equity financing, strategic relationships or
other arrangements. There can be no assurance that such
financing will be available on acceptable terms, if at all, or
that such financing will not be dilutive to our stockholders.
69
Negative
conditions in the market for certain auction rate securities may
result in us incurring a loss on such investments
As of September 30, 2008, HLTH had a total of approximately
$355.8 million (face value) of investments in certain
auction rate securities (ARS) of which $165.5 million (face
value) relate to WebMD. Those ARS had a fair value of
$284.4 million of which ($132.8 million relates to
WebMD). The types of ARS investments that HLTH owns are backed
by student loans, 97% of which are guaranteed under the Federal
Family Education Loan Program (FFELP), and all had credit
ratings of AAA or Aaa when purchased. HLTH and its subsidiaries
do not own any other type of ARS investments.
Since February 2008, negative conditions in the regularly held
auctions for these securities have prevented holders from being
able to liquidate their holdings through that type of sale. In
the event HLTH needs to or wants to sell its ARS investments, it
may not be able to do so until a future auction on these types
of investments is successful or until a buyer is found outside
the auction process. If potential buyers are unwilling to
purchase the investments at their carrying amount, HLTH would
incur a loss on any such sales.
Our
decision to sell Porex may have a negative impact on that
business
As a result of our announcement that we plan to divest Porex,
the financial results and operations of that business may be
adversely affected by the diversion of management resources to
the sale process and by uncertainty regarding the outcome of the
process. For example, the uncertainty of who will own Porex in
the future could lead Porex to lose or fail to attract
employees, customers or business partners. Although we have
taken steps to address these risks, there can be no assurance
that any such losses or distractions will not adversely affect
the operations or financial results of Porex and, as a result,
the sale price that we may receive for Porex.
70
|
|
ITEM 3.
|
Quantitative
and Qualitative Disclosures about Market Risk
|
Interest
Rate Sensitivity
The primary objective of our investment activities is to
preserve principal and maintain adequate liquidity, while at the
same time maximizing the yield we receive from our investment
portfolio.
Changes in prevailing interest rates will cause the fair value
of certain of our investments to fluctuate, such as our
investments in auction rate securities that generally bear
interest at rates indexed to LIBOR. As of September 30,
2008, the fair market value of our auction rate securities was
approximately $284 million. However, the fair values of our
cash and money market investments, which approximated
$1.4 billion at September 30, 2008 are not subject to
changes in interest rates.
The
31/8% Notes
and the 1.75% Notes that we have issued have fixed interest
rates; changes in interest rates will not impact our financial
condition or results of operations as it relates to these Notes.
HLTH and WHC have each entered into a non-recourse credit
facility (each a Credit Facility) with Citigroup
that is secured by their respective ARS holdings (including, in
some circumstances, interest payable on the ARS holdings), that
will allow HLTH and WHC to borrow up to 75% of the face amount
of the ARS holdings pledged as collateral under the respective
Credit Facilities. The interest rate applicable to such
borrowings will be one-month LIBOR plus 250 basis points.
No borrowings have been made under either Credit Facility to
date.
Exchange
Rate Sensitivity
Currently, substantially all of our sales and expenses are
denominated in United States dollars; however, certain of our
Porex subsidiaries (currently reflected as discontinued
operations) are exposed to fluctuations in foreign currency
exchange rates, primarily the rate of exchange of the United
States dollar against the Euro. This exposure arises primarily
as a result of translating the results of Porexs foreign
operations to the United States dollar at exchange rates that
have fluctuated from the beginning of the accounting period.
Porex has not engaged in foreign currency hedging activities to
date. Foreign currency translation losses were $4.5 million
and $1.2 million for the three and nine months ended
September 30, 2008, respectively, and foreign currency
translation gains were $1.6 million and $2.4 million
for the three and nine months ended September 30, 2007,
respectively. We believe that future exchange rate sensitivity
related to Porex will not have a material effect on our
financial condition or results of operations.
|
|
ITEM 4.
|
Controls
and Procedures
|
As required by Exchange Act
Rule 13a-15(b),
HLTH management, including the Chief Executive Officer and Chief
Financial Officer, conducted an evaluation of the effectiveness
of HLTHs disclosure controls and procedures, as defined in
Exchange Act
Rule 13a-15(e),
as of September 30, 2008. Based on that evaluation, the
Chief Executive Officer and Chief Financial Officer concluded
that HLTHs disclosure controls and procedures were
effective as of September 30, 2008.
In connection with the evaluation required by Exchange Act
Rule 13a-15(d),
HLTH management, including the Chief Executive Officer and Chief
Financial Officer, concluded that no changes in HLTHs
internal control over financial reporting occurred during the
third quarter of 2008 that have materially affected, or are
reasonably likely to materially affect, HLTHs internal
control over financial reporting.
71
PART II
OTHER INFORMATION
|
|
ITEM 1.
|
Legal
Proceedings
|
The information relating to legal proceedings contained in
Note 12 to the Consolidated Financial Statements included
in Part I, Item 1 of this Quarterly Report is
incorporated herein by this reference.
|
|
ITEM 2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
(c) The following table provides information about
purchases by HLTH during the three months ended
September 30, 2008 of equity securities that are registered
by us pursuant to Section 12 of the Exchange Act:
Issuer
Purchases of Equity Securities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Approximate
|
|
|
|
|
|
|
|
|
|
Total Number of
|
|
|
Dollar Value of
|
|
|
|
|
|
|
|
|
|
Shares Purchased as
|
|
|
Shares that May Yet
|
|
|
|
Total Number of
|
|
|
|
|
|
Part of Publicly
|
|
|
Be Purchased Under
|
|
|
|
Shares
|
|
|
Average Price
|
|
|
Announced Plans or
|
|
|
the Plans or
|
|
Period
|
|
Purchased (1)
|
|
|
Paid per Share
|
|
|
Programs (2)
|
|
|
Programs (2)
|
|
|
7/01/08 - 7/31/08
|
|
|
6,448
|
|
|
$
|
11.41
|
|
|
|
|
|
|
$
|
41,553,120
|
|
8/01/08 - 8/31/08
|
|
|
3,295
|
|
|
$
|
11.88
|
|
|
|
|
|
|
$
|
41,553,120
|
|
9/01/08 - 9/30/08
|
|
|
2,745
|
|
|
$
|
12.35
|
|
|
|
|
|
|
$
|
41,553,120
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
12,488
|
|
|
$
|
11.74
|
|
|
|
|
|
|
$
|
41,553,120
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
Represents shares withheld from
HLTH Restricted Stock that vested during the respective periods
in order to satisfy withholding tax requirements related to the
vesting of the awards. The value of these shares was determined
based on the closing price of HLTH Common Stock on the date of
vesting.
|
|
(2)
|
|
Relates to the repurchase program
that we announced in December 2006, at which time HLTH was
authorized to use up to $100 million to purchase shares of
its common stock from time to time. For additional information
and for information regarding the tender offer commenced by HLTH
on October 27, 2008 (the Pending Tender Offer),
see Note 8 to the Consolidated Financial Statements
included in this Quarterly Report. The Pending Tender Offer is
being conducted under a separate authorization and does not
affect the amount available under this repurchase program.
|
ITEM 6. Exhibits
The exhibits listed in the accompanying Exhibit Index on
page E-1
are filed or furnished as part of this Quarterly Report.
72
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
HLTH
Corporation
Mark D. Funston
Executive Vice President and
Chief Financial Officer
Date: November 10, 2008
73
EXHIBIT INDEX
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
2
|
.1*
|
|
Agreement and Plan of Merger, dated as of September 12,
2008, by and among WebMD Health Corp., Charlottes
Corporation and Marketing Technology Solutions Inc.
(incorporated by reference to Exhibit 2.1 to the Quarterly
Report on
Form 10-Q
filed by the WebMD Health Corp. on November 10, 2008)
|
|
2
|
.2*
|
|
Agreement and Plan of Merger, dated as of February 20,
2008, between WebMD Health Corp. and the Registrant
(incorporated by reference to Exhibit 2.1 to Amendment
No. 1, filed by the Registrant on February 25, 2008,
to the Current Report on
Form 8-K
filed by the Registrant on February 21, 2008)
|
|
2
|
.3
|
|
Amendment No. 1, dated as of May 6, 2008, to Agreement
and Plan of Merger, dated as of February 20, 2008, between
WebMD Health Corp. and the Registrant (incorporated by reference
to Exhibit 2.1 to the Current Report on
Form 8-K
filed by the WebMD Health Corp. on May 7, 2008)
|
|
2
|
.4
|
|
Amendment No. 2, dated as of September 12, 2008, to
Agreement and Plan of Merger, dated as of February 20,
2008, between WebMD Health Corp. and the Registrant
(incorporated by reference to Exhibit 2.1 to the Current
Report on
Form 8-K
filed by the Registrant on September 15, 2008)
|
|
2
|
.5
|
|
Termination Agreement, dated as of October 19, 2008,
between HLTH Corporation and WebMD Health Corp. (incorporated by
reference to Exhibit 2.1 to the Current Report on
Form 8-K
filed by the Registrant on October 20, 2008)
|
|
3
|
.1
|
|
Eleventh Amended and Restated Certificate of Incorporation of
the Registrant, as amended (incorporated by reference to
Exhibit 3.1 to the Registrants Quarterly Report on
Form 10-Q
for the quarter ended September 30, 2004)
|
|
3
|
.2
|
|
Certificate of Ownership and Merger Amending the
Registrants Eleventh Amended and Restated Certificate of
Incorporation to Change the Registrants Name to HLTH
Corporation (incorporated by reference to Exhibit 3.1 to
Registrants Current Report on
Form 8-K
filed on May 21, 2007)
|
|
3
|
.3
|
|
Amended and Restated Bylaws of Registrant, as currently in
effect (incorporated by reference to Exhibit 3.2 of the
Registrants Quarterly Report on
Form 10-Q
for the quarter ended September 30, 2004)
|
|
31
|
.1
|
|
Rule 13a-14(a)/15d-14(a)
Certification of Chief Executive Officer of Registrant
|
|
31
|
.2
|
|
Rule 13a-14(a)/15d-14(a)
Certification of Chief Financial Officer of Registrant
|
|
32
|
.1
|
|
Section 1350 Certification of Chief Executive Officer of
Registrant
|
|
32
|
.2
|
|
Section 1350 Certification of Chief Financial Officer of
Registrant
|
|
|
|
* |
|
Certain of the exhibits and schedules to this agreement have
been omitted pursuant to Item 601(b)(2) of
Regulation S-K.
The Registrant will furnish copies of any of the exhibits and
schedules to the Securities and Exchange Commission upon request. |
E-1